tkiatkiikkekzcfkhmpqhssiueqsmcvaisgolkss length 6 322396 page 322396 

<!DOCTYPE html>

<html id="doc" lang="en" class="page-article">
<head id="Head1">
    <!-- charset must appear in the first 1024 bytes of the document -->
    <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />

<script>
      var SCM = SCM || {};
      if (SCM.AMA && SCM.AMA.DataLayerAsync) {
        SCM.AMA.DataLayerAsync.push("arrSisAffinity", "", "array");
        SCM.AMA.DataLayerAsync.push("SubStatus", "no", "string");
      }

      var googletag = window.googletag || {};
      googletag.cmd = googletag.cmd || [];

          
          if (typeof Storage !== "undefined")
          {
              var targetingParamStr = localStorage.getItem("bcDFPTargetingParams");
              if (targetingParamStr)
              {
                  var targetingParameters = JSON.parse(targetingParamStr);     // set page-level targeting parameters
                  jQuery.each(targetingParameters, function (index, param) {
                      googletag.cmd.push(function () {
                          window.googletag.pubads().setTargeting(param.key, param.value);
                      });
                  });
              }
          }
          
      if (!googletag.pubads) {
        (function () {
          var gads = document.createElement('script');
          var useSSL = 'https:' == document.location.protocol;
          gads.src = (useSSL ? 'https:' : 'http:') +
            '//securepubads.g.doubleclick.net/tag/js/gpt.js';
              gads.setAttribute("async", "");
              gads.setAttribute("defer", "");
          var node = document.getElementsByTagName('script')[0];
          node.parentNode.insertBefore(gads, node);
          })();

        var App = App || {};
        App.Ads = App.Ads || {};
        App.Ads.adPath = App.Ads.adPath || '/6479/' + 'ama.jama';
        App.Ads.Mappings = App.Ads.Mappings || {};
        App.Ads.slots = App.Ads.slots || [];
        App.Ads.fromGoogle = !('yes' === 'yes');

        App.isCollection = App.isCollection || !!document.getElementsByClassName('pg_collection').length;

        
        googletag.cmd.push(function () {

          googletag.pubads()
            .setTargeting('environment', ['newjama'])
            .setTargeting('site', ['ama.jama'])
            .setTargeting('sect', ['scholarly'])
            .setTargeting('sub', ['no'])
            .setTargeting('device', ['cis5550-crawler'])
            .setTargeting('usaphys', ['no'])
            .setTargeting('memberstat', ['no'])
            .setTargeting('pracset', [''])
            .setTargeting('specialty', ['other'])
            .setTargeting('occupation', [''])
            .setTargeting('useraffinity', [''])
            .setTargeting('direct', ['yes'])
            .setTargeting('bot', ['yes'])
            .setTargeting('datacenter', ['no'])
            .setTargeting('selfMPA', [''])
            .setTargeting('selfSpecialty', ['']);

          if (App.isCollection) {
            googletag.pubads().setTargeting('collection', ['']);
          }

          var testParam = getQueryVariable('test');

          if (testParam) {
            googletag.pubads().setTargeting('test', [testParam]);
          }

          function getQueryVariable(variable) {
            var query = window.location.search.substring(1);
            var vars = query.split('&');
            for (var i = 0; i < vars.length; i++) {
              var pair = vars[i].split('=');
              if (decodeURIComponent(pair[0]) == variable) {
                return decodeURIComponent(pair[1]);
              }
            }
          }

          googletag.pubads().disableInitialLoad();
          googletag.enableServices();
        });
      }
</script>


<meta name="viewport" content="width=device-width, initial-scale=1" /><meta name="format-detection" content="telephone=no" /><link rel="shortcut icon" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon.ico">
<link rel="icon" type="image/png" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon-192x192.png" sizes="192x192">
<link rel="apple-touch-icon" sizes="180x180" href="//cdn.jamanetwork.com/UI/app/img/favicons/jama/apple-touch-icon-180x180.png">
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
    
    <link rel="stylesheet" href="//cdn.jamanetwork.com/UI/app/dist/app.min.css?v=638488852237037766">
    
    
    
    
    <link href="//cdn.jsdelivr.net/chartist.js/latest/chartist.min.css" type="text/css" rel="stylesheet" />
    

    <meta property="og:title" content="Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women" />
    <meta property="og:type" content="Article" />
    <meta property="og:url" content="https://jamanetwork.com/journals/jama/fullarticle/195120" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f1.gif?Expires=2147483647&amp;Signature=h87qjFBNtDabiIgVVYP9CWOAlFe8nx~yUDXYcqmnpsjjykbGMwT-IR25gMdbUsIicFV1IgH05cmK7b1obuXbSnjd-awMIdeRjWTw~nbG9uFh0TSyd6T21MUAkiIaTsTpBf-Fl29THRYL2OddrWY7OHQOYLgXy9dNmInWmrOOAm1lmyGFLb9roSpjoOHem9hRgTOtwHs0gzp-~bRpiLibR1AVAxFn18F2ZyLM221uzs-T4ITBRBDRx6P~3nLElIXISoEizR3c6Op9FnikMR3tP3OMg1zZqfuaJjbkMiw3LzNzyuyJryUWy5JhSmFaM1jaHNpYtdFVy~AlmFR4HQfvxA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t1a.png?Expires=2147483647&amp;Signature=pIws7gt7xRq3ufPCLOHf~3ZqcaRfik-mpg--T-7ppCgFN51l0XjjwoAeXSIyRXzRb~2KdgmAOJZhgAot3VadPHpu09hshjP7UiTEp4wfqra5xAXA485uUR6alf9wqk0c7C11F0pxei64Sx3PfKR2C5q~vVSsU9dvdlGlJjiEIj~7d9i5a0HxMl4ThJq5L3Ix-Xn8lRJBWVLQbgxDHjeTK-uXDKr6qh8iUDlBiuzn2OueX87aDdJ3MqI8GnwOCNt0tUmhLGCqH89-bUrL0Ej2THVr9E93oo~qTcW92cbaYeyfPS3D6G6G5cIJwtCvb86nzSo7bnke6REGFBRWRaJeLg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t1b.png?Expires=2147483647&amp;Signature=XsW40Rn5030Oi-vfqoWuW2RcrC2iIMX8UC0CnL1r3v1FQcXRrzKgbPoeIgzD8xLlaA7z4cMtorfAgcsqHab9qv0ow7qzQt0gA2Su3TncR~vnUIK07D1mUCaqDeXCyKWpkK4bQw50kZ~CB09~FqnlKsp9Dilyi~pY1qxRLSfEIVyQ-1YpZH2nc8F7dNh9bZX0NifK~9413UL4QbSyKWv0tqRtgSNxiDjb-2xk2MrtsNQPREP504gMhPGWyxT1mhzXcnMGEIe98TOV9ICPYyG5BC6UA5h8jKJOKAFpYpyBDOYH1iVLblAgxP-Pw~iE27ZMU5sVH3AlEeDf1wgEDWFeJA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f2.gif?Expires=2147483647&amp;Signature=jjX3kkKLkc8-rbGq0PEJcqm48sR5BWnwlYwY~ZPEHkJ6hAtFBwM19WAcDQYx5fkkU~SDPvL5JU-Xd2VNiehJWIYa6J0bZNcZgmEK-hk~Jzr6fRyW5uLc4DOWH9aiEc-vnXAOoUkklyZckZBNHZ9tM-i-Y02LeUmhQsyRWbwvD0vNcPf9OLrnGWhH0~xtnbuR1wU2KN-y94Ae5l~bWu0mjjdDKn4m7Txg93susHb47H6EM6pWnauesDVS5tKvLjFbZ9z1rGFbim3pa9FUW3V0mDmpk7ntKdIMRfl3yB5CgMqjEDb3phu65c-I94CNdxoIqoxdo~vL2uK~4fKErhniDg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t2.png?Expires=2147483647&amp;Signature=YCAO02IbeopDhHFRoXAN0ebAB2IcSD-RfTUdag5uh0oXn3TvBvdfa6g~1dMaYlO2Mm6lwN43HnWtB~CmM2aecsJ2v~UTfVQknmvFMpoL6acuro8zS2j9UfI2W235gsVOx8ILPpk2ikzDIh4-mefdyKZRoJLaImm-sgX19kkCGnsHvsaOrmUEU-arfYvo4jYkgD3bXTf2S4M3m4hEFtrcTwzb4tV63QMIwISIpc1udviuGhPTvsbIJUHKXVEsgRXh0O-RJvYst53sZx0xyIjSRuLDVtD18wkmPDlBv01fqM0XNYgvKXFjEElO0tjr8-Ntu0nt0Bt~ePFTYaunl6gl1g__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t3.png?Expires=2147483647&amp;Signature=bph0JFzJlseQfNIGiD1Y~lnwIp8JRIshKeoR4g0jvJRBJmQfEQWEPSHfjlUIoNFd6omcDldOYZ5Gz0CI0K~7YRItRFEr7j4R2OOOv8HHS6MmirxmTIYa4D97cD-dnKqFuA~FAi0oEV4b2-f62e0QbgU5CkUHFGUoutFFV~tckUVeXRn1mYyAZPW~GefvQTJebAA6G3avyLHXFnqM3gBhNbjwhZg00MY6oiB9cDIhzTsxpWnu46S~4dy6246IBZKrT6bWRp7dTgWGUtttkoBIJCbhhvXMJgolGDwTPLvLlTqvVebBXVpIJHnl4qzw1S0ojaKN~YM3oD3v7wnpFfiu8w__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f3.gif?Expires=2147483647&amp;Signature=V3aFXqLpN-Ourd2P3aPI7jIZaTck0WNBvbTZ-pPVHsXlTPxGECWXUduVBP-zg1LobiGKNwblIMmbA7M8aFyxl7f02zkoDc1WXrWT-UAcCSeO9xrCQgPNXgQ-2~3luF1CJBpMw3h17e8c8sTYxsJLFwqI1piD4LnF4bWZY8Hqr2HhKKaP4CRH7kTRAk5BK0t9Ybb2AGOuw-QiUHsWLGmaROLiUSpCa2KOujKNBEMELkUKq0CtfSfmibW1tEcVkSMintHglMMSmKmhXCqyBUpG2qWVKeJBWAHXnShMrsHO~Xx9iNSZZzkmo5tsZWWeocUuYhajF1eQcOpBRXyP~RAmxA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f4.gif?Expires=2147483647&amp;Signature=B65mHtRpDKXGWFdZbiQ7E-IxEc4wkR4bEn7wV-nTl5HJyJjfUqWWIdzv1N2StHersspCfFs~fXKSkmzY9wbtBRADQI5029OZLb0YoupepsHcAyiOHWriaTxzGac9~QYCcAYSHLw59I7VbjnONSpgaKHa6ifhqv1jw4-G~0GWMcMX1aRbqcGSHcaBaWX8OwqiExDg~T~Dc~VRYdd1Gy0-rHjiu9UjZlh2fbeqJyMpos1tib9ruLkxkq-xpCDNzh0PhFZyadI0OHXpdr0K1N8YbQ0WzJlBgj~-Cr5XO4drbEi8k~qxp9-9Dqv-hFHs~btEd217uGMTaYHr~yTd-GCpYA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t4.png?Expires=2147483647&amp;Signature=ZFpVKnaq1yMXmof~T-8NT-BhDFGIKnKEIqsQsI8i81jnVA3SSek4cgHG-tM3INhk11g7PRqny8eICKNvbV1OaMWIkRnMPZl8bJiZp1jG2U7-Y8Xn0N8b921Dx~8zgMi8m1HPNx1ZIhTJ68E1UrFYv0OY2vQL6RuZspd~lD6kOV2SShpAeIqFRD2tMGOXUWabe7ULc5kmhxjQsdhwhxXAetltnmAqiXqG-W-ytGQJjvs-nYSBLPRLqZcKF6QHb-8D0OOqDO5A~lYyOd5USEmG54Nqku3h5xJEir2xc7n-UWlt87mtU1gdTR6EyzbaPLAtU6ZLgemVKPAao1J3LDo3vw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />
    <meta property="og:description" content="Context&#160;Despite decades of accumulated observational evidence, the balance of
risks and benefits for hormone use in healthy postmenopausal women remains
uncertain.Objective&#160;To assess the major health benefits and risks of the most commonly used
combined hormone preparation in the United..." />
        <meta property="fb:pages" content="87087958340" />
        <meta property="fb:pages" content="122228711814384" />
        <meta property="fb:pages" content="1648414928738217" />
        <meta property="fb:pages" content="117506346528" />
        <meta property="fb:pages" content="97538728726" />
        <meta property="fb:pages" content="114116793520" />
        <meta property="fb:pages" content="100679858757" />
        <meta property="fb:pages" content="759822190741773" />
        <meta property="fb:pages" content="100265333750" />
        <meta property="fb:pages" content="234770525256" />
        <meta property="fb:pages" content="98784919862" />
        <meta property="fb:pages" content="120829458202" />
        <meta property="fb:pages" content="124842870398" />
        <meta property="fb:pages" content="110245330325636" />
        <meta name="twitter:card" content="summary_large_image" />
        <meta name="twitter:site" content="@JAMA_current" />
        <meta name="twitter:image" content="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f1.gif?Expires=2147483647&amp;Signature=h87qjFBNtDabiIgVVYP9CWOAlFe8nx~yUDXYcqmnpsjjykbGMwT-IR25gMdbUsIicFV1IgH05cmK7b1obuXbSnjd-awMIdeRjWTw~nbG9uFh0TSyd6T21MUAkiIaTsTpBf-Fl29THRYL2OddrWY7OHQOYLgXy9dNmInWmrOOAm1lmyGFLb9roSpjoOHem9hRgTOtwHs0gzp-~bRpiLibR1AVAxFn18F2ZyLM221uzs-T4ITBRBDRx6P~3nLElIXISoEizR3c6Op9FnikMR3tP3OMg1zZqfuaJjbkMiw3LzNzyuyJryUWy5JhSmFaM1jaHNpYtdFVy~AlmFR4HQfvxA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" />




<script type="application/ld+json">
    {
  "@context": "https://schema.org/",
  "@type": "Article",
  "headline": "Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women : Principal Results From the",
  "author": "Writing Group for the Women's Health Initiative Investigators",
  "url": "https://jamanetwork.com/journals/jama/fullarticle/195120",
  "datePublished": "2002-07-17",
  "description": "Context Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain. Objective To assess the major health benefits and risks of the most commonly used combined hormone preparation in the United States. Design Estrogen plus progestin component of the Women's Health Initiative, a randomized controlled primary prevention trial (planned duration, 8.5 years) in which 16608 postmenopausal women aged 50-79 years with an intact uterus at baseline were recruited by 40 US clinical centers in 1993-1998. Interventions Participants received conjugated equine estrogens, 0.625 mg/d, plus medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n = 8102). Main Outcomes Measures The primary outcome was coronary heart disease (CHD) (nonfatal myocardial infarction and CHD death), with invasive breast cancer as the primary adverse outcome. A global index summarizing the balance of risks and benefits included the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer, colorectal cancer, hip fracture, and death due to other causes. Results On May 31, 2002, after a mean of 5.2 years of follow-up, the data and safety monitoring board recommended stopping the trial of estrogen plus progestin vs placebo because the test statistic for invasive breast cancer exceeded the stopping boundary for this adverse effect and the global index statistic supported risks exceeding benefits. This report includes data on the major clinical outcomes through April 30, 2002. Estimated hazard ratios (HRs) (nominal 95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with 286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85) with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases; colorectal cancer, 0.63 (0.43-0.92) with 112 cases; endometrial cancer, 0.83 (0.47-1.47) with 47 cases; hip fracture, 0.66 (0.45-0.98) with 106 cases; and death due to other causes, 0.92...",
  "publisher": {
    "@type": "Organization",
    "name": "JAMA Network",
    "logo": {
      "@type": "ImageObject",
      "url": "//cdn.jamanetwork.com/UI/app/img/favicons/jama/favicon.ico"
    }
  },
  "image": [
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f1.gif?Expires=2147483647&Signature=h87qjFBNtDabiIgVVYP9CWOAlFe8nx~yUDXYcqmnpsjjykbGMwT-IR25gMdbUsIicFV1IgH05cmK7b1obuXbSnjd-awMIdeRjWTw~nbG9uFh0TSyd6T21MUAkiIaTsTpBf-Fl29THRYL2OddrWY7OHQOYLgXy9dNmInWmrOOAm1lmyGFLb9roSpjoOHem9hRgTOtwHs0gzp-~bRpiLibR1AVAxFn18F2ZyLM221uzs-T4ITBRBDRx6P~3nLElIXISoEizR3c6Op9FnikMR3tP3OMg1zZqfuaJjbkMiw3LzNzyuyJryUWy5JhSmFaM1jaHNpYtdFVy~AlmFR4HQfvxA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t1a.png?Expires=2147483647&Signature=pIws7gt7xRq3ufPCLOHf~3ZqcaRfik-mpg--T-7ppCgFN51l0XjjwoAeXSIyRXzRb~2KdgmAOJZhgAot3VadPHpu09hshjP7UiTEp4wfqra5xAXA485uUR6alf9wqk0c7C11F0pxei64Sx3PfKR2C5q~vVSsU9dvdlGlJjiEIj~7d9i5a0HxMl4ThJq5L3Ix-Xn8lRJBWVLQbgxDHjeTK-uXDKr6qh8iUDlBiuzn2OueX87aDdJ3MqI8GnwOCNt0tUmhLGCqH89-bUrL0Ej2THVr9E93oo~qTcW92cbaYeyfPS3D6G6G5cIJwtCvb86nzSo7bnke6REGFBRWRaJeLg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t1b.png?Expires=2147483647&Signature=XsW40Rn5030Oi-vfqoWuW2RcrC2iIMX8UC0CnL1r3v1FQcXRrzKgbPoeIgzD8xLlaA7z4cMtorfAgcsqHab9qv0ow7qzQt0gA2Su3TncR~vnUIK07D1mUCaqDeXCyKWpkK4bQw50kZ~CB09~FqnlKsp9Dilyi~pY1qxRLSfEIVyQ-1YpZH2nc8F7dNh9bZX0NifK~9413UL4QbSyKWv0tqRtgSNxiDjb-2xk2MrtsNQPREP504gMhPGWyxT1mhzXcnMGEIe98TOV9ICPYyG5BC6UA5h8jKJOKAFpYpyBDOYH1iVLblAgxP-Pw~iE27ZMU5sVH3AlEeDf1wgEDWFeJA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f2.gif?Expires=2147483647&Signature=jjX3kkKLkc8-rbGq0PEJcqm48sR5BWnwlYwY~ZPEHkJ6hAtFBwM19WAcDQYx5fkkU~SDPvL5JU-Xd2VNiehJWIYa6J0bZNcZgmEK-hk~Jzr6fRyW5uLc4DOWH9aiEc-vnXAOoUkklyZckZBNHZ9tM-i-Y02LeUmhQsyRWbwvD0vNcPf9OLrnGWhH0~xtnbuR1wU2KN-y94Ae5l~bWu0mjjdDKn4m7Txg93susHb47H6EM6pWnauesDVS5tKvLjFbZ9z1rGFbim3pa9FUW3V0mDmpk7ntKdIMRfl3yB5CgMqjEDb3phu65c-I94CNdxoIqoxdo~vL2uK~4fKErhniDg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t2.png?Expires=2147483647&Signature=YCAO02IbeopDhHFRoXAN0ebAB2IcSD-RfTUdag5uh0oXn3TvBvdfa6g~1dMaYlO2Mm6lwN43HnWtB~CmM2aecsJ2v~UTfVQknmvFMpoL6acuro8zS2j9UfI2W235gsVOx8ILPpk2ikzDIh4-mefdyKZRoJLaImm-sgX19kkCGnsHvsaOrmUEU-arfYvo4jYkgD3bXTf2S4M3m4hEFtrcTwzb4tV63QMIwISIpc1udviuGhPTvsbIJUHKXVEsgRXh0O-RJvYst53sZx0xyIjSRuLDVtD18wkmPDlBv01fqM0XNYgvKXFjEElO0tjr8-Ntu0nt0Bt~ePFTYaunl6gl1g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t3.png?Expires=2147483647&Signature=bph0JFzJlseQfNIGiD1Y~lnwIp8JRIshKeoR4g0jvJRBJmQfEQWEPSHfjlUIoNFd6omcDldOYZ5Gz0CI0K~7YRItRFEr7j4R2OOOv8HHS6MmirxmTIYa4D97cD-dnKqFuA~FAi0oEV4b2-f62e0QbgU5CkUHFGUoutFFV~tckUVeXRn1mYyAZPW~GefvQTJebAA6G3avyLHXFnqM3gBhNbjwhZg00MY6oiB9cDIhzTsxpWnu46S~4dy6246IBZKrT6bWRp7dTgWGUtttkoBIJCbhhvXMJgolGDwTPLvLlTqvVebBXVpIJHnl4qzw1S0ojaKN~YM3oD3v7wnpFfiu8w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f3.gif?Expires=2147483647&Signature=V3aFXqLpN-Ourd2P3aPI7jIZaTck0WNBvbTZ-pPVHsXlTPxGECWXUduVBP-zg1LobiGKNwblIMmbA7M8aFyxl7f02zkoDc1WXrWT-UAcCSeO9xrCQgPNXgQ-2~3luF1CJBpMw3h17e8c8sTYxsJLFwqI1piD4LnF4bWZY8Hqr2HhKKaP4CRH7kTRAk5BK0t9Ybb2AGOuw-QiUHsWLGmaROLiUSpCa2KOujKNBEMELkUKq0CtfSfmibW1tEcVkSMintHglMMSmKmhXCqyBUpG2qWVKeJBWAHXnShMrsHO~Xx9iNSZZzkmo5tsZWWeocUuYhajF1eQcOpBRXyP~RAmxA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f4.gif?Expires=2147483647&Signature=B65mHtRpDKXGWFdZbiQ7E-IxEc4wkR4bEn7wV-nTl5HJyJjfUqWWIdzv1N2StHersspCfFs~fXKSkmzY9wbtBRADQI5029OZLb0YoupepsHcAyiOHWriaTxzGac9~QYCcAYSHLw59I7VbjnONSpgaKHa6ifhqv1jw4-G~0GWMcMX1aRbqcGSHcaBaWX8OwqiExDg~T~Dc~VRYdd1Gy0-rHjiu9UjZlh2fbeqJyMpos1tib9ruLkxkq-xpCDNzh0PhFZyadI0OHXpdr0K1N8YbQ0WzJlBgj~-Cr5XO4drbEi8k~qxp9-9Dqv-hFHs~btEd217uGMTaYHr~yTd-GCpYA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA",
    "https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t4.png?Expires=2147483647&Signature=ZFpVKnaq1yMXmof~T-8NT-BhDFGIKnKEIqsQsI8i81jnVA3SSek4cgHG-tM3INhk11g7PRqny8eICKNvbV1OaMWIkRnMPZl8bJiZp1jG2U7-Y8Xn0N8b921Dx~8zgMi8m1HPNx1ZIhTJ68E1UrFYv0OY2vQL6RuZspd~lD6kOV2SShpAeIqFRD2tMGOXUWabe7ULc5kmhxjQsdhwhxXAetltnmAqiXqG-W-ytGQJjvs-nYSBLPRLqZcKF6QHb-8D0OOqDO5A~lYyOd5USEmG54Nqku3h5xJEir2xc7n-UWlt87mtU1gdTR6EyzbaPLAtU6ZLgemVKPAao1J3LDo3vw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA"
  ],
  "articleSection": [
    "Abstract",
    "Methods",
    "Study Population",
    "Study Regimens, Randomization, and Blinding",
    "Follow-up",
    "Data Collection, Management, and Quality Assurance",
    "Maintenance/Discontinuation of Study Medications",
    "Outcome Ascertainment",
    "Statistical Analyses",
    "Data and Safety Monitoring",
    "Results",
    "Baseline Characteristics",
    "Table 1. Baseline Characteristics of the Women's Health Initiative Estrogen Plus Progestin Trial Participants (N = 16 608) by Randomization Assignment*",
    "Table 2b",
    "Follow-up, Adherence, and Unblinding",
    "Intermediate Cardiovascular Disease End Points",
    "Clinical Outcomes",
    "Table 2. Clinical Outcomes by Randomization Assignment*",
    "Table 3. Cause of Death by Randomization Assignment",
    "Time Trends",
    "Table 4. Selected Clinical Outcomes by Follow-up Year and Randomization Assignment*",
    "Subgroup Analyses",
    "Further Analyses",
    "Comment",
    "Cardiovascular Disease",
    "Cancer",
    "Fractures",
    "Overall Risks and Benefits",
    "Limitations",
    "Implications",
    "References"
  ],
  "keyWords": "progestins, cardiovascular diseases, estrogens, fracture, hormones, posttreatment followup, malignant neoplasm of breast, cerebrovascular accident, carcinoma of the large intestine, women's health initiative, malignant neoplasms, hip fractures, postmenopause"
}
</script>
<meta name="citation_author" content="Writing Group for the Women's Health Initiative Investigators, Writing Group for the Women's Health Initiative Investigators" /><meta name="citation_title" content="Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial" /><meta name="citation_firstpage" content="321" /><meta name="citation_lastpage" content="333" /><meta name="citation_doi" content="10.1001/jama.288.3.321" /><meta name="citation_keyword" content="progestins" /><meta name="citation_keyword" content="cardiovascular diseases" /><meta name="citation_keyword" content="estrogen" /><meta name="citation_keyword" content="fractures" /><meta name="citation_keyword" content="hormones" /><meta name="citation_keyword" content="follow-up" /><meta name="citation_keyword" content="breast cancer" /><meta name="citation_keyword" content="cerebrovascular accident" /><meta name="citation_keyword" content="colorectal cancer" /><meta name="citation_keyword" content="women's health initiative" /><meta name="citation_keyword" content="cancer" /><meta name="citation_keyword" content="hip fractures" /><meta name="citation_keyword" content="postmenopause" /><meta name="citation_abstract" content="ContextDespite decades of accumulated observational evidence, the balance of
risks and benefits for hormone use in healthy postmenopausal women remains
uncertain.ObjectiveTo assess the major health benefits and risks of the most commonly used
combined hormone preparation in the United States.DesignEstrogen plus progestin component of the Women&#39;s Health Initiative,
a randomized controlled primary prevention trial (planned duration, 8.5 years)
in which 16608 postmenopausal women aged 50-79 years with an intact uterus
at baseline were recruited by 40 US clinical centers in 1993-1998.InterventionsParticipants received conjugated equine estrogens, 0.625 mg/d, plus
medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n
= 8102).Main Outcomes MeasuresThe primary outcome was coronary heart disease (CHD) (nonfatal myocardial
infarction and CHD death), with invasive breast cancer as the primary adverse
outcome. A global index summarizing the balance of risks and benefits included
the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer,
colorectal cancer, hip fracture, and death due to other causes.ResultsOn May 31, 2002, after a mean of 5.2 years of follow-up, the data and
safety monitoring board recommended stopping the trial of estrogen plus progestin
vs placebo because the test statistic for invasive breast cancer exceeded
the stopping boundary for this adverse effect and the global index statistic
supported risks exceeding benefits. This report includes data on the major
clinical outcomes through April 30, 2002. Estimated hazard ratios (HRs) (nominal
95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with
286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85)
with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases; colorectal cancer, 0.63
(0.43-0.92) with 112 cases; endometrial cancer, 0.83 (0.47-1.47) with 47 cases;
hip fracture, 0.66 (0.45-0.98) with 106 cases; and death due to other causes,
0.92 (0.74-1.14) with 331 cases. Corresponding HRs (nominal 95% CIs) for composite
outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial
and venous disease), 1.03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for
combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28)
for the global index. Absolute excess risks per 10&#160;000 person-years attributable
to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8 more
PEs, and 8 more invasive breast cancers, while absolute risk reductions per
10&#160;000 person-years were 6 fewer colorectal cancers and 5 fewer hip fractures.
The absolute excess risk of events included in the global index was 19 per
10&#160;000 person-years.ConclusionsOverall health risks exceeded benefits from use of combined estrogen
plus progestin for an average 5.2-year follow-up among healthy postmenopausal
US women. All-cause mortality was not affected during the trial. The risk-benefit
profile found in this trial is not consistent with the requirements for a
viable intervention for primary prevention of chronic diseases, and the results
indicate that this regimen should not be initiated or continued for primary
prevention of CHD." /><meta name="citation_journal_title" content="JAMA" /><meta name="citation_journal_abbrev" content="JAMA" /><meta name="citation_volume" content="288" /><meta name="citation_issue" content="3" /><meta name="citation_publication_date" content="2002/07/17" /><meta name="citation_issn" content="0098-7484" /><meta name="citation_publisher" content="American Medical Association" /><meta name="citation_reference" content="citation_org=The Women's Health Initiative Study Group; citation_title=Design of the Women's Health Initiative clinical trial and observational study.;  citation_journal_title=Control Clin Trials.;  citation_year=1998;  citation_volume=19;  citation_pages=61-109.; " /><meta name="citation_reference" content="citation_title=Estrogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence.;  citation_authors=Stampfer  M; Colditz  G;  citation_journal_title=Prev Med.;  citation_year=1991;  citation_volume=20;  citation_pages=47-63.; " /><meta name="citation_reference" content="citation_title=Hormone therapy to prevent disease and prolong life in postmenopausal women.;  citation_authors=Grady  D; Rueben  SB; Pettiti  DB;  citation_journal_title=Ann Intern Med.;  citation_year=1992;  citation_volume=117;  citation_pages=1016-1037.; " /><meta name="citation_reference" content="citation_title=Effects of postmenopausal estrogen-progesterone therapy on serum lipids and lipoproteins: a review.;  citation_authors=Rijpkema  AH; van der Sanden  AA; Ruijs  AH;  citation_journal_title=Maturitas.;  citation_year=1990;  citation_volume=12;  citation_pages=259-285.; " /><meta name="citation_reference" content="citation_title=Inhibition of coronary artery atherosclerosis by 17-beta estradiol in ovariectomized monkeys: lack of an effect of added progesterone.;  citation_authors=Adams  MR; Kaplan  JR; Manuck  SB;  citation_journal_title=Arteriosclerosis.;  citation_year=1990;  citation_volume=10;  citation_pages=1051-1057.; " /><meta name="citation_reference" content="citation_title=Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen.;  citation_authors=Weiss  NS; Ure  CL; Ballard  JH; Williams  AR; Daling  JR;  citation_journal_title=N Engl J Med.;  citation_year=1980;  citation_volume=303;  citation_pages=1195-1198.; " /><meta name="citation_reference" content="citation_title=Effect of estrone sulfate on postmenopausal bone loss.;  citation_authors=Genant  HK; Baylink  DJ; Gallagher  JC; Harris  ST; Steiger  P; Herber  M;  citation_journal_title=Obstet Gynecol.;  citation_year=1990;  citation_volume=76;  citation_pages=579-584.; " /><meta name="citation_reference" content="citation_title=A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer.;  citation_authors=Steinberg  KA; Thacker  SB; Smith  SJ;  citation_journal_title=JAMA.;  citation_year=1991;  citation_volume=265;  citation_pages=1985-1990.; " /><meta name="citation_reference" content="citation_title=Reproductive factors, exogenous female hormones, and colorectal cancer by subsite.;  citation_authors=Gerhardsson de  VM; London  S;  citation_journal_title=Cancer Causes Control.;  citation_year=1992;  citation_volume=3;  citation_pages=355-360.; " /><meta name="citation_reference" content="citation_title=Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women.;  citation_authors=Hulley  S; Grady  D; Bush  T;  citation_journal_title=JAMA.;  citation_year=1998;  citation_volume=280;  citation_pages=605-613.; " /><meta name="citation_reference" content="citation_title=Postmenopausal hormone use and secondary prevention of coronary events in the Nurses' Health Study.;  citation_authors=Grodstein  F; Manson  JE; Stampfer  MJ;  citation_journal_title=Ann Intern Med.;  citation_year=2001;  citation_volume=135;  citation_pages=1-8.; " /><meta name="citation_reference" content="citation_title=Initiation of hormone replacement therapy after acute myocardial infarction is associated with more cardiac events during follow-up.;  citation_authors=Alexander  KP; Newby  LK; Hellkamp  AS;  citation_journal_title=J Am Coll Cardiol.;  citation_year=2001;  citation_volume=38;  citation_pages=1-7.; " /><meta name="citation_reference" content="citation_title=Risk of recurrent coronary events in relation to use and recent initiation of postmenopausal hormone therapy.;  citation_authors=Heckbert  SR; Kaplan  RC; Weiss  NS;  citation_journal_title=Arch Intern Med.;  citation_year=2001;  citation_volume=161;  citation_pages=1709-1173.; " /><meta name="citation_reference" content="citation_title=A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease.;  citation_authors=Grodstein  F; Manson  JE; Colditz  GA; Willit  WC; Speizer  FE; Stampfer  MJ;  citation_journal_title=Ann Intern Med.;  citation_year=2000;  citation_volume=133;  citation_pages=933-941.; " /><meta name="citation_reference" content="citation_org=The Writing Group for the PEPI Trial; citation_title=Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.;  citation_journal_title=JAMA.;  citation_year=1996;  citation_volume=275;  citation_pages=370-375.; " /><meta name="citation_reference" content="citation_title=Surveillance and ascertainment of cardiovascular events: the Cardiovascular Health Study.;  citation_authors=Ives  DG; Fitzpatrick  AL; Bild  DE;  citation_journal_title=Ann Epidemiol.;  citation_year=1995;  citation_volume=5;  citation_pages=275-285.; " /><meta name="citation_reference" content="citation_title=Regression analysis and life tables.;  citation_author=Cox  DR;  citation_journal_title=J R Stat Soc.;  citation_year=1972;  citation_volume=34;  citation_pages=187-220.; " /><meta name="citation_reference" content="citation_title=A multiple testing procedure for clinical trials.;  citation_authors=O'Brien  PC; Fleming  RT;  citation_journal_title=Biometrics.;  citation_year=1979;  citation_volume=35;  citation_pages=549-556.; " /><meta name="citation_reference" content="citation_title=Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative.;  citation_authors=Freedman  LS; Anderson  G; Kipnis  V;  citation_journal_title=Control Clin Trials.;  citation_year=1996;  citation_volume=17;  citation_pages=509-525.; " /><meta name="citation_reference" content="citation_title=Projecting individualized probabilities of developing breast cancer for white females who are being examined annually.;  citation_authors=Gail  MH; Brinton  LA; Byar  DP;  citation_journal_title=J Natl Cancer Inst.;  citation_year=1989;  citation_volume=81;  citation_pages=1879-1886.; " /><meta name="citation_reference" content="citation_title=Estrogen replacement therapy: determinants of persistence with treatment.;  citation_authors=Pilon  D; Castilloux  AM; Lelorier  J;  citation_journal_title=Obstet Gynecol.;  citation_year=2001;  citation_volume=97;  citation_pages=97-100.; " /><meta name="citation_reference" content="citation_org=Writing Group for the PEPI Trial; citation_title=Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women.;  citation_journal_title=JAMA.;  citation_year=1995;  citation_volume=273;  citation_pages=199-208.; " /><meta name="citation_reference" content="citation_title=Effects of estrogen replacement on the progression of coronary artery atherosclerosis.;  citation_authors=Herrington  DM; Reboussin  DM; Brosnihan  KB;  citation_journal_title=N Engl J Med.;  citation_year=2000;  citation_volume=343;  citation_pages=522-529.; " /><meta name="citation_reference" content="citation_title=Effects of acute hormone therapy on recurrent ischemia in postmenopausal women with unstable angina.;  citation_authors=Schulman  SP; Thiemann  DR; Ouyang  P;  citation_journal_title=J Am Coll Cardiol.;  citation_year=2002;  citation_volume=39;  citation_pages=231-237.; " /><meta name="citation_reference" content="citation_org=for the HERS Research Group; citation_title=Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study Follow-up (HERS II).;  citation_authors=Grady  D; Herrington  D; Bittner  V;  citation_journal_title=JAMA.;  citation_year=2002;  citation_volume=288;  citation_pages=49-57.; " /><meta name="citation_reference" content="citation_title=Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS).;  citation_authors=Simon  JA; Hsia  J; Cauley  JA;  citation_journal_title=Circulation.;  citation_year=2001;  citation_volume=103;  citation_pages=638-642.; " /><meta name="citation_reference" content="citation_title=A clinical trial of estrogen-replacement therapy after ischemic stroke.;  citation_authors=Viscoli  CM; Brass  LM; Kernan  WN; Sarrel  PM; Suissa  S; Horwitz  RI;  citation_journal_title=N Engl J Med.;  citation_year=2001;  citation_volume=345;  citation_pages=1243-1249.; " /><meta name="citation_reference" content="citation_title=Estrogen in the prevention of atherosclerosis: a randomized, double-blind controlled trial.;  citation_authors=Hodis  HN; Mack  WJ; Lobo  RA;  citation_journal_title=Ann Intern Med.;  citation_year=2001;  citation_volume=135;  citation_pages=939-953.; " /><meta name="citation_reference" content="citation_title=Effect of oral postmenopausal hormone replacement on progression of atherosclerosis: a randomized, controlled trial.;  citation_authors=Angerer  P; Stork  S; Kothny  W; Schmitt  P; von Schacky  C;  citation_journal_title=Arterioscler Thromb Vasc Biol.;  citation_year=2001;  citation_volume=21;  citation_pages=262-268.; " /><meta name="citation_reference" content="citation_title=Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism: a review.;  citation_authors=Castellsague  J; Perez Gutthann  S; Garcia Rodriguez  LA;  citation_journal_title=Drug Saf.;  citation_year=1998;  citation_volume=18;  citation_pages=117-123.; " /><meta name="citation_reference" content="citation_title=Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the Heart and Estrogen/progestin Replacement Study.;  citation_authors=Grady  D; Wenger  NK; Herrington  D;  citation_journal_title=Ann Intern Med.;  citation_year=2000;  citation_volume=132;  citation_pages=689-696.; " /><meta name="citation_reference" content="citation_org=Collaborative Group on Hormonal Factors in Breast Cancer; citation_title=Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer.;  citation_journal_title=Lancet.;  citation_year=1997;  citation_volume=350;  citation_pages=1047-1059.; " /><meta name="citation_reference" content="citation_org=for the HERS Research Group; citation_title=Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study Follow-up (HERS II).;  citation_authors=Hulley  S; Furberg  C; Barrett-Connor  E;  citation_journal_title=JAMA.;  citation_year=2002;  citation_volume=288;  citation_pages=58-66.; " /><meta name="citation_reference" content="citation_title=Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk.;  citation_authors=Schairer  C; Lubin  J; Troisi  R; Sturgeon  S; Brinton  L; Hoover  R;  citation_journal_title=JAMA.;  citation_year=2000;  citation_volume=283;  citation_pages=485-491.; " /><meta name="citation_reference" content="citation_title=Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin.;  citation_authors=Ross  RK; Paganini-Hill  A; Wan  PC; Pike  MC;  citation_journal_title=J Natl Cancer Inst.;  citation_year=2000;  citation_volume=92;  citation_pages=328-332.; " /><meta name="citation_reference" content="citation_title=The use of estrogens and progestins and the risk of breast cancer in postmenopausal women.;  citation_authors=Colditz  GA; Hankinson  SE; Hunter  DJ;  citation_journal_title=N Engl J Med.;  citation_year=1995;  citation_volume=332;  citation_pages=1589-1593.; " /><meta name="citation_reference" content="citation_title=Breast-cancer risk following long-term oestrogen and oestrogen-progestin-replacement therapy.;  citation_authors=Magnusson  C; Baron  JA; Correia  N; Bergstrom  R; Adami  H-O; Persson  I;  citation_journal_title=Int J Cancer.;  citation_year=1999;  citation_volume=81;  citation_pages=339-344.; " /><meta name="citation_reference" content="citation_title=Effects of estrogen and estrogen-progestin on mammographic parenchymal density.;  citation_authors=Greendale  GA; Reboussin  BA; Sie  A;  citation_journal_title=Ann Intern Med.;  citation_year=1999;  citation_volume=130;  citation_pages=262-269.; " /><meta name="citation_reference" content="citation_title=Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis.;  citation_authors=Grodstein  F; Newcomb  PA; Stampfer  MJ;  citation_journal_title=Am J Med.;  citation_year=1999;  citation_volume=106;  citation_pages=574-582.; " /><meta name="citation_reference" content="citation_title=Hormone replacement therapy and cardiovascular disease: the case for a randomized controlled trial.;  citation_authors=Vickers  MR; Meade  TW; Wilkes  HC;  citation_journal_title=Ciba Found Symp.;  citation_year=1995;  citation_volume=191;  citation_pages=150-160.; " /><meta name="citation_reference" content="citation_title=Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials.;  citation_authors=Torgerson  DJ; Bell-Seyer  SE;  citation_journal_title=JAMA.;  citation_year=2001;  citation_volume=285;  citation_pages=2891-2897.; " /><meta name="citation_reference" content="citation_org=Writing Group for the PEPI Trial; citation_title=Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.;  citation_journal_title=JAMA.;  citation_year=1996;  citation_volume=275;  citation_pages=1389-1396.; " /><meta name="citation_reference" content="citation_title=Hormone replacement therapy and cardiovascular disease: a statement for healthcare professionals from the American Heart Association.;  citation_authors=Mosca  L; Collins  P; Herrington  DM;  citation_journal_title=Circulation.;  citation_year=2001;  citation_volume=104;  citation_pages=499-503.; " /><meta name="citation_fulltext_world_readable" content="" /><meta name="citation_pdf_url" content="https://jamanetwork.com/journals/jama/articlepdf/195120/joc21036.pdf" />

    
        <title>Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial | Breast Cancer | JAMA | JAMA Network</title>

    <meta name="description" content="ContextDespite decades of accumulated observational evidence, the balance of
risks and benefits for hormone use in healthy postmenopausal women">


    <link rel="canonical" href="https://jamanetwork.com/journals/jama/fullarticle/195120" />









    
    <script src="//cdn.jamanetwork.com/UI/app/dist/head.min.js?v=638488852268208351"></script>
     
     <script src="https://r451.jamanetwork.com/script.js"></script>
        <div class="widget-WidgetLoader widget-instance-AMA_AdTag_HeaderScript">
        
    <meta class="SCM-SharedWidgets-AsyncHeaderAdLoader" data-url="/AMA/AdTag/AMA_AdTag_HeaderScript" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:0,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}">
 
    </div>
</head>

<body data-sitename="jama" class="pg_article " data-thm="jama">
    
    <script>
        
        var App = App || {};
        App.suppressAds = App.suppressAds || !!document.getElementsByClassName('suppress-ads').length;
        App.suppressGtm = App.suppressGtm || !!document.getElementsByClassName('suppress-gtm').length;
    </script>

    

        <div id="ad-interstitial" class="ad-interstitial">
            <script>
      googletag.cmd.push(function() {
        if (App.suppressAds) { return; }
        App.Ads.slots[13] = googletag.defineOutOfPageSlot(App.Ads.adPath + '/scholarly', 'ad-interstitial')
          .setTargeting('pos', ['interstitial'])
          .addService(googletag.pubads());
        googletag.display('ad-interstitial');
        googletag.pubads().refresh([App.Ads.slots[13]], {changeCorrelator: false});
      });
            </script>
        </div>




    
    <a class="accessible js-skip-to-navigation" href="#skip-to-navigation">[Skip to Navigation]</a>

    <!-- Google Tag Manager --><noscript><iframe src="//www.googletagmanager.com/ns.html?id=GTM-WNKSNP" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript><script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='//www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-WNKSNP');</script><!-- End Google Tag Manager -->

    
    
    <span class="hide tagmanagervalue" data-attribute="productName" data-value="JAMA" data-type="string"></span>
    <form method="post" action="./195120" id="webform" class="m0">
<input type="hidden" name="__VIEWSTATE" id="__VIEWSTATE" value="lMerW+jYJBRPlMW6T1w8zzAY9pJBsbHkfOXNm+IIxzQGYD0YqSUBwat2dR+glBR20X8d8ltGaxofTUwddiZLswNU8VA=" />

<input type="hidden" name="__VIEWSTATEGENERATOR" id="__VIEWSTATEGENERATOR" value="2173C2F0" />
<input type="hidden" name="__EVENTVALIDATION" id="__EVENTVALIDATION" value="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" />
        
        <input id="hdnSiteID" type="hidden" value="3" />
        <input id="hdnDomain" type="hidden" value=".jamanetwork.com" />

        
        

        
        

    <section class="master-header">
        


<script type='text/javascript'>
    var App = App || {};
    App.LoginUserInfo = {
        isInstLoggedIn: [0],
        currentSessionId: 'oah5pfi3oh1jltlxiplz3wny'
    };
</script>



<input name="ctl00$ctl00$BodyContent$Header$hfGlobalSearchSiteURL" type="hidden" id="hfGlobalSearchSiteURL" value="https://jamanetwork.com/" />

<input name="ctl00$ctl00$BodyContent$Header$hfAppIsPaidUser" type="hidden" id="hfAppIsPaidUser" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsMember" type="hidden" id="hfAppIsMember" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppSubscribedTo" type="hidden" id="hfAppSubscribedTo" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsIndividual" type="hidden" id="hfAppIsIndividual" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppHasAccess" type="hidden" id="hfAppHasAccess" value="false" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsReferredFromGoogle" type="hidden" id="hfAppIsReferredFromGoogle" value="False" />
<input name="ctl00$ctl00$BodyContent$Header$hfSolrAutoSuggestMinimumCharactersLength" type="hidden" id="hfSolrAutoSuggestMinimumCharactersLength" value="2" />
<input name="ctl00$ctl00$BodyContent$Header$hfSolrJournalName" type="hidden" id="hfSolrJournalName" value="JAMA" />
<input name="ctl00$ctl00$BodyContent$Header$hfSolrJournalID" type="hidden" id="hfSolrJournalID" value="J67" />
<input name="ctl00$ctl00$BodyContent$Header$hfAppIsLucy" type="hidden" id="hfAppIsLucy" value="false" />


<div class="header-wrap">
    <header class="header">
            <div class="widget-GdprCookieBanner widget-instance-GdprCookieBanner">
        <div class="gdpr-cookie-wrapper js-gdpr-banner">
	<div class="gdpr-cookie-body">
Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our <a href="https://jamanetwork.com/pages/privacy-policy#cookies">Cookie Policy</a>&nbsp;<span class="pipe">|</span>&nbsp;<a href="javascript:;" class="js-gdpr-cookie-acceptLink at-acceptgdpr">Continue</a>	</div>
            <input id="hdnDomain" type="hidden" value=".jamanetwork.com" />

    <input id="hdnDomainGdpr" type="hidden" value=".jamanetwork.com" />
    <input id="hdnClientIdGdpr" type="hidden" value="3" />

</div> 
    </div>

        <div class="network-bar">
            <a class="jama-network" href="/" title="JAMA Network Home">
                <img alt="JAMA Network Home" class="title-image" width="443" height="52" src="//cdn.jamanetwork.com/UI/app/svg/Jama_Network_Logo.svg">
            </a>
            
        </div>

        <a class="nav-toggler" href="#nav">
            <div class="nav-toggler-indicator">
                <span class="indicator-stroke"></span>
                <span class="indicator-stroke"></span>
                <span class="indicator-stroke"></span>
                <span class="indicator-stroke"></span>
            </div>
            <div class="nav-toggler-site">
                <span id="BodyContent_Header_siteFullNamenav" class="nav-toggler-microsite"><span class='network'>JAMA</span></span>
            </div>
        </a>
        <nav id="nav" class="nav hide" >
            <div class="nav-journal-level sb-nav-journal-level">
                <a href="https://jamanetwork.com/journals/jama" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_0" class="home">Home</a><a href="https://jamanetwork.com/journals/jama/newonline" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_1" class="new-online">New Online</a><a href="https://jamanetwork.com/journals/jama/currentissue" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_2" class="current-issue">Current Issue</a><a href="https://jamanetwork.com/journals/jama/pages/for-authors" id="BodyContent_Header_rptMicrositeHeaders_aItemResourceList_3" class="for-authors">For Authors</a>
            </div>
            <div class="nav-journals">
                    <div class="widget-SelfServeContent widget-instance-HamburgerPublicationMenu">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="HamburgerPublicationMenu" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .nav-journals {margin-bottom: 1em;}
    .nav-heading {color: #B9B9B9;border-bottom: 1px solid #242424;border-top: 1px solid #242424;font-size: 1.15em;font-weight: 400;margin: 0;padding: .7em .75em;text-transform: uppercase;}
    a.no-bullet:before {content:none !important;}
    .nav-heading {font-size: 1.15em;margin-bottom:0;padding-left: 38px;}
    .nav-journals a.theme-jama {background-color: #242424;border-bottom: 1px solid #fff;border-top: 1px solid #fff;color: #fff;font-size: 1.15em;margin-bottom: 8px;padding: 11px 0 9px 37px;}
    .nav-journals a.theme-jama::before {background: unset;content: "\e91b";display: none;font-family: ama_icons !important;font-size: 1.25em;line-height: 1;}
    .nav-journals a.theme-jama-network-open {border-bottom:0;}
    .nav .widget-instance-HamburgerPublicationMenu a {padding-left: 36px;}
    .fake-ribbon {border-left: 8px solid #BE1E32;}
    .fake-ribbon a:before {content:none;}
    .nav .widget-instance-HamburgerPublicationMenu .fake-ribbon a {padding-left:30px;}
</style>
<h2 class="nav-heading">Journals</h2>
<a href="/journals/jama" class="theme-jama">JAMA</a>
<a href="/journals/jamanetworkopen" class="theme-jama-network-open">JAMA Network Open</a>
<a href="/journals/jamacardiology" class="theme-jama-cardiology">JAMA Cardiology</a>
<a href="/journals/jamadermatology" class="theme-jama-dermatology">JAMA Dermatology</a>
<a href="/journals/jama-health-forum" class="theme-jama-health-forum">JAMA Health Forum</a>
<a href="/journals/jamainternalmedicine" class="theme-jama-internal-medicine">JAMA Internal Medicine</a>
<a href="/journals/jamaneurology" class="theme-jama-neurology">JAMA Neurology</a>
<a href="/journals/jamaoncology" class="theme-jama-oncology">JAMA Oncology</a>
<a href="/journals/jamaophthalmology" class="theme-jama-ophthalmology">JAMA Ophthalmology </a>
<a href="/journals/jamaotolaryngology" class="theme-jama-otolaryngology-head-neck-surgery">JAMA OtolaryngologyHead &amp; Neck Surgery</a>
<a href="/journals/jamapediatrics" class="theme-jama-pediatrics">JAMA Pediatrics</a>
<a href="/journals/jamapsychiatry" class="theme-jama-psychiatry">JAMA Psychiatry</a>
<a href="/journals/jamasurgery" class="theme-jama-surgery">JAMA Surgery</a>
<a href="/journals/archneurpsyc" class="theme-archives-of-neurology-psychiatry-1919-1959-">Archives of Neurology &amp; Psychiatry (1919-1959)</a>
<h2 class="nav-heading">Podcasts</h2>
<a href="/journals/jama/pages/jama-clinical-reviews">Clinical Reviews</a>
<a href="/journals/jama/pages/jama-editors-summary">Editors' Summary</a>
<a href="/journals/jama/pages/jama-medical-news">Medical News</a>
<a href="/journals/jama/pages/jama-author-interviews">Author Interviews</a>
<a href="/pages/audio" class="no-bullet">More</a>


</div>

 
    </div>
    
            </div>
            <div class="nav-network-other">
                <a href="https://edhub.ama-assn.org/jn-learning" id="BodyContent_Header_rptOtherResources_aItemResourceList_0" class="is-b link-jn-learning-cme" target="_blank">JN Learning / CME</a><a href="https://store.jamanetwork.com/index.aspx?productcode=64" id="BodyContent_Header_rptOtherResources_aItemResourceList_1" class="is-b link-subscribe" target="_blank">Subscribe</a><a href="https://careers.jamanetwork.com/" id="BodyContent_Header_rptOtherResources_aItemResourceList_2" class="is-b link-jobs" target="_blank">Jobs</a><a href="https://jamanetwork.com/pages/resources-for-librarians" id="BodyContent_Header_rptOtherResources_aItemResourceList_3" class="is-b link-institutions-librarians">Institutions / Librarians</a><a href="https://jamanetwork.com/pages/reprints-and-permissions" id="BodyContent_Header_rptOtherResources_aItemResourceList_4" class="is-b link-reprints-permissions" rel="nofollow">Reprints &amp; Permissions</a>
            </div>
            <div class="white text-xxs">
                <div class="p05 ml4 mr3 mb1 mt10 flex hamburger-menu-legal">
                    <a href="/pages/conditions-of-use" class="p0" rel="nofollow">Terms of Use</a>
                    <span class="pl1 pr1">| </span>
                    <a href="/pages/privacy-policy" class="p0" rel="nofollow">Privacy Policy</a>
                    <span class="pl1 pr1">| </span>
                    <a href="/pages/accessibility-statement" class="p0" rel="nofollow">Accessibility Statement</a>
                </div>
                <div class="ta-c">
                    <span class="pb1">2024 American Medical Association. All Rights Reserved</span>
                </div>
            </div>
        </nav>

        

        
        <a class="toolbar-search-trigger is-b" data-mobile-tog-target=".site-search"></a>

        
        <div id="site-search" role="search" class="site-search">
            <div class="site-search-bar">
                
                <div role="search">
                    <select name="ctl00$ctl00$BodyContent$Header$ddlForSearch" id="BodyContent_Header_ddlForSearch" Name="dropDownList" class="cs-select cs-skin-border" title="Search Site Selector" role="options" aria-labelledby="searchLabel">
	<option value="J*">Search All</option>
	<option value="3">JAMA</option>
	<option value="214">JAMA Network Open</option>
	<option value="192">JAMA Cardiology</option>
	<option value="12">JAMA Dermatology</option>
	<option value="261">JAMA Forum Archive</option>
	<option value="193">JAMA Health Forum</option>
	<option value="15">JAMA Internal Medicine</option>
	<option value="16">JAMA Neurology</option>
	<option value="159">JAMA Oncology</option>
	<option value="17">JAMA Ophthalmology</option>
	<option value="18">JAMA OtolaryngologyHead &amp; Neck Surgery</option>
	<option value="19">JAMA Pediatrics</option>
	<option value="14">JAMA Psychiatry</option>
	<option value="20">JAMA Surgery</option>
	<option value="23">Archives of Neurology &amp; Psychiatry</option>

</select>
                </div>
                
                <div class="search-input-container">
                    <input type="search" name="textbox" autocomplete="off" role="textbox" id="search-term" aria-labelledby="searchLabel" class="search-term at-microsite-search-term" placeholder="Enter Search Term" maxlength="255" title="Enter Search Term">
                  
                    <ul id="umbrellaSiteAutoCompleteResults" class="term-list hidden"></ul>
                    
                    <label style="display:none" for="umbrellaSiteSearchInputHint" id="searchLabel">Input Search Term</label>
                      <input class="searchTerm search-input" name="textbox" role="textbox" type="text" id="umbrellaSiteSearchInputHint" aria-labelledby="searchLabel" title="Input Search Term" autocomplete="off">
                </div>
                <!-- /.search-input-container -->
                
                <a name="button" role="button" class="search-button is-b" alt="search button" href="javascript:;"></a>
            </div>
        </div>
        
        <div id="BodyContent_Header_GlobalSignIn_auth" class="auth">
            <a class="auth--trigger is-b is-a" href="javascript:;">
                <span id="BodyContent_Header_GlobalSignIn_spnUserFullName" class="user-full-name">Sign In</span>
            </a>

            <div class="auth--dropdown js-signIn-dropdown">
                
                <div class="auth--option auth--ind">
                    
                    <div id="BodyContent_Header_GlobalSignIn_divUserFullName" class="auth--ind-user"></div>                    
                    
                    <div id="BodyContent_Header_GlobalSignIn_divIndSignIn" class="auth--ind-auth">
                        <div class="auth--title">Individual Sign In</div>
                        <a href="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195120" id="BodyContent_Header_GlobalSignIn_oauthSignInLink" rel="nofollow" class="auth--ind-sign-in">Sign in</a><a href="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195120" id="BodyContent_Header_GlobalSignIn_oauthSignUpLink" rel="nofollow" class="auth--ind-create">Create an Account</a>
                    </div>
                </div>

                
                <div id="BodyContent_Header_GlobalSignIn_divInstSignIn" class="auth--option auth--inst">

                    
                    
                    <div class="auth--inst-auth">
                        <div class="auth--title">Access through your institution</div>
                        <a href="/signinshibboleth?returnUrl=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195120" id="BodyContent_Header_GlobalSignIn_institutionSignIn" rel="nofollow" class="auth--shib">Sign In</a>
                    </div>
                    </div>
 
                                               
                <div id="BodyContent_Header_GlobalSignIn_divPurchaseOptions" class="auth--option auth--purchase">
                    <div class="auth--title">Purchase Options:</div>
                    
                    <a id="BodyContent_Header_GlobalSignIn_lnkSubscribeJournal" class="auth--subscribe" rel="nofollow" href="https://store.jamanetwork.com/index.aspx?productcode=64">Subscribe to the JAMA journal</a>
                </div>

                
                

                
            </div>
        </div>




    </header>
</div>


<div class="editors-choice-header">
</div>

<div id="BodyContent_Header_divAds" class="header-ad-wrap sb-background-primary-dark">
        <div class="leader-ad desktop-only">
            
                <div class="widget-WidgetLoader widget-instance-AMA_AdTag_LeaderboardAd">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_LeaderboardAd" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:1,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;atf&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

        </div>
    </div>

<!-- /.header-ad-wrap -->


    </section>


    <section class="master-main">
        
    <div class="social-share hide" data-share-journal="JAMA_current" data-share-title="Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women"></div>

        <div class="widget-UserContentAccessWrite widget-instance-AMA_LocalStorage_Article">
        <div class="SCM-SharedWidgets-LocalStorage-UserContentAccessWrite" data-values='{"id":"195120","type":"Article","date":"5/5/2024 6:38:56 AM"}'></div>
 
    </div>
    <div class="widget-ArticleToggleView widget-instance-AMA_ArticleToggleView">
        
    <div class="widget-ArticleFullView widget-instance-AMA_ArticleFullView">
        
<script>
    (function () {
        var bodyElem = document.querySelector('body');
        var className = 'split-screen';

        if (bodyElem.classList) {
            bodyElem.classList.add(className);
        } else {
            el.className += ' ' + className;
        }
    })();
</script>


<div id="resources-panel" class="resources-panel">
                <span class="hide tagmanagervalue" data-attribute="template" data-value="splitscreen" data-type="string"></span>


    <div class="tab-nav">
        <a class="tab-nav-trigger tab-nav-full-text tablet-down" href="#full-text-tab">
            <i class="icon-full_text"><span class="sr-t">full text icon</span></i>
            <div class="tab-nav-tab-name">Full Text</div>
        </a>
        <a class="tab-nav-trigger tab-nav-contents target-tab-active" href="#contents-tab">
            <i class="icon-contents"><span class="sr-t">contents icon</span></i>
            <div class="tab-nav-tab-name">Contents</div>
        </a>
        <a class="tab-nav-trigger tab-nav-figure-table" href="#figure-table-tab">
            <i class="icon-figures"><span class="sr-t">figure icon</span></i>
            <div class="tab-nav-tab-name">Figures / <br> Tables</div>
        </a>
        <a class="tab-nav-trigger tab-nav-multimedia" href="#multimedia-tab">
            <i class="icon-multimedia"><span class="sr-t">multimedia icon</span></i>
            <div class="tab-nav-tab-name">Multimedia</div>
        </a>
        <a class="tab-nav-trigger tab-nav-supplemental" href="#supplemental-tab">
            <i class="icon-attach"><span class="sr-t">attach icon</span></i>
            <div class="tab-nav-tab-name">Supplemental <br> Content</div>
        </a>
        <a class="tab-nav-trigger tab-nav-references" href="#references-tab">
            <i class="icon-references"><span class="sr-t">references icon</span></i>
            <div class="tab-nav-tab-name">References</div>
        </a>
        <a class="tab-nav-trigger tab-nav-related" href="#related-tab">
            <i class="icon-related"><span class="sr-t">related icon</span></i>
            <div class="tab-nav-tab-name">Related</div>
        </a>
        <a class="tab-nav-trigger tab-nav-comments" href="#comments-tab">
            <i class="icon-user-comments"><span class="sr-t">comments icon</span></i>
            <div class="tab-nav-tab-name">Comments</div>
        </a>
    </div>



    <div class="resource-tabs">
        <div id="contents-tab" class="resource-tab js-resource-tab contents-tab tab-active">
            <div class="contents-tab-contents">
            <a id="pdf-link" class="toolbar-tool toolbar-pdf al-link pdfaccess" data-article-id="195120" data-article-url="/journals/jama/articlepdf/195120/joc21036.pdf" data-ajax-url="/Content/CheckPdfAccess"><span class="toolbar-pdf-text"><span class="toolbar-link-text-extra">Download </span><span class="toolbar-link-text">PDF</span></span>
            </a>
    <div class="widget-ArticleJumpLinks widget-instance-AMA_ArticleJumpLinks_Widget">
            <a href="#top" class="section-jump-link contents-tab-jump-link top-of-article" data-tab-toggle=".tab-nav-full-text">Top of Article</a>
    <ul class="section-jump-links bullet ml2 pl1">
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#25024139" data-tab-toggle=".tab-nav-full-text">Abstract</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#25024150" data-tab-toggle=".tab-nav-full-text">Methods</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#25024175" data-tab-toggle=".tab-nav-full-text">Results</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#25024210" data-tab-toggle=".tab-nav-full-text">Comment</a></li>
                <li><a class="section-jump-link contents-tab-jump-link scroll-to head-1" href="#25024238" data-tab-toggle=".tab-nav-full-text">References</a></li>
    </ul>
 
    </div>
    <div class="widget-SelfServeContent widget-instance-AMA_Contents_Tab_SelfServe">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="v2_article_content_tab" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="bc_right_rail_article_promo"><!-- Content Goes Here --></div>


</div>

 
    </div>

            </div>
            <div class="contents-tab-ad">
                <div id="split-screen-contab"></div>
            </div>
        </div>

        
        <div id="figure-table-tab" class="resource-tab js-resource-tab figure-table-tab need-jobs-ad">
    <div class="widget-ArticleFiguresAndTables widget-instance-AMA_Article_Figures_Tab">
        <div class="figure-table-wrapper figure-no-label thm-bd-top"><strong>Figure 1.</strong> Profile of the Estrogen Plus Progestin
Component of the Women's Health Initiative<a id="Joc21036f1" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="Joc21036f1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f1.gif?Expires=1717486247&amp;Signature=OKs5z8BnuBPLl7OHepCDspVVDAr4lgltoBlGXXGjIglUezf2oXmUcLqZpV~LfFgWOwNQzl~REy6lVCNzqaVpQ4JZOcISh7wKhOLNP12FyUMKm14QZm~4m53-fhMhS6UcMxby8snVIyvyvoAS-09RfJF-tM5g1NdghmvRzvSxeBkKoCR4VbY5TKdggp2RnawpBE95QdwKG5LqPiGk~p7q9mjTw0TpQowi6ztzgqQxH3XtnDpGKoskjEnug5X~cJSEpE1Vwjw33v~1JVqgFTgBSNKCiSQgYK6Keu4kC-DhHq45WXTMhYEFqn1SB2Vifo6ShbyvUxMGmBGgCKngxr34aQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="Joc21036f1" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f1.gif?Expires=1717486247&Signature=OKs5z8BnuBPLl7OHepCDspVVDAr4lgltoBlGXXGjIglUezf2oXmUcLqZpV~LfFgWOwNQzl~REy6lVCNzqaVpQ4JZOcISh7wKhOLNP12FyUMKm14QZm~4m53-fhMhS6UcMxby8snVIyvyvoAS-09RfJF-tM5g1NdghmvRzvSxeBkKoCR4VbY5TKdggp2RnawpBE95QdwKG5LqPiGk~p7q9mjTw0TpQowi6ztzgqQxH3XtnDpGKoskjEnug5X~cJSEpE1Vwjw33v~1JVqgFTgBSNKCiSQgYK6Keu4kC-DhHq45WXTMhYEFqn1SB2Vifo6ShbyvUxMGmBGgCKngxr34aQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25024156&ar=195120&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f1.gif?Expires=1717486247&amp;Signature=OKs5z8BnuBPLl7OHepCDspVVDAr4lgltoBlGXXGjIglUezf2oXmUcLqZpV~LfFgWOwNQzl~REy6lVCNzqaVpQ4JZOcISh7wKhOLNP12FyUMKm14QZm~4m53-fhMhS6UcMxby8snVIyvyvoAS-09RfJF-tM5g1NdghmvRzvSxeBkKoCR4VbY5TKdggp2RnawpBE95QdwKG5LqPiGk~p7q9mjTw0TpQowi6ztzgqQxH3XtnDpGKoskjEnug5X~cJSEpE1Vwjw33v~1JVqgFTgBSNKCiSQgYK6Keu4kC-DhHq45WXTMhYEFqn1SB2Vifo6ShbyvUxMGmBGgCKngxr34aQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="Joc21036f1" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/m_joc21036f1.gif?Expires=1717486247&amp;Signature=iAcFVpMxlbasLgMQH97XiK-2uXxc6VI1p7yjX01UB1kHCZURN21qArF-Pf5L0LFA25gtymHit7mctLDf33xDSpUcGKE-FlpcssWhPGjyr~-h9ebPowtzBUraaO3R0DC6S4yOSXKK7vkD16V3O69x4mfGEe2h8OtBMSdMmCsMYxd-My2pobHqmyYFrRZWKP3e6lAJ-Iavpcb7gcEzF9MxBLPywOzhjJy2ahEhs8uR8PpDHdVV~JKJAlO22Xi54AiXYEC7mt~hcVFHq7keJAcr1cagVPEs5az3Y9OyUNE4ZnxfPhWyN-Z19Chrm89yJIEUoItRmSSNlOLQsvsrwQjJ4A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="Joc21036f1" /></a></div></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><strong>Figure 2.</strong> Cumulative Dropout and Drop-in Rates
by Randomization Assignment and Follow-up Duration<a id="Joc21036f2" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="Joc21036f2" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f2.gif?Expires=1717486247&amp;Signature=4ifT-hz4ZNz8dtKhHOs-XxS~MJkEmGCOl137~AuxLZA7xYp1g-ubm83cvcrcO0sxnhyVDp~W8xRCRw4yjsQKH72lG7KBA92QJjl8nxSS~3IeF1A0BBiNSubN1DL~sdRLaWtVcra8ydHgsWiC0EOymg3XUKJB3KkkY-ROX35G7eihMsyLQ-4wOnh0CGdYCzjmc8upoInfn8~1sP7GAsEscpdXtC5BwnvJuEKxldmeJXE-JBUYntl~Cp5~4aWnbcxeRUQyRJ89HfpLWRFRGpWx7XVXMrdjk6O~RGztd52o5RVl11BeHmwpubc9YB-5NUEnhdgYOIJoaJXW4ywPII3j-A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="Joc21036f2" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f2.gif?Expires=1717486247&Signature=4ifT-hz4ZNz8dtKhHOs-XxS~MJkEmGCOl137~AuxLZA7xYp1g-ubm83cvcrcO0sxnhyVDp~W8xRCRw4yjsQKH72lG7KBA92QJjl8nxSS~3IeF1A0BBiNSubN1DL~sdRLaWtVcra8ydHgsWiC0EOymg3XUKJB3KkkY-ROX35G7eihMsyLQ-4wOnh0CGdYCzjmc8upoInfn8~1sP7GAsEscpdXtC5BwnvJuEKxldmeJXE-JBUYntl~Cp5~4aWnbcxeRUQyRJ89HfpLWRFRGpWx7XVXMrdjk6O~RGztd52o5RVl11BeHmwpubc9YB-5NUEnhdgYOIJoaJXW4ywPII3j-A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25024186&ar=195120&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f2.gif?Expires=1717486247&amp;Signature=4ifT-hz4ZNz8dtKhHOs-XxS~MJkEmGCOl137~AuxLZA7xYp1g-ubm83cvcrcO0sxnhyVDp~W8xRCRw4yjsQKH72lG7KBA92QJjl8nxSS~3IeF1A0BBiNSubN1DL~sdRLaWtVcra8ydHgsWiC0EOymg3XUKJB3KkkY-ROX35G7eihMsyLQ-4wOnh0CGdYCzjmc8upoInfn8~1sP7GAsEscpdXtC5BwnvJuEKxldmeJXE-JBUYntl~Cp5~4aWnbcxeRUQyRJ89HfpLWRFRGpWx7XVXMrdjk6O~RGztd52o5RVl11BeHmwpubc9YB-5NUEnhdgYOIJoaJXW4ywPII3j-A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="Joc21036f2" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/m_joc21036f2.gif?Expires=1717486247&amp;Signature=vkzdiG6DA6~yHmaoVGeNmfuZp8esv712Dg82YVjF4VD~iSumZiJWeJytn05gXDCIunqNvhuWPw0JvL1DQfRGCbAnNGL5RsMi7zS8-Tb5uHPWmHeA4K4okg38mKbG0MFd5jnAePfKi0qQMjWGpNfD2top~B47dtdgZjFI75zuMh21gvaGB9TT7QJe2FfrVb9ryaDGkgX4rOEVRl8C2zzpP08hyAfgKQPIWGCZe9SkUxmU6icrX2uwA6TNeI3YJMY-EppH9Cu2lBjfaxOFrZGV4gaFyR3MQ3B3rHl-GSdsQPXnhZmXW-zFsmQsIqFpgADxN40PCH51cYkea1C-vXZ3SA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="Joc21036f2" /></a></div></div><div class="figure-caption clip-last-child">Dropout refers to women who discontinued study medication; drop-in,
women who discontinued study medication and received postmenopausal hormones
through their own clinician.</div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><strong>Figure 3.</strong> Kaplan-Meier Estimates of Cumulative
Hazards for Selected Clinical Outcomes<a id="Joc21036f3" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="Joc21036f3" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f3.gif?Expires=1717486247&amp;Signature=zIkjp930G1~Nhopa0slerXQesCPGkTtR0QOk-mc6uqf9X7ABmdsjaPAmGf5dfFHR9GpoiTGpIjvKNypMfcBlroE0ovC1C6vB5BSAk6GxwGMYwMtYFwaRripxc1TEMrkPU8tQLU4fujDdFxZEzUOuj2dB4lRPhpMCi-uGdZcD4~YhVPHYnsalsfzjDdhoNnFPxzZZnleeBcmW-gmhACMWB3N0kqLBEMO~kS8wbHNBOj4y8xi8Ofr7hW4k6fj7AkYDt97nvhmsHI6n29cMQYmrN0KzcI75d-9BgpJ9YF-28mjFLvhVyRYAU~yYDjf4urz9wiIwJx-f-DL235S3nPGcfg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="Joc21036f3" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f3.gif?Expires=1717486247&Signature=zIkjp930G1~Nhopa0slerXQesCPGkTtR0QOk-mc6uqf9X7ABmdsjaPAmGf5dfFHR9GpoiTGpIjvKNypMfcBlroE0ovC1C6vB5BSAk6GxwGMYwMtYFwaRripxc1TEMrkPU8tQLU4fujDdFxZEzUOuj2dB4lRPhpMCi-uGdZcD4~YhVPHYnsalsfzjDdhoNnFPxzZZnleeBcmW-gmhACMWB3N0kqLBEMO~kS8wbHNBOj4y8xi8Ofr7hW4k6fj7AkYDt97nvhmsHI6n29cMQYmrN0KzcI75d-9BgpJ9YF-28mjFLvhVyRYAU~yYDjf4urz9wiIwJx-f-DL235S3nPGcfg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25024200&ar=195120&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f3.gif?Expires=1717486247&amp;Signature=zIkjp930G1~Nhopa0slerXQesCPGkTtR0QOk-mc6uqf9X7ABmdsjaPAmGf5dfFHR9GpoiTGpIjvKNypMfcBlroE0ovC1C6vB5BSAk6GxwGMYwMtYFwaRripxc1TEMrkPU8tQLU4fujDdFxZEzUOuj2dB4lRPhpMCi-uGdZcD4~YhVPHYnsalsfzjDdhoNnFPxzZZnleeBcmW-gmhACMWB3N0kqLBEMO~kS8wbHNBOj4y8xi8Ofr7hW4k6fj7AkYDt97nvhmsHI6n29cMQYmrN0KzcI75d-9BgpJ9YF-28mjFLvhVyRYAU~yYDjf4urz9wiIwJx-f-DL235S3nPGcfg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="Joc21036f3" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/m_joc21036f3.gif?Expires=1717486247&amp;Signature=N6Hy9rfkk-ESZmUxgP~Yt4pQJSNCFT-7Hb0QVqDe2mSJrDtiVmZ787B1MJrzqJ6wRJ0jxk8Hq3INFmj5Zp~UYILqmTZdDnA3CYxTavNcTUhKkTB9axqr2mDqlzjRvTDSHvhZ7J-v7IhYHnzXC6AzQn5uqceFYjA65Wsq8z78FVeVDPSh70q~mOXJCNspU0DpUdBPXd27kTQqvb83jTuxBRdBnWUo2y6IZCbI9LutUgvUXS-QTLF~E7xFXz-7ze~ssMuf2ylxGGQ0V9kD5DvlJU9yvg3XAtqe2CDwANDrTi2hRH1Xrjlsd9t4h94miSwQJNr8K8KX1idD4dubkw24Ng__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="Joc21036f3" /></a></div></div><div class="figure-caption clip-last-child">HR indicates hazard ratio; nCI, nominal confidence interval; and
aCI, adjusted confidence interval.</div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><strong>Figure 4.</strong> Kaplan-Meier Estimates of Cumulative
Hazards for Global Index and Death<a id="Joc21036f4" class="figure-table-anchor"> </a><div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="Joc21036f4" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f4.gif?Expires=1717486247&amp;Signature=KXBaFOeybi26iEubMZY20UaRpL5LX61UEeF77JsWAet0gzg0kNYjEB5sY3Nf8~kK6VRW3Hte-iQzkzubvPGuuFtPRRpOCM~UJ1K2RirOiV8YkdW~u2uplJvTGPqTGdKZYBKJbuYjGudUF6CNH3xv5SWStKQOeQd0V7tvezczyICc2Mal6PthBqYIpn~xH0FjA0GKxNnvWAjYMN1WhSQ4aSpzLpkIcDk2AZh8VNle3KFySb~BrixPxS7MF2h4iXRAUDplDhiTk7GUdtAdWULGwgBPcAtrI2FbD9ISaZX3bYjbEzA1oGZBxjr6SgsOOMi1L1U2ZTlFO7Kho6PmTXImcA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="Joc21036f4" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f4.gif?Expires=1717486247&Signature=KXBaFOeybi26iEubMZY20UaRpL5LX61UEeF77JsWAet0gzg0kNYjEB5sY3Nf8~kK6VRW3Hte-iQzkzubvPGuuFtPRRpOCM~UJ1K2RirOiV8YkdW~u2uplJvTGPqTGdKZYBKJbuYjGudUF6CNH3xv5SWStKQOeQd0V7tvezczyICc2Mal6PthBqYIpn~xH0FjA0GKxNnvWAjYMN1WhSQ4aSpzLpkIcDk2AZh8VNle3KFySb~BrixPxS7MF2h4iXRAUDplDhiTk7GUdtAdWULGwgBPcAtrI2FbD9ISaZX3bYjbEzA1oGZBxjr6SgsOOMi1L1U2ZTlFO7Kho6PmTXImcA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25024201&ar=195120&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036f4.gif?Expires=1717486247&amp;Signature=KXBaFOeybi26iEubMZY20UaRpL5LX61UEeF77JsWAet0gzg0kNYjEB5sY3Nf8~kK6VRW3Hte-iQzkzubvPGuuFtPRRpOCM~UJ1K2RirOiV8YkdW~u2uplJvTGPqTGdKZYBKJbuYjGudUF6CNH3xv5SWStKQOeQd0V7tvezczyICc2Mal6PthBqYIpn~xH0FjA0GKxNnvWAjYMN1WhSQ4aSpzLpkIcDk2AZh8VNle3KFySb~BrixPxS7MF2h4iXRAUDplDhiTk7GUdtAdWULGwgBPcAtrI2FbD9ISaZX3bYjbEzA1oGZBxjr6SgsOOMi1L1U2ZTlFO7Kho6PmTXImcA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="Joc21036f4" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/m_joc21036f4.gif?Expires=1717486247&amp;Signature=zWowDB4gnPEo3O~hphYQ7TbQyrCttYzg55NgS40X~y7~5MP9JxrW~WFbBdIbPg0qcF1iZvE7CTEsfy73EFh5~K6lH7OQmLwYeJn5nS2SpKZZIWZqdiYJg0EA1bSkCr9AREwvh4htXiCTApbLBilP1adgj81tBb4xTtztb1gFCFxc0xwhRHoLhbkoxOJuPTjusUxxVMS99bJLvPvxW~QdzpuMH-tnyrK~SWm39gQeOMtVXkZXx4FB8BB7GI1tlxnP04RrhzaCF2dH0I4vo5ix5zPO-bK11GaG70lWe~jy7rDa11cQKF~1s1j2k9sg4N3nTfQnLGmgkxJBWPARRk59zQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="Joc21036f4" /></a></div></div><div class="figure-caption clip-last-child">HR indicates hazard ratio; nCI, nominal confidence interval; and
aCI, adjusted confidence interval.</div></div> 
    </div>
    <div class="widget-ArticleFiguresAndTables widget-instance-AMA_Article_Tables_Tab">
        <div class="figure-table-wrapper figure-no-label thm-bd-top"><a id="JOC21036T1" class="figure-table-anchor"> </a><strong>Table 1.</strong> Baseline Characteristics of the Women's
Health Initiative Estrogen Plus Progestin Trial Participants (N = 16608)
by Randomization Assignment*<div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="JOC21036T1" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t1a.png?Expires=1717486247&amp;Signature=jmNjlI6I2mn2pNpRKpfbXfNns2~Xcz1TbzM7JNN9OoogX0qjpjR5XWbhhG92HxzjItowE6hiuOn4UqMQh9pjsMxbXLhEcT81qx4twdcH7hh7LHPLEnX5fWCx7Dy8k22akVmpmNB0iwtTJP3kM-u60M2ML0IGbbbVuhfkGvB~mIYlyk~DHpoBWEsnDucgbSo9XwwmJRpvl8s7iftkiFRO6oB6vWQqjyGqGKMnnBNmM8GBgwvOU8LqIbZIJzV5IB0JY7KbVmBjmzf7OJGlo8aKkcYPvy1u1RGr57j77UkwHQjl7ZI7gGnQyUusNglfgnuqcwCzwttVHbIUJq~YI-Oq1g__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="JOC21036T1" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t1a.png?Expires=1717486247&Signature=jmNjlI6I2mn2pNpRKpfbXfNns2~Xcz1TbzM7JNN9OoogX0qjpjR5XWbhhG92HxzjItowE6hiuOn4UqMQh9pjsMxbXLhEcT81qx4twdcH7hh7LHPLEnX5fWCx7Dy8k22akVmpmNB0iwtTJP3kM-u60M2ML0IGbbbVuhfkGvB~mIYlyk~DHpoBWEsnDucgbSo9XwwmJRpvl8s7iftkiFRO6oB6vWQqjyGqGKMnnBNmM8GBgwvOU8LqIbZIJzV5IB0JY7KbVmBjmzf7OJGlo8aKkcYPvy1u1RGr57j77UkwHQjl7ZI7gGnQyUusNglfgnuqcwCzwttVHbIUJq~YI-Oq1g__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25024180&ar=195120&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t1a.png?Expires=1717486247&amp;Signature=jmNjlI6I2mn2pNpRKpfbXfNns2~Xcz1TbzM7JNN9OoogX0qjpjR5XWbhhG92HxzjItowE6hiuOn4UqMQh9pjsMxbXLhEcT81qx4twdcH7hh7LHPLEnX5fWCx7Dy8k22akVmpmNB0iwtTJP3kM-u60M2ML0IGbbbVuhfkGvB~mIYlyk~DHpoBWEsnDucgbSo9XwwmJRpvl8s7iftkiFRO6oB6vWQqjyGqGKMnnBNmM8GBgwvOU8LqIbZIJzV5IB0JY7KbVmBjmzf7OJGlo8aKkcYPvy1u1RGr57j77UkwHQjl7ZI7gGnQyUusNglfgnuqcwCzwttVHbIUJq~YI-Oq1g__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="JOC21036T1" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/m_joc21036t1a.png?Expires=1717486247&amp;Signature=TAZ6xAgGvsmBWkjn1wPIoXHY8tHDwKcBzaYMpq6X66L~2Sd67xIl6S5-g8gMedKDk1j6qtU~4RXMVMrxR4UdYoSkldKICCx8rLrsie5jQeOXT68xoQ3EjtoZSuPFN0Oa1QWf77sPiJ1XdO4k3Lnn-rmmrf2SZl9EQjOVDF~A3V6ZLEDe7UOLJu4p5GL5fUR85-B0u3knusvfSAfptbC6keOgR0pbxAgmpNJRma4TFU61WDMsfAztBhEOZtzt8PzB05VuDRWVDLgVK6IZx-Cih8hp6hRALl7d~4twS6muqJ~Ox-xFchzC-uPUADWBFdSplGMzChdyrxpp2uhUgijWIg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="JOC21036T1" /></a></div></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><a id="joc21036t1b" class="figure-table-anchor"> </a>Table 2b<div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="joc21036t1b" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t1b.png?Expires=1717486247&amp;Signature=3ECuRkZTSYb56qM4-991DmOUhl6hTUZo6trm5Tq7mfm9EqyUwbCqqbL~Cfq0o7fLnHKTmJZAARNsTzA7sujWf~VIYMTy8W59-IEheIxzrebYyFXn74hQ9fg6EI-BUkSkM0bdAf8MEULOngAr-7jOJZ1ei6IP-7zzev~Ry8BOdCMw6ovb3CxqJmExdX15CzwbjDMGwthQvTZ46rKIX9oMZt9MnE86OCOZ~9kS8aSOrDMB-bfxciH89Otd~e-ipScbpDCfPiYVYHJfaUL4W5cepkA89mDriGS1K2Ceh8POptu9WnMi7KP3Lf2-DQIdGkSryzGE9i~C8DLJUV17rPBwMw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="joc21036t1b" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t1b.png?Expires=1717486247&Signature=3ECuRkZTSYb56qM4-991DmOUhl6hTUZo6trm5Tq7mfm9EqyUwbCqqbL~Cfq0o7fLnHKTmJZAARNsTzA7sujWf~VIYMTy8W59-IEheIxzrebYyFXn74hQ9fg6EI-BUkSkM0bdAf8MEULOngAr-7jOJZ1ei6IP-7zzev~Ry8BOdCMw6ovb3CxqJmExdX15CzwbjDMGwthQvTZ46rKIX9oMZt9MnE86OCOZ~9kS8aSOrDMB-bfxciH89Otd~e-ipScbpDCfPiYVYHJfaUL4W5cepkA89mDriGS1K2Ceh8POptu9WnMi7KP3Lf2-DQIdGkSryzGE9i~C8DLJUV17rPBwMw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25024181&ar=195120&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t1b.png?Expires=1717486247&amp;Signature=3ECuRkZTSYb56qM4-991DmOUhl6hTUZo6trm5Tq7mfm9EqyUwbCqqbL~Cfq0o7fLnHKTmJZAARNsTzA7sujWf~VIYMTy8W59-IEheIxzrebYyFXn74hQ9fg6EI-BUkSkM0bdAf8MEULOngAr-7jOJZ1ei6IP-7zzev~Ry8BOdCMw6ovb3CxqJmExdX15CzwbjDMGwthQvTZ46rKIX9oMZt9MnE86OCOZ~9kS8aSOrDMB-bfxciH89Otd~e-ipScbpDCfPiYVYHJfaUL4W5cepkA89mDriGS1K2Ceh8POptu9WnMi7KP3Lf2-DQIdGkSryzGE9i~C8DLJUV17rPBwMw__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="joc21036t1b" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/m_joc21036t1b.png?Expires=1717486247&amp;Signature=zp9gMJaosaLfjkwcfqVxN-djp5i2o8l772UXmQZXiVRz7fLzJBUg6YAh9zILqPS8DcP-gOZxhKo6gPKMggNaztk-saqgP5TAk9G5HA9S0krdyuKhFBQRXKltKF7IYec-nFBMO1VIIK9OExfcixUnlK7qf12jewoxLF5TaDm3Fyh059C2GJiEY4o1N3g~92h83CO3MHX5x78zvyopxyduKIuwPTJjnVVIXWiOvSjgd9pQ6I7KjWe0rOSuwB7K4ueU4ek6y6beCLXVrv-zDSYp7ooR7oKw-7o3OxjcxO9dySCyzMr-x0zQuQPrgg~5XFmwCcWUrtriH1EipjVuFA-R9g__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="joc21036t1b" /></a></div></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><a id="JOC21036T2" class="figure-table-anchor"> </a><strong>Table 2.</strong> Clinical Outcomes by Randomization
Assignment*<div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="JOC21036T2" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t2.png?Expires=1717486247&amp;Signature=G4hdMz4LXAIpZ2HrDyHuaqg4sOoLL1zxUKsEpQUgLnmgPceX2r77ypNBOQP5L1ME493RY0AouROjaryKIom9Y-4hV4ENs2KsBCrueKje62yOOnVFrbAxFrp5WQUBWZE6CR6lIxnBXYUTFSnybDfOUCNgpNpQ4A3MHGCvjpTtSMM4scxi1olo6x2rGS7VxDBtDLpIYthAC8NAonYSrzGd2wE7DHvm9yG1JJ3c6yXSsRF8GQp7CbI49jDj~IDn6qmg4N1H1j9CbEeqhEOh0~HpLtiOqMoAh7DeXAeTNYyOzWUU8mpC6ZiYbDGFrGXEKX8pHG~VqTaBYMKwcLiJJ8QG7A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="JOC21036T2" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t2.png?Expires=1717486247&Signature=G4hdMz4LXAIpZ2HrDyHuaqg4sOoLL1zxUKsEpQUgLnmgPceX2r77ypNBOQP5L1ME493RY0AouROjaryKIom9Y-4hV4ENs2KsBCrueKje62yOOnVFrbAxFrp5WQUBWZE6CR6lIxnBXYUTFSnybDfOUCNgpNpQ4A3MHGCvjpTtSMM4scxi1olo6x2rGS7VxDBtDLpIYthAC8NAonYSrzGd2wE7DHvm9yG1JJ3c6yXSsRF8GQp7CbI49jDj~IDn6qmg4N1H1j9CbEeqhEOh0~HpLtiOqMoAh7DeXAeTNYyOzWUU8mpC6ZiYbDGFrGXEKX8pHG~VqTaBYMKwcLiJJ8QG7A__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25024192&ar=195120&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t2.png?Expires=1717486247&amp;Signature=G4hdMz4LXAIpZ2HrDyHuaqg4sOoLL1zxUKsEpQUgLnmgPceX2r77ypNBOQP5L1ME493RY0AouROjaryKIom9Y-4hV4ENs2KsBCrueKje62yOOnVFrbAxFrp5WQUBWZE6CR6lIxnBXYUTFSnybDfOUCNgpNpQ4A3MHGCvjpTtSMM4scxi1olo6x2rGS7VxDBtDLpIYthAC8NAonYSrzGd2wE7DHvm9yG1JJ3c6yXSsRF8GQp7CbI49jDj~IDn6qmg4N1H1j9CbEeqhEOh0~HpLtiOqMoAh7DeXAeTNYyOzWUU8mpC6ZiYbDGFrGXEKX8pHG~VqTaBYMKwcLiJJ8QG7A__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="JOC21036T2" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/m_joc21036t2.png?Expires=1717486247&amp;Signature=YSe0LmsqsE1CrsG~DXtuY9EPkGRR0tExLXRHMsNwYnp-oKRslHIT7-8HX-F2zyuHKMYTG8DM8Ga2tiLOGZs0Kw5ToeRVSPljMctBnOeoucGVieFQdQusz6OGHWhy30KGYzlxKVR~OVSgrl~qtY-LOBxhNyXaKsAE9ufKeGzPp8efdyvEN2EEvTvC3dLHvYYnBh2txtodtt-LD0RE2RibIaefiwtGr0BNg1-IRIpsFPJcNyFIxo0za3pdBL01ws4Uz0dPFW2YuQEN7c79Zs36JAFcnqmFJE~gJEmZRxrN17dirSefaMCa8DRtDLKKo8NYVijbPUkOv0PPimZi1uTJPA__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="JOC21036T2" /></a></div></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><a id="JOC21036T3" class="figure-table-anchor"> </a><strong>Table 3.</strong> Cause of Death by Randomization Assignment<div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="JOC21036T3" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t3.png?Expires=1717486247&amp;Signature=pJuIxwcoAa3ejgaPCQQO5OGXFbJ8ouHAbAj9PHBfvD1IhLl-GvCkCQVLchR6nYd9E7nn2nZu2o7qTNEH80VAGSwi1ggvSFVfVrMyfsEmjuV-rJyQzjMFSDDaEIjuQNDBdE2qPumKX2ni60sQWYhqIJz1HbdPSuP7VphKS4Fz4zofkK-UQNvu5nmZGcQXmDbGv-3JpWaLvJEGdMFCCAB5XS82vNjnPoGW8FzpryNNCQxWQIGV8oKEwH2LdDErNHvxVbEGxpcX2RKFXsVIX18bWlOQHb5xn6s3N1LkJFGpHW-0wFt8DZguwQBbIUtUH4ysKa5Jhwjs-aEKLsXewwsL4w__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="JOC21036T3" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t3.png?Expires=1717486247&Signature=pJuIxwcoAa3ejgaPCQQO5OGXFbJ8ouHAbAj9PHBfvD1IhLl-GvCkCQVLchR6nYd9E7nn2nZu2o7qTNEH80VAGSwi1ggvSFVfVrMyfsEmjuV-rJyQzjMFSDDaEIjuQNDBdE2qPumKX2ni60sQWYhqIJz1HbdPSuP7VphKS4Fz4zofkK-UQNvu5nmZGcQXmDbGv-3JpWaLvJEGdMFCCAB5XS82vNjnPoGW8FzpryNNCQxWQIGV8oKEwH2LdDErNHvxVbEGxpcX2RKFXsVIX18bWlOQHb5xn6s3N1LkJFGpHW-0wFt8DZguwQBbIUtUH4ysKa5Jhwjs-aEKLsXewwsL4w__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25024196&ar=195120&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t3.png?Expires=1717486247&amp;Signature=pJuIxwcoAa3ejgaPCQQO5OGXFbJ8ouHAbAj9PHBfvD1IhLl-GvCkCQVLchR6nYd9E7nn2nZu2o7qTNEH80VAGSwi1ggvSFVfVrMyfsEmjuV-rJyQzjMFSDDaEIjuQNDBdE2qPumKX2ni60sQWYhqIJz1HbdPSuP7VphKS4Fz4zofkK-UQNvu5nmZGcQXmDbGv-3JpWaLvJEGdMFCCAB5XS82vNjnPoGW8FzpryNNCQxWQIGV8oKEwH2LdDErNHvxVbEGxpcX2RKFXsVIX18bWlOQHb5xn6s3N1LkJFGpHW-0wFt8DZguwQBbIUtUH4ysKa5Jhwjs-aEKLsXewwsL4w__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="JOC21036T3" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/m_joc21036t3.png?Expires=1717486247&amp;Signature=3~VjBDI7gMs9OBHtMfVogZu7C8I4cRG2V4Y8TfzE6Eun4hS8qj97Gv1u2lLw696ipKzz9T97b~6Fs8XRbvg-wOVr1v6Wq1b5Phe5p0SWdRLnaDZhzPLykwIMObhFN9tyOyP10cKuVeJCf~x8G0RNf7I~MKXObFUub2bH-GAQ6vICzDWR43SWpaj-Jwa2jin6XgR0gGfn5xzJYlPx3JuLeMQ7zzWBxDgr6mIoJC7BVUb2Vo3oiw2qtpBNCFFe58dUkJvxwuhugCoYU3QcnKPtcKsLS6RaaJPv8uuNFnSdyD9WCGJf2fxjMe76XXpI33DyPdAhOQIbJEvyPPR10cFgmg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="JOC21036T3" /></a></div></div></div><div class="figure-table-wrapper figure-no-label thm-bd-top"><a id="JOC21036T4" class="figure-table-anchor"> </a><strong>Table 4.</strong> Selected Clinical Outcomes by Follow-up
Year and Randomization Assignment*<div class="figure-table-links right"><a class="view-large figure-table-link is-b desktop-only" path-from-xml="JOC21036T4" href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t4.png?Expires=1717486247&amp;Signature=HAS8caarZTU7uO4~zGo2yzgVxKs7DZ6Q52Xb83DZVPvjT~4EagtAm3wWM3Ws-rMrFEeU60o6GZ3Jj3Pe46ZfLaeQiuJG4X4nptdIM5QfAvGft3LCPZDTSHXfejKkoAk9xtRYvVFAC0V~P95R2jnJZ9XHuIzJH2xOHcsNIolc2nRO9figQjg6lyTtGqB60szWxhuRHR44bSg-uE23~0HsphsktwSNAj7wY5N9oHOuJ8NsUlpQpNwTqbKFCwyGfJgbvp6poOpDyGXy6MZbGX-VYAy6wpOBNqigEvp~V-xhyAlrO5nQl48dWfJ8E6h4-EHAAA44JDIWWZOWcf2ehpj8IQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" rel="nofollow"><span class="view-large-text">View Large</span></a><a class="download-ppt figure-table-link is-b stats-download-figure-table" path-from-xml="JOC21036T4" href="/downloadimage.aspx?image=https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t4.png?Expires=1717486247&Signature=HAS8caarZTU7uO4~zGo2yzgVxKs7DZ6Q52Xb83DZVPvjT~4EagtAm3wWM3Ws-rMrFEeU60o6GZ3Jj3Pe46ZfLaeQiuJG4X4nptdIM5QfAvGft3LCPZDTSHXfejKkoAk9xtRYvVFAC0V~P95R2jnJZ9XHuIzJH2xOHcsNIolc2nRO9figQjg6lyTtGqB60szWxhuRHR44bSg-uE23~0HsphsktwSNAj7wY5N9oHOuJ8NsUlpQpNwTqbKFCwyGfJgbvp6poOpDyGXy6MZbGX-VYAy6wpOBNqigEvp~V-xhyAlrO5nQl48dWfJ8E6h4-EHAAA44JDIWWZOWcf2ehpj8IQ__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA&sec=25024204&ar=195120&imagename=&siteId=3" rel="nofollow"><span class="download-ppt-text">Download</span></a><a class="figure-table-twitter figure-table-link figure-table-social addthis_button_twitter is-b" rel="nofollow"><span class="share-text"> </span></a><a class="figure-table-facebook figure-table-link figure-table-social addthis_button_facebook is-b" rel="nofollow"><span class="share-text"> </span></a></div><div class="figure-table cf cb"><div class="figure-table-image"><a href="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/joc21036t4.png?Expires=1717486247&amp;Signature=HAS8caarZTU7uO4~zGo2yzgVxKs7DZ6Q52Xb83DZVPvjT~4EagtAm3wWM3Ws-rMrFEeU60o6GZ3Jj3Pe46ZfLaeQiuJG4X4nptdIM5QfAvGft3LCPZDTSHXfejKkoAk9xtRYvVFAC0V~P95R2jnJZ9XHuIzJH2xOHcsNIolc2nRO9figQjg6lyTtGqB60szWxhuRHR44bSg-uE23~0HsphsktwSNAj7wY5N9oHOuJ8NsUlpQpNwTqbKFCwyGfJgbvp6poOpDyGXy6MZbGX-VYAy6wpOBNqigEvp~V-xhyAlrO5nQl48dWfJ8E6h4-EHAAA44JDIWWZOWcf2ehpj8IQ__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" target="_blank" path-from-xml="JOC21036T4" rel="nofollow"><img data-original="https://cdn.jamanetwork.com/ama/content_public/journal/jama/4840/m_joc21036t4.png?Expires=1717486247&amp;Signature=E9cgvj00fDzo2riG1wm2EQL6J9MGYnHX6XLXQUcvp0ysbZoO~fivkYSlsB0U1MXolAQMMZ1abjTW-c2gnW~wl3tkQ-9A5G0Hex3vxHiH23XXfpsfYKMVKG75T~fFpnAuLaN1VtKyFX35jAYMhS0Vzy-nFj0u9vIwWf8a7sE05Ql1ps9IkQ5ApDwM8YHN-ed-718ZDwE8PRSWW75porGbNY909D~~XuyQip5zyI6kCx79msCM~LoSrhxh3K0UL7Whn1zYFnHsgkSaLm51OPLrRPxfNQ~VOk6NNy5BRwukAL~iGCw2jczic1dwlQ-A2wMK3LYYM5TUmgmz62fg-olXyg__&amp;Key-Pair-Id=APKAIE5G5CRDK6RD3PGA" alt="Image description not available." class="content-img lazy" path-from-xml="JOC21036T4" /></a></div></div></div> 
    </div>

        </div>

        
        <div id="multimedia-tab" class="resource-tab js-resource-tab multimedia-tab need-jobs-ad">

        </div>

        
        <div id="supplemental-tab" class="resource-tab js-resource-tab supplemental-tab need-jobs-ad">

        </div>

        
        <div id="references-tab" class="resource-tab js-resource-tab references-tab need-jobs-ad">
            <div class="references-wrap">
    <div class="widget-SectionDisplay widget-instance-AMA_References_Tab">
        
<div class="references"><div class="reference"><a class="reference-number" id="ref-joc21036-1">1.</a><div class="reference-content">The Women's Health Initiative Study Group.Design of the Women's Health Initiative clinical trial and observational
study.<I xmlns:helper="urn:XsltStringHelper">Control Clin Trials.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1998;19:61-109.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Design%20of%20the%20Women%27s%20Health%20Initiative%20clinical%20trial%20and%20observational%20study.&amp;publication_year=&amp;journal=Control%20Clin%20Trials.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-2">2.</a><div class="reference-content">StampferM, ColditzG.Estrogen replacement therapy and coronary heart disease: a quantitative
assessment of the epidemiologic evidence.<I xmlns:helper="urn:XsltStringHelper">Prev Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1991;20:47-63.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Estrogen%20replacement%20therapy%20and%20coronary%20heart%20disease%3A%20a%20quantitative%20assessment%20of%20the%20epidemiologic%20evidence.&amp;author=M%20Stampfer&amp;author=G%20Colditz&amp;publication_year=&amp;journal=Prev%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-3">3.</a><div class="reference-content">GradyD, RuebenSB, PettitiDB.
    et al.Hormone therapy to prevent disease and prolong life in postmenopausal
women.<I xmlns:helper="urn:XsltStringHelper">Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1992;117:1016-1037.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Hormone%20therapy%20to%20prevent%20disease%20and%20prolong%20life%20in%20postmenopausal%20women.&amp;author=D%20Grady&amp;author=SB%20Rueben&amp;author=DB%20Pettiti&amp;publication_year=&amp;journal=Ann%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-4">4.</a><div class="reference-content">RijpkemaAH, van der SandenAA, RuijsAH.Effects of postmenopausal estrogen-progesterone therapy on serum lipids
and lipoproteins: a review.<I xmlns:helper="urn:XsltStringHelper">Maturitas.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;12:259-285.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20postmenopausal%20estrogen-progesterone%20therapy%20on%20serum%20lipids%20and%20lipoproteins%3A%20a%20review.&amp;author=AH%20Rijpkema&amp;author=AA%20van der Sanden&amp;author=AH%20Ruijs&amp;publication_year=&amp;journal=Maturitas.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-5">5.</a><div class="reference-content">AdamsMR, KaplanJR, ManuckSB.
    et al.Inhibition of coronary artery atherosclerosis by 17-beta estradiol
in ovariectomized monkeys: lack of an effect of added progesterone.<I xmlns:helper="urn:XsltStringHelper">Arteriosclerosis.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;10:1051-1057.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Inhibition%20of%20coronary%20artery%20atherosclerosis%20by%2017-beta%20estradiol%20in%20ovariectomized%20monkeys%3A%20lack%20of%20an%20effect%20of%20added%20progesterone.&amp;author=MR%20Adams&amp;author=JR%20Kaplan&amp;author=SB%20Manuck&amp;publication_year=&amp;journal=Arteriosclerosis.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-6">6.</a><div class="reference-content">WeissNS, UreCL, BallardJH, WilliamsAR, DalingJR.Decreased risk of fractures of the hip and lower forearm with postmenopausal
use of estrogen.<I xmlns:helper="urn:XsltStringHelper">N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1980;303:1195-1198.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Decreased%20risk%20of%20fractures%20of%20the%20hip%20and%20lower%20forearm%20with%20postmenopausal%20use%20of%20estrogen.&amp;author=NS%20Weiss&amp;author=CL%20Ure&amp;author=JH%20Ballard&amp;author=AR%20Williams&amp;author=JR%20Daling&amp;publication_year=&amp;journal=N%20Engl%20J%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-7">7.</a><div class="reference-content">GenantHK, BaylinkDJ, GallagherJC, HarrisST, SteigerP, HerberM.Effect of estrone sulfate on postmenopausal bone loss.<I xmlns:helper="urn:XsltStringHelper">Obstet Gynecol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;76:579-584.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20estrone%20sulfate%20on%20postmenopausal%20bone%20loss.&amp;author=HK%20Genant&amp;author=DJ%20Baylink&amp;author=JC%20Gallagher&amp;author=ST%20Harris&amp;author=P%20Steiger&amp;author=M%20Herber&amp;publication_year=&amp;journal=Obstet%20Gynecol.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-8">8.</a><div class="reference-content">SteinbergKA, ThackerSB, SmithSJ.
    et al.A meta-analysis of the effect of estrogen replacement therapy on the
risk of breast cancer.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1991;265:1985-1990.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20meta-analysis%20of%20the%20effect%20of%20estrogen%20replacement%20therapy%20on%20the%20risk%20of%20breast%20cancer.&amp;author=KA%20Steinberg&amp;author=SB%20Thacker&amp;author=SJ%20Smith&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-9">9.</a><div class="reference-content">Gerhardsson deVM, LondonS.Reproductive factors, exogenous female hormones, and colorectal cancer
by subsite.<I xmlns:helper="urn:XsltStringHelper">Cancer Causes Control.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1992;3:355-360.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Reproductive%20factors%2C%20exogenous%20female%20hormones%2C%20and%20colorectal%20cancer%20by%20subsite.&amp;author=VM%20Gerhardsson de&amp;author=S%20London&amp;publication_year=&amp;journal=Cancer%20Causes%20Control.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-10">10.</a><div class="reference-content">HulleyS, GradyD, BushT.
    et al.Randomized trial of estrogen plus progestin for secondary prevention
of coronary heart disease in postmenopausal women.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1998;280:605-613.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Randomized%20trial%20of%20estrogen%20plus%20progestin%20for%20secondary%20prevention%20of%20coronary%20heart%20disease%20in%20postmenopausal%20women.&amp;author=S%20Hulley&amp;author=D%20Grady&amp;author=T%20Bush&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-11">11.</a><div class="reference-content">GrodsteinF, MansonJE, StampferMJ.Postmenopausal hormone use and secondary prevention of coronary events
in the Nurses' Health Study.<I xmlns:helper="urn:XsltStringHelper">Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;135:1-8.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Postmenopausal%20hormone%20use%20and%20secondary%20prevention%20of%20coronary%20events%20in%20the%20Nurses%27%20Health%20Study.&amp;author=F%20Grodstein&amp;author=JE%20Manson&amp;author=MJ%20Stampfer&amp;publication_year=&amp;journal=Ann%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-12">12.</a><div class="reference-content">AlexanderKP, NewbyLK, HellkampAS.
    et al.Initiation of hormone replacement therapy after acute myocardial infarction
is associated with more cardiac events during follow-up.<I xmlns:helper="urn:XsltStringHelper">J Am Coll Cardiol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;38:1-7.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Initiation%20of%20hormone%20replacement%20therapy%20after%20acute%20myocardial%20infarction%20is%20associated%20with%20more%20cardiac%20events%20during%20follow-up.&amp;author=KP%20Alexander&amp;author=LK%20Newby&amp;author=AS%20Hellkamp&amp;publication_year=&amp;journal=J%20Am%20Coll%20Cardiol.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-13">13.</a><div class="reference-content">HeckbertSR, KaplanRC, WeissNS.
    et al.Risk of recurrent coronary events in relation to use and recent initiation
of postmenopausal hormone therapy.<I xmlns:helper="urn:XsltStringHelper">Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;161:1709-1173.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Risk%20of%20recurrent%20coronary%20events%20in%20relation%20to%20use%20and%20recent%20initiation%20of%20postmenopausal%20hormone%20therapy.&amp;author=SR%20Heckbert&amp;author=RC%20Kaplan&amp;author=NS%20Weiss&amp;publication_year=&amp;journal=Arch%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-14">14.</a><div class="reference-content">GrodsteinF, MansonJE, ColditzGA, WillitWC, SpeizerFE, StampferMJ.A prospective, observational study of postmenopausal hormone therapy
and primary prevention of cardiovascular disease.<I xmlns:helper="urn:XsltStringHelper">Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;133:933-941.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20prospective%2C%20observational%20study%20of%20postmenopausal%20hormone%20therapy%20and%20primary%20prevention%20of%20cardiovascular%20disease.&amp;author=F%20Grodstein&amp;author=JE%20Manson&amp;author=GA%20Colditz&amp;author=WC%20Willit&amp;author=FE%20Speizer&amp;author=MJ%20Stampfer&amp;publication_year=&amp;journal=Ann%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-15">15.</a><div class="reference-content">The Writing Group for the PEPI Trial.Effects of hormone replacement therapy on endometrial histology in
postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions
(PEPI) Trial.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1996;275:370-375.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20hormone%20replacement%20therapy%20on%20endometrial%20histology%20in%20postmenopausal%20women%3A%20the%20Postmenopausal%20Estrogen%2FProgestin%20Interventions%20%28PEPI%29%20Trial.&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-16">16.</a><div class="reference-content">IvesDG, FitzpatrickAL, BildDE.
    et al.Surveillance and ascertainment of cardiovascular events: the Cardiovascular
Health Study.<I xmlns:helper="urn:XsltStringHelper">Ann Epidemiol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1995;5:275-285.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Surveillance%20and%20ascertainment%20of%20cardiovascular%20events%3A%20the%20Cardiovascular%20Health%20Study.&amp;author=DG%20Ives&amp;author=AL%20Fitzpatrick&amp;author=DE%20Bild&amp;publication_year=&amp;journal=Ann%20Epidemiol.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-17">17.</a><div class="reference-content">CoxDR.Regression analysis and life tables.<I xmlns:helper="urn:XsltStringHelper">J R Stat Soc.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1972;34:187-220.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Regression%20analysis%20and%20life%20tables.&amp;author=DR%20Cox&amp;publication_year=&amp;journal=J%20R%20Stat%20Soc.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-18">18.</a><div class="reference-content">O'BrienPC, FlemingRT.A multiple testing procedure for clinical trials.<I xmlns:helper="urn:XsltStringHelper">Biometrics.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1979;35:549-556.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20multiple%20testing%20procedure%20for%20clinical%20trials.&amp;author=PC%20O'Brien&amp;author=RT%20Fleming&amp;publication_year=&amp;journal=Biometrics.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-19">19.</a><div class="reference-content">FreedmanLS, AndersonG, KipnisV.
    et al.Approaches to monitoring the results of long-term disease prevention
trials: examples from the Women's Health Initiative.<I xmlns:helper="urn:XsltStringHelper">Control Clin Trials.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1996;17:509-525.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Approaches%20to%20monitoring%20the%20results%20of%20long-term%20disease%20prevention%20trials%3A%20examples%20from%20the%20Women%27s%20Health%20Initiative.&amp;author=LS%20Freedman&amp;author=G%20Anderson&amp;author=V%20Kipnis&amp;publication_year=&amp;journal=Control%20Clin%20Trials.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-20">20.</a><div class="reference-content">GailMH, BrintonLA, ByarDP.
    et al.Projecting individualized probabilities of developing breast cancer
for white females who are being examined annually.<I xmlns:helper="urn:XsltStringHelper">J Natl Cancer Inst.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1989;81:1879-1886.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Projecting%20individualized%20probabilities%20of%20developing%20breast%20cancer%20for%20white%20females%20who%20are%20being%20examined%20annually.&amp;author=MH%20Gail&amp;author=LA%20Brinton&amp;author=DP%20Byar&amp;publication_year=&amp;journal=J%20Natl%20Cancer%20Inst.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-21">21.</a><div class="reference-content">PilonD, CastillouxAM, LelorierJ.Estrogen replacement therapy: determinants of persistence with treatment.<I xmlns:helper="urn:XsltStringHelper">Obstet Gynecol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;97:97-100.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Estrogen%20replacement%20therapy%3A%20determinants%20of%20persistence%20with%20treatment.&amp;author=D%20Pilon&amp;author=AM%20Castilloux&amp;author=J%20Lelorier&amp;publication_year=&amp;journal=Obstet%20Gynecol.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-22">22.</a><div class="reference-content">Writing Group for the PEPI Trial.Effects of estrogen or estrogen/progestin regimens on heart disease
risk factors in postmenopausal women.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1995;273:199-208.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20estrogen%20or%20estrogen%2Fprogestin%20regimens%20on%20heart%20disease%20risk%20factors%20in%20postmenopausal%20women.&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-23">23.</a><div class="reference-content">HerringtonDM, ReboussinDM, BrosnihanKB.
    et al.Effects of estrogen replacement on the progression of coronary artery
atherosclerosis.<I xmlns:helper="urn:XsltStringHelper">N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;343:522-529.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20estrogen%20replacement%20on%20the%20progression%20of%20coronary%20artery%20atherosclerosis.&amp;author=DM%20Herrington&amp;author=DM%20Reboussin&amp;author=KB%20Brosnihan&amp;publication_year=&amp;journal=N%20Engl%20J%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-24">24.</a><div class="reference-content">SchulmanSP, ThiemannDR, OuyangP.
    et al.Effects of acute hormone therapy on recurrent ischemia in postmenopausal
women with unstable angina.<I xmlns:helper="urn:XsltStringHelper">J Am Coll Cardiol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;39:231-237.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20acute%20hormone%20therapy%20on%20recurrent%20ischemia%20in%20postmenopausal%20women%20with%20unstable%20angina.&amp;author=SP%20Schulman&amp;author=DR%20Thiemann&amp;author=P%20Ouyang&amp;publication_year=&amp;journal=J%20Am%20Coll%20Cardiol.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-25">25.</a><div class="reference-content">GradyD, HerringtonD, BittnerV.
    et al.for the HERS Research Group.Cardiovascular disease outcomes during 6.8 years of hormone therapy:
Heart and Estrogen/progestin Replacement Study Follow-up (HERS II).<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;288:49-57.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cardiovascular%20disease%20outcomes%20during%206.8%20years%20of%20hormone%20therapy%3A%20Heart%20and%20Estrogen%2Fprogestin%20Replacement%20Study%20Follow-up%20%28HERS%20II%29.&amp;author=D%20Grady&amp;author=D%20Herrington&amp;author=V%20Bittner&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-26">26.</a><div class="reference-content">SimonJA, HsiaJ, CauleyJA.
    et al.Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin
Replacement Study (HERS).<I xmlns:helper="urn:XsltStringHelper">Circulation.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;103:638-642.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Postmenopausal%20hormone%20therapy%20and%20risk%20of%20stroke%3A%20the%20Heart%20and%20Estrogen-progestin%20Replacement%20Study%20%28HERS%29.&amp;author=JA%20Simon&amp;author=J%20Hsia&amp;author=JA%20Cauley&amp;publication_year=&amp;journal=Circulation.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-27">27.</a><div class="reference-content">ViscoliCM, BrassLM, KernanWN, SarrelPM, SuissaS, HorwitzRI.A clinical trial of estrogen-replacement therapy after ischemic stroke.<I xmlns:helper="urn:XsltStringHelper">N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;345:1243-1249.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20clinical%20trial%20of%20estrogen-replacement%20therapy%20after%20ischemic%20stroke.&amp;author=CM%20Viscoli&amp;author=LM%20Brass&amp;author=WN%20Kernan&amp;author=PM%20Sarrel&amp;author=S%20Suissa&amp;author=RI%20Horwitz&amp;publication_year=&amp;journal=N%20Engl%20J%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-28">28.</a><div class="reference-content">HodisHN, MackWJ, LoboRA.
    et al.Estrogen in the prevention of atherosclerosis: a randomized, double-blind
controlled trial.<I xmlns:helper="urn:XsltStringHelper">Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;135:939-953.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Estrogen%20in%20the%20prevention%20of%20atherosclerosis%3A%20a%20randomized%2C%20double-blind%20controlled%20trial.&amp;author=HN%20Hodis&amp;author=WJ%20Mack&amp;author=RA%20Lobo&amp;publication_year=&amp;journal=Ann%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-29">29.</a><div class="reference-content">AngererP, StorkS, KothnyW, SchmittP, von SchackyC.Effect of oral postmenopausal hormone replacement on progression of
atherosclerosis: a randomized, controlled trial.<I xmlns:helper="urn:XsltStringHelper">Arterioscler Thromb Vasc Biol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;21:262-268.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20oral%20postmenopausal%20hormone%20replacement%20on%20progression%20of%20atherosclerosis%3A%20a%20randomized%2C%20controlled%20trial.&amp;author=P%20Angerer&amp;author=S%20Stork&amp;author=W%20Kothny&amp;author=P%20Schmitt&amp;author=C%20von Schacky&amp;publication_year=&amp;journal=Arterioscler%20Thromb%20Vasc%20Biol.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-30">30.</a><div class="reference-content">CastellsagueJ, Perez GutthannS, Garcia RodriguezLA.Recent epidemiological studies of the association between hormone replacement
therapy and venous thromboembolism: a review.<I xmlns:helper="urn:XsltStringHelper">Drug Saf.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1998;18:117-123.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Recent%20epidemiological%20studies%20of%20the%20association%20between%20hormone%20replacement%20therapy%20and%20venous%20thromboembolism%3A%20a%20review.&amp;author=J%20Castellsague&amp;author=S%20Perez Gutthann&amp;author=LA%20Garcia Rodriguez&amp;publication_year=&amp;journal=Drug%20Saf.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-31">31.</a><div class="reference-content">GradyD, WengerNK, HerringtonD.
    et al.Postmenopausal hormone therapy increases risk for venous thromboembolic
disease: the Heart and Estrogen/progestin Replacement Study.<I xmlns:helper="urn:XsltStringHelper">Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;132:689-696.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Postmenopausal%20hormone%20therapy%20increases%20risk%20for%20venous%20thromboembolic%20disease%3A%20the%20Heart%20and%20Estrogen%2Fprogestin%20Replacement%20Study.&amp;author=D%20Grady&amp;author=NK%20Wenger&amp;author=D%20Herrington&amp;publication_year=&amp;journal=Ann%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-32">32.</a><div class="reference-content">Collaborative Group on Hormonal Factors in Breast Cancer.Breast cancer and hormone replacement therapy: collaborative reanalysis
of data from 51 epidemiological studies of 52,705 women with breast cancer
and 108,411 women without breast cancer.<I xmlns:helper="urn:XsltStringHelper">Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;350:1047-1059.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Breast%20cancer%20and%20hormone%20replacement%20therapy%3A%20collaborative%20reanalysis%20of%20data%20from%2051%20epidemiological%20studies%20of%2052%2C705%20women%20with%20breast%20cancer%20and%20108%2C411%20women%20without%20breast%20cancer.&amp;publication_year=&amp;journal=Lancet.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-33">33.</a><div class="reference-content">HulleyS, FurbergC, Barrett-ConnorE.
    et al.for the HERS Research Group.Noncardiovascular disease outcomes during 6.8 years of hormone therapy:
Heart and Estrogen/progestin Replacement Study Follow-up (HERS II).<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;288:58-66.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Noncardiovascular%20disease%20outcomes%20during%206.8%20years%20of%20hormone%20therapy%3A%20Heart%20and%20Estrogen%2Fprogestin%20Replacement%20Study%20Follow-up%20%28HERS%20II%29.&amp;author=S%20Hulley&amp;author=C%20Furberg&amp;author=E%20Barrett-Connor&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-34">34.</a><div class="reference-content">SchairerC, LubinJ, TroisiR, SturgeonS, BrintonL, HooverR.Menopausal estrogen and estrogen-progestin replacement therapy and
breast cancer risk.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;283:485-491.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Menopausal%20estrogen%20and%20estrogen-progestin%20replacement%20therapy%20and%20breast%20cancer%20risk.&amp;author=C%20Schairer&amp;author=J%20Lubin&amp;author=R%20Troisi&amp;author=S%20Sturgeon&amp;author=L%20Brinton&amp;author=R%20Hoover&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-35">35.</a><div class="reference-content">RossRK, Paganini-HillA, WanPC, PikeMC.Effect of hormone replacement therapy on breast cancer risk: estrogen
versus estrogen plus progestin.<I xmlns:helper="urn:XsltStringHelper">J Natl Cancer Inst.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;92:328-332.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20hormone%20replacement%20therapy%20on%20breast%20cancer%20risk%3A%20estrogen%20versus%20estrogen%20plus%20progestin.&amp;author=RK%20Ross&amp;author=A%20Paganini-Hill&amp;author=PC%20Wan&amp;author=MC%20Pike&amp;publication_year=&amp;journal=J%20Natl%20Cancer%20Inst.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-36">36.</a><div class="reference-content">ColditzGA, HankinsonSE, HunterDJ.
    et al.The use of estrogens and progestins and the risk of breast cancer in
postmenopausal women.<I xmlns:helper="urn:XsltStringHelper">N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1995;332:1589-1593.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20use%20of%20estrogens%20and%20progestins%20and%20the%20risk%20of%20breast%20cancer%20in%20postmenopausal%20women.&amp;author=GA%20Colditz&amp;author=SE%20Hankinson&amp;author=DJ%20Hunter&amp;publication_year=&amp;journal=N%20Engl%20J%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-37">37.</a><div class="reference-content">MagnussonC, BaronJA, CorreiaN, BergstromR, AdamiH-O, PerssonI.Breast-cancer risk following long-term oestrogen and oestrogen-progestin-replacement
therapy.<I xmlns:helper="urn:XsltStringHelper">Int J Cancer.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;81:339-344.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Breast-cancer%20risk%20following%20long-term%20oestrogen%20and%20oestrogen-progestin-replacement%20therapy.&amp;author=C%20Magnusson&amp;author=JA%20Baron&amp;author=N%20Correia&amp;author=R%20Bergstrom&amp;author=H-O%20Adami&amp;author=I%20Persson&amp;publication_year=&amp;journal=Int%20J%20Cancer.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-38">38.</a><div class="reference-content">GreendaleGA, ReboussinBA, SieA.
    et al.Effects of estrogen and estrogen-progestin on mammographic parenchymal
density.<I xmlns:helper="urn:XsltStringHelper">Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;130:262-269.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20estrogen%20and%20estrogen-progestin%20on%20mammographic%20parenchymal%20density.&amp;author=GA%20Greendale&amp;author=BA%20Reboussin&amp;author=A%20Sie&amp;publication_year=&amp;journal=Ann%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-39">39.</a><div class="reference-content">GrodsteinF, NewcombPA, StampferMJ.Postmenopausal hormone therapy and the risk of colorectal cancer: a
review and meta-analysis.<I xmlns:helper="urn:XsltStringHelper">Am J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;106:574-582.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Postmenopausal%20hormone%20therapy%20and%20the%20risk%20of%20colorectal%20cancer%3A%20a%20review%20and%20meta-analysis.&amp;author=F%20Grodstein&amp;author=PA%20Newcomb&amp;author=MJ%20Stampfer&amp;publication_year=&amp;journal=Am%20J%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-40">40.</a><div class="reference-content">VickersMR, MeadeTW, WilkesHC.Hormone replacement therapy and cardiovascular disease: the case for
a randomized controlled trial.<I xmlns:helper="urn:XsltStringHelper">Ciba Found Symp.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1995;191:150-160.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Hormone%20replacement%20therapy%20and%20cardiovascular%20disease%3A%20the%20case%20for%20a%20randomized%20controlled%20trial.&amp;author=MR%20Vickers&amp;author=TW%20Meade&amp;author=HC%20Wilkes&amp;publication_year=&amp;journal=Ciba%20Found%20Symp.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-41">41.</a><div class="reference-content">TorgersonDJ, Bell-SeyerSE.Hormone replacement therapy and prevention of nonvertebral fractures:
a meta-analysis of randomized trials.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;285:2891-2897.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Hormone%20replacement%20therapy%20and%20prevention%20of%20nonvertebral%20fractures%3A%20a%20meta-analysis%20of%20randomized%20trials.&amp;author=DJ%20Torgerson&amp;author=SE%20Bell-Seyer&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-42">42.</a><div class="reference-content">Writing Group for the PEPI Trial.Effects of hormone therapy on bone mineral density: results from the
Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1996;275:1389-1396.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20hormone%20therapy%20on%20bone%20mineral%20density%3A%20results%20from%20the%20Postmenopausal%20Estrogen%2FProgestin%20Interventions%20%28PEPI%29%20Trial.&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-43">43.</a><div class="reference-content">MoscaL, CollinsP, HerringtonDM.
    et al.Hormone replacement therapy and cardiovascular disease: a statement
for healthcare professionals from the American Heart Association.<I xmlns:helper="urn:XsltStringHelper">Circulation.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;104:499-503.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Hormone%20replacement%20therapy%20and%20cardiovascular%20disease%3A%20a%20statement%20for%20healthcare%20professionals%20from%20the%20American%20Heart%20Association.&amp;author=L%20Mosca&amp;author=P%20Collins&amp;author=DM%20Herrington&amp;publication_year=&amp;journal=Circulation.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div></div> 
    </div>

            </div>
        </div>

        
        <div id="related-tab" class="resource-tab js-resource-tab related-tab need-jobs-ad">
    <div class="widget-ArticleLinks widget-instance-AMA_See_Also_Related_Content">
        
    <ul class="article-links related-content">

            <li class="article-link related-article odd">
                <a href="https://jamanetwork.com/journals/jama/fullarticle/195112" class="td-n">
                        <div class="related-article-title">Failure of Estrogen Plus Progestin Therapy for Prevention</div>
                                            <div class="related-journal-name">JAMA</div>
                    <div class="related-article-type">Editorial</div>
                    <div class="related-article-date">July 17, 2002</div>
                    <div class="related-article-excerpt"></div>
                    <div class="related-article-authors">Suzanne W. Fletcher, MD, MSc; Graham A. Colditz, MD, DrPH</div>
                </a>
            </li>
    </ul>
 
    </div>
    <div class="widget-EditorsChoice widget-instance-AMA_EditorsChoice_Links">
        
 
    </div>
    <div class="widget-RelatedTopics widget-instance-AMA_Related_Topics">
        
        <div class="related-topics-block">
            <h4 class="related-topics-heading topic-suggestions-heading sb-sc">
See More About            </h4>
            <div class="related-topics topic-suggestions">
    <a href="https://jamanetwork.com/collections/5538/breast-cancer" id="item_Link" class="related-topic topic-suggestion no-wrap sb-anchor-light">Breast Cancer</a>    <a href="https://jamanetwork.com/collections/5571/colorectal-cancer" id="item_Link_1" class="related-topic topic-suggestion no-wrap sb-anchor-light">Colorectal Cancer</a>    <a href="https://jamanetwork.com/collections/5655/gastroenterology" id="item_Link_2" class="related-topic topic-suggestion no-wrap sb-anchor-light">Gastroenterology</a>    <a href="https://jamanetwork.com/collections/5657/gastrointestinal-cancer" id="item_Link_3" class="related-topic topic-suggestion no-wrap sb-anchor-light">Gastrointestinal Cancer</a>    <a href="https://jamanetwork.com/collections/5801/oncology" id="item_Link_4" class="related-topic topic-suggestion no-wrap sb-anchor-light">Oncology</a>    <a href="https://jamanetwork.com/collections/5808/orthopedics" id="item_Link_5" class="related-topic topic-suggestion no-wrap sb-anchor-light">Orthopedics</a>    <a href="https://jamanetwork.com/collections/42111/gynecology" id="item_Link_6" class="related-topic topic-suggestion no-wrap sb-anchor-light">Gynecology</a>    <a href="https://jamanetwork.com/collections/42136/trauma-and-injury" id="item_Link_7" class="related-topic topic-suggestion no-wrap sb-anchor-light">Trauma and Injury</a>    <a href="https://jamanetwork.com/collections/42139/womens-health" id="item_Link_8" class="related-topic topic-suggestion no-wrap sb-anchor-light">Women's Health</a>    <a href="https://jamanetwork.com/collections/44012/gastroenterology-and-hepatology" id="item_Link_9" class="related-topic topic-suggestion no-wrap sb-anchor-light">Gastroenterology and Hepatology</a>    <a href="https://jamanetwork.com/collections/44013/obstetrics-and-gynecology" id="item_Link_10" class="related-topic topic-suggestion no-wrap sb-anchor-light">Obstetrics and Gynecology</a>            </div>
        </div>
 
    </div>
                <div class="ymal--footer">
    <div class="widget-WidgetLoader widget-instance-AMA_PersonalizedContent_SplitScreenView_Footer">
        <div class="SCM-SharedWidgets-AsyncWidgetLoader" data-url="/Personalization/PersonalizedContent/AMA_PersonalizedContent_SplitScreenView_Footer" data-params="{&quot;parameters&quot;:{&quot;resourceIdToExclude&quot;:195120,&quot;resourceTypeToExclude&quot;:3},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

                </div>
                <hr />
                <div class="manage-interest">
                    <h4><a href="#" class="manage-interests-link-no-access thm-col-sec">Select Your Interests</a></h4>
    <div class="widget-ManageCollectionInterests widget-instance-ManageCollectionInterests_SplitScreen">
        <div class="manage-interests-modal reveal-modal small modal" data-reveal>
<div class="manage-interests--header">
    <div class="widget-SelfServeContent widget-instance-AMA_ManageInterests_Header">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="AllSitesManageInterestsHeader" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style>
    h4 {
    font-size: 20px !important;
    }
</style>
<h4>Select Your Interests</h4>
<p>Customize your JAMA Network experience by selecting one or more topics from the list below.</p>


</div>

 
    </div>

</div><div class="manage-interests--categories">
    <ul class="category-list">
            <li><span class="category-list-item " data-categoryid="46425">Academic Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5489">Acid Base, Electrolytes, Fluids</span></li>
            <li><span class="category-list-item " data-categoryid="5504">Allergy and Clinical Immunology</span></li>
            <li><span class="category-list-item " data-categoryid="46447">American Indian or Alaska Natives</span></li>
            <li><span class="category-list-item " data-categoryid="5510">Anesthesiology</span></li>
            <li><span class="category-list-item " data-categoryid="42143">Anticoagulation</span></li>
            <li><span class="category-list-item " data-categoryid="6261">Art and Images in Psychiatry</span></li>
            <li><span class="category-list-item " data-categoryid="44024">Artificial Intelligence</span></li>
            <li><span class="category-list-item " data-categoryid="42097">Assisted Reproduction</span></li>
            <li><span class="category-list-item " data-categoryid="42099">Bleeding and Transfusion</span></li>
            <li><span class="category-list-item " data-categoryid="5548">Cardiology</span></li>
            <li><span class="category-list-item " data-categoryid="44036">Caring for the Critically Ill Patient</span></li>
            <li><span class="category-list-item " data-categoryid="6255">Challenges in Clinical Electrocardiography</span></li>
            <li><span class="category-list-item " data-categoryid="46435">Climate and Health</span></li>
            <li><span class="category-list-item " data-categoryid="46448">Climate Change</span></li>
            <li><span class="category-list-item " data-categoryid="44038">Clinical Challenge</span></li>
            <li><span class="category-list-item " data-categoryid="5589">Clinical Decision Support</span></li>
            <li><span class="category-list-item " data-categoryid="44039">Clinical Implications of Basic Neuroscience</span></li>
            <li><span class="category-list-item " data-categoryid="5614">Clinical Pharmacy and Pharmacology</span></li>
            <li><span class="category-list-item " data-categoryid="5575">Complementary and Alternative Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="44040">Consensus Statements</span></li>
            <li><span class="category-list-item " data-categoryid="46099">Coronavirus (COVID-19)</span></li>
            <li><span class="category-list-item " data-categoryid="5584">Critical Care Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="46325">Cultural Competency</span></li>
            <li><span class="category-list-item " data-categoryid="44019">Dental Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5598">Dermatology</span></li>
            <li><span class="category-list-item " data-categoryid="44011">Diabetes and Endocrinology</span></li>
            <li><span class="category-list-item " data-categoryid="46320">Diagnostic Test Interpretation</span></li>
            <li><span class="category-list-item " data-categoryid="42054">Drug Development</span></li>
            <li><span class="category-list-item " data-categoryid="5620">Electronic Health Records</span></li>
            <li><span class="category-list-item " data-categoryid="5621">Emergency Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5819">End of Life, Hospice, Palliative Care</span></li>
            <li><span class="category-list-item " data-categoryid="42107">Environmental Health</span></li>
            <li><span class="category-list-item " data-categoryid="46387">Equity, Diversity, and Inclusion</span></li>
            <li><span class="category-list-item " data-categoryid="42108">Ethics</span></li>
            <li><span class="category-list-item " data-categoryid="5644">Facial Plastic Surgery</span></li>
            <li><span class="category-list-item " data-categoryid="44012">Gastroenterology and Hepatology</span></li>
            <li><span class="category-list-item " data-categoryid="5664">Genetics and Genomics</span></li>
            <li><span class="category-list-item " data-categoryid="44041">Genomics and Precision Health</span></li>
            <li><span class="category-list-item " data-categoryid="5668">Geriatrics</span></li>
            <li><span class="category-list-item " data-categoryid="5670">Global Health</span></li>
            <li><span class="category-list-item " data-categoryid="46427">Guide to Statistics and Methods</span></li>
            <li><span class="category-list-item " data-categoryid="5672">Guidelines</span></li>
            <li><span class="category-list-item " data-categoryid="5674">Hair Disorders</span></li>
            <li><span class="category-list-item " data-categoryid="42113">Health Care Delivery Models</span></li>
            <li><span class="category-list-item " data-categoryid="42114">Health Care Economics, Insurance, Payment</span></li>
            <li><span class="category-list-item " data-categoryid="42116">Health Care Quality</span></li>
            <li><span class="category-list-item " data-categoryid="5680">Health Care Reform</span></li>
            <li><span class="category-list-item " data-categoryid="5830">Health Care Safety</span></li>
            <li><span class="category-list-item " data-categoryid="5682">Health Care Workforce</span></li>
            <li><span class="category-list-item " data-categoryid="5679">Health Disparities</span></li>
            <li><span class="category-list-item " data-categoryid="46328">Health Inequities</span></li>
            <li><span class="category-list-item " data-categoryid="44020">Health Policy</span></li>
            <li><span class="category-list-item " data-categoryid="46451">Health Systems Science</span></li>
            <li><span class="category-list-item " data-categoryid="5688">Hematology</span></li>
            <li><span class="category-list-item " data-categoryid="5692">History of Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5514">Humanities</span></li>
            <li><span class="category-list-item " data-categoryid="5697">Hypertension</span></li>
            <li><span class="category-list-item " data-categoryid="44043">Images in Neurology</span></li>
            <li><span class="category-list-item " data-categoryid="45887">Implementation Science</span></li>
            <li><span class="category-list-item " data-categoryid="5702">Infectious Diseases</span></li>
            <li><span class="category-list-item " data-categoryid="44044">Innovations in Health Care Delivery</span></li>
            <li><span class="category-list-item " data-categoryid="44070">JAMA Infographic</span></li>
            <li><span class="category-list-item " data-categoryid="5716">Law and Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="45308">Leading Change</span></li>
            <li><span class="category-list-item " data-categoryid="44045">Less is More</span></li>
            <li><span class="category-list-item " data-categoryid="46327">LGBTQIA Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5720">Lifestyle Behaviors</span></li>
            <li><span class="category-list-item " data-categoryid="45311">Medical Coding</span></li>
            <li><span class="category-list-item " data-categoryid="5738">Medical Devices and Equipment</span></li>
            <li><span class="category-list-item " data-categoryid="44023">Medical Education</span></li>
            <li><span class="category-list-item " data-categoryid="5739">Medical Education and Training</span></li>
            <li><span class="category-list-item " data-categoryid="5713">Medical Journals and Publishing</span></li>
            <li><span class="category-list-item " data-categoryid="5746">Melanoma</span></li>
            <li><span class="category-list-item " data-categoryid="44025">Mobile Health and Telemedicine</span></li>
            <li><span class="category-list-item " data-categoryid="5766">Narrative Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5769">Nephrology</span></li>
            <li><span class="category-list-item " data-categoryid="5777">Neurology</span></li>
            <li><span class="category-list-item " data-categoryid="44052">Neuroscience and Psychiatry</span></li>
            <li><span class="category-list-item " data-categoryid="44053">Notable Notes</span></li>
            <li><span class="category-list-item " data-categoryid="5787">Nursing</span></li>
            <li><span class="category-list-item " data-categoryid="5788">Nutrition</span></li>
            <li><span class="category-list-item " data-categoryid="44027">Nutrition, Obesity, Exercise</span></li>
            <li><span class="category-list-item " data-categoryid="5791">Obesity</span></li>
            <li><span class="category-list-item " data-categoryid="44013">Obstetrics and Gynecology</span></li>
            <li><span class="category-list-item " data-categoryid="5796">Occupational Health</span></li>
            <li><span class="category-list-item " data-categoryid="5801">Oncology</span></li>
            <li><span class="category-list-item " data-categoryid="5804">Ophthalmology</span></li>
            <li><span class="category-list-item " data-categoryid="5808">Orthopedics</span></li>
            <li><span class="category-list-item " data-categoryid="5811">Otolaryngology</span></li>
            <li><span class="category-list-item " data-categoryid="44028">Pain Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="46446">Palliative Care</span></li>
            <li><span class="category-list-item " data-categoryid="44029">Pathology and Laboratory Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="45306">Patient Care</span></li>
            <li><span class="category-list-item " data-categoryid="6258">Patient Information</span></li>
            <li><span class="category-list-item " data-categoryid="5843">Pediatrics</span></li>
            <li><span class="category-list-item " data-categoryid="44060">Performance Improvement</span></li>
            <li><span class="category-list-item " data-categoryid="45315">Performance Measures</span></li>
            <li><span class="category-list-item " data-categoryid="42050">Perioperative Care and Consultation</span></li>
            <li><span class="category-list-item " data-categoryid="42125">Pharmacoeconomics</span></li>
            <li><span class="category-list-item " data-categoryid="42126">Pharmacoepidemiology</span></li>
            <li><span class="category-list-item " data-categoryid="5851">Pharmacogenetics</span></li>
            <li><span class="category-list-item " data-categoryid="44030">Pharmacy and Clinical Pharmacology</span></li>
            <li><span class="category-list-item " data-categoryid="5856">Physical Medicine and Rehabilitation</span></li>
            <li><span class="category-list-item " data-categoryid="42059">Physical Therapy</span></li>
            <li><span class="category-list-item " data-categoryid="45313">Physician Leadership</span></li>
            <li><span class="category-list-item " data-categoryid="44061">Poetry</span></li>
            <li><span class="category-list-item " data-categoryid="45316">Population Health</span></li>
            <li><span class="category-list-item " data-categoryid="46445">Primary Care</span></li>
            <li><span class="category-list-item " data-categoryid="45309">Professional Well-being</span></li>
            <li><span class="category-list-item " data-categoryid="44064">Professionalism</span></li>
            <li><span class="category-list-item " data-categoryid="5871">Psychiatry and Behavioral Health</span></li>
            <li><span class="category-list-item " data-categoryid="42128">Public Health</span></li>
            <li><span class="category-list-item " data-categoryid="5877">Pulmonary Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="42129">Radiology</span></li>
            <li><span class="category-list-item " data-categoryid="42058">Regulatory Agencies</span></li>
            <li><span class="category-list-item " data-categoryid="46443">Reproductive Health</span></li>
            <li><span class="category-list-item " data-categoryid="5916">Research, Methods, Statistics</span></li>
            <li><span class="category-list-item " data-categoryid="42142">Resuscitation</span></li>
            <li><span class="category-list-item " data-categoryid="5896">Rheumatology</span></li>
            <li><span class="category-list-item " data-categoryid="46326">Risk Management</span></li>
            <li><span class="category-list-item " data-categoryid="38802">Scientific Discovery and the Future of Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5833">Shared Decision Making and Communication</span></li>
            <li><span class="category-list-item " data-categoryid="5912">Sleep Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5915">Sports Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5533">Stem Cell Transplantation</span></li>
            <li><span class="category-list-item " data-categoryid="5921">Substance Use and Addiction Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="5923">Surgery</span></li>
            <li><span class="category-list-item " data-categoryid="44065">Surgical Innovation</span></li>
            <li><span class="category-list-item " data-categoryid="44066">Surgical Pearls</span></li>
            <li><span class="category-list-item " data-categoryid="44067">Teachable Moment</span></li>
            <li><span class="category-list-item " data-categoryid="45310">Technology and Finance</span></li>
            <li><span class="category-list-item " data-categoryid="44034">The Art of JAMA</span></li>
            <li><span class="category-list-item " data-categoryid="44037">The Arts and Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="6257">The Rational Clinical Examination</span></li>
            <li><span class="category-list-item " data-categoryid="5936">Tobacco and e-Cigarettes</span></li>
            <li><span class="category-list-item " data-categoryid="5938">Toxicology</span></li>
            <li><span class="category-list-item " data-categoryid="46433">Translational Medicine</span></li>
            <li><span class="category-list-item " data-categoryid="42136">Trauma and Injury</span></li>
            <li><span class="category-list-item " data-categoryid="5942">Treatment Adherence</span></li>
            <li><span class="category-list-item " data-categoryid="46323">Ultrasonography</span></li>
            <li><span class="category-list-item " data-categoryid="5947">Urology</span></li>
            <li><span class="category-list-item " data-categoryid="44069">Users&#39; Guide to the Medical Literature</span></li>
            <li><span class="category-list-item " data-categoryid="5950">Vaccination</span></li>
            <li><span class="category-list-item " data-categoryid="5955">Venous Thromboembolism</span></li>
            <li><span class="category-list-item " data-categoryid="45312">Veterans Health</span></li>
            <li><span class="category-list-item " data-categoryid="5957">Violence</span></li>
            <li><span class="category-list-item " data-categoryid="42139">Women&#39;s Health</span></li>
            <li><span class="category-list-item " data-categoryid="45307">Workflow and Process</span></li>
            <li><span class="category-list-item " data-categoryid="42140">Wound Care, Infection, Healing</span></li>
    </ul>
</div>

    
<div class="manage-interests--save-preferences">
    <div class="save-preferences-btn thm-bg ">
        <span class="save-preferences-btn-text fw-b">Save Preferences</span>
    </div>
</div>
<div class="manage-interests--privacy-terms"> <a class="manage-interests--privacy-terms-color" href="/pages/privacy-policy">Privacy Policy</a> | <a class="manage-interests--privacy-terms-color" href="/pages/terms-of-use">Terms of Use</a></div>

    
    <a class="close-reveal-modal icon-close"></a>
</div> 
    </div>

                </div>
                <h4 class="thm-col-sec" align="center">
                    Others Also Liked
                </h4>
                <div id="trendmd-suggestions"></div>

        </div>


        
        <div id="comments-tab" class="resource-tab js-resource-tab comments-tab js-comments-tab single-comment-view">



        </div>
    </div>
</div>

<a id="skip-to-navigation" href="#" tabindex="-1"></a>
<div id="content-panel" class="content-panel">
    <a id="top"></a>

    <div id="full-text-tab" class="resource-tab js-resource-tab full-text-tab">
    <div class="widget-ArticleLinks widget-instance-AMA_ErrataArticleLinks_FullText">
         
    </div>
    <div class="widget-ArticleLinks widget-instance-AMA_ArticleLinks_ToErrata_FullText">
        
 
    </div>
    <div class="widget-ArticleNavLinks widget-instance-AMA_ArticleNavLinks">
                <a class="toc-link btn" href="https://jamanetwork.com/journals/jama/issue/288/3">This Issue</a>
 
    </div>



            <div class="article-metrics-wrapper" id="divArticleLevelMetrics">
    <div class="widget-ArticleLevelMetrics widget-instance-AMA_ArticleMetrics">
        

    <div class="artmet-condensed-wrap clearfix">
        <div class="artmet-condensed-stats clearfix">
                                <div class="artmet-item artmet-citations">
                            <a class="artmet-citations-link" href="https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=silverchair&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000176807000024&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL" target="_blank">
                                <span class="artmet-text">Citations</span>
                                <span class="artmet-number">11,812</span>
                            </a>
                    </div>
            
        </div>

        <div class="artmet-modal-trigger-wrap">
            <a rel="nofollow" class="artmet-modal-trigger" data-article-id="195120"><i class="icon-metrics"></i><span>View Metrics</span></a>
        </div>
    </div>

 
    </div>

            </div>
        <ul class="toolbar">
            <li class="toolbar-pdf-wrap toolbar-tool-wrap">
            <a id="pdf-link" class="toolbar-tool toolbar-pdf al-link pdfaccess" data-article-id="195120" data-article-url="/journals/jama/articlepdf/195120/joc21036.pdf" data-ajax-url="/Content/CheckPdfAccess"><span class="toolbar-pdf-text"><span class="toolbar-link-text-extra">Download </span><span class="toolbar-link-text">PDF</span></span>
            </a>

            </li>
            <li class="toolbar-share-wrap toolbar-tool-wrap">
                <div class="toolbar-tool">
                    <a class="st-custom-button addthis_button_twitter is-b toolbar-twitter toolbar-share"
                       data-network="twitter"
                       data-title=""
                       data-url=""
                       data-email-subject=""
                       rel="nofollow"
                       href="javascript:;">
                        <span class="share-text">X</span>
                    </a>
                    <a class="st-custom-button addthis_button_facebook is-b toolbar-facebook toolbar-share"
                       data-network="facebook"
                       data-title=""
                       data-url=""
                       data-email-subject=""
                       rel="nofollow"
                       href="javascript:;">
                        <span class="share-text">Facebook</span>
                    </a>
                    <a class="toolbar-share-more-link is-a" rel="nofollow"><span class="icon icon-carrot_down social-arrow"></span><span class="more-text-wrap">More</span></a>
                    <div class="toolbar-share-more">
                        <a class="st-custom-button addthis_button_linkedin is-b toolbar-linkedin toolbar-share"
                           data-network="linkedin"
                           data-title=""
                           data-url=""
                           data-email-subject=""
                           rel="nofollow"
                           href="javascript:;">
                            <span class="share-text">LinkedIn</span>
                        </a>
                    </div>
                </div>
            </li>

            <li class="toolbar-citation-wrap toolbar-tool-wrap">
    <div class="widget-ToolboxGetCitation widget-instance-AMA_Get_Citation">
        
        <a class="toolbar-tool toolbar-citation is-b stats-citation" rel="nofollow" data-reveal-id="get-citation" data-reveal>
            <span class="toolbar-link-text">Cite</span>
            <span class="toolbar-link-text-extra">This</span>
        </a>
    <div id="get-citation" class="reveal-modal get-citation" data-reveal>
        <h3 class="get-citation-title">Citation</h3>
        <p class="get-citation-citation">Writing Group for the Women's Health Initiative Investigators. Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women<span class="subtitle"><span class="colon-for-citation-subtitle">: </span>Principal Results From the Women's Health Initiative Randomized Controlled Trial</span>. <em>JAMA.</em> 2002;288(3):321333. doi:10.1001/jama.288.3.321</p>
        <h4 class="get-citation-download-heading">Manage citations:</h4>
        <div class="get-citation-types">
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195120&amp;resourceType=3&amp;citationFormat=0">Ris (Zotero)</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195120&amp;resourceType=3&amp;citationFormat=1">EndNote</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195120&amp;resourceType=3&amp;citationFormat=2">BibTex</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195120&amp;resourceType=3&amp;citationFormat=3">Medlars</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195120&amp;resourceType=3&amp;citationFormat=0">ProCite</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195120&amp;resourceType=3&amp;citationFormat=3">RefWorks</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195120&amp;resourceType=3&amp;citationFormat=0">Reference Manager</a>
            <a class="get-citation-format" rel="nofollow" href="/Citation/Download?resourceId=195120&amp;resourceType=3&amp;citationFormat=0">Mendeley</a>
        </div>

        <p class="get-citation-copyright">&#169; 2024 </p>
        <a class="close-reveal-modal icon-close" rel="nofollow"></a>
    </div>


 
    </div>

            </li>
            <li class="toolbar-permissions-wrap toolbar-tool-wrap">
    <div class="widget-ToolboxPermissions widget-instance-AMA_Get_Permissions">
            <a href="http://s100.copyright.com/AppDispatchServlet?publisherName=AMA&amp;publication=0098-7484&amp;title=Risks+and+Benefits+of+Estrogen+Plus+Progestin+in+Healthy+Postmenopausal+Women%26lt%3bspan+class%3d%26quot%3bsubtitle%26quot%3b%26gt%3b%26lt%3bspan+class%3d%26quot%3bcolon-for-citation-subtitle%26quot%3b%26gt%3b%3a+%26lt%3b%2fspan%26gt%3bPrincipal+Results+From+the+Women%26apos%3bs+Health+Initiative+Randomized+Controlled+Trial%26lt%3b%2fspan%26gt%3b&amp;publicationDate=2002-07-17&amp;volumeNum=288&amp;issueNum=3&amp;author=Writing+Group+for+the+Women%27s+Health+Initiative+Investigators&amp;startPage=321&amp;endPage=333&amp;contentId=10.1001%2fjama.288.3.321&amp;oa=&amp;orderBeanReset=True" rel="nofollow" id="PermissionsLink" class="toolbar-tool toolbar-permissions is-b" target="_blank"><span class="toolbar-link-text">Permissions</span></a>
 
    </div>

            </li>
        </ul>

    <div class="widget-ArticleTopInfo widget-instance-AMA_ArticleTop_Info_Widget">
        

    <div class="meta-access-type free-access is-b"></div>


            <span class="hide tagmanagervalue" data-attribute="articleId" data-value="195120" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="arrArticleAuthor" data-value="Writing%20Group%20for%20the%20Women%27s%20Health%20Initiative%20Investigators" data-type="array"></span>
            <span class="hide tagmanagervalue" data-attribute="articleDOI" data-value="10.1001/jama.288.3.321" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="articleTitle" data-value="Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women&lt;span class=&quot;subtitle&quot;&gt;&lt;span class=&quot;colon-for-citation-subtitle&quot;&gt;: &lt;/span&gt;Principal Results From the Women&#39;s Health Initiative Randomized Controlled Trial&lt;/span&gt;" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="type" data-value="Original Contribution" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="issueVolume" data-value="288" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="issueNo" data-value="3" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="publishDate" data-value="July 17, 2002" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="topics" data-value="Breast Cancer, Colorectal Cancer, Gastroenterology, Gastrointestinal Cancer, Oncology, Orthopedics, Gynecology, Trauma and Injury, Women&#39;s Health, Gastroenterology and Hepatology, Obstetrics and Gynecology" data-type="array"></span>
            <span class="hide tagmanagervalue" data-attribute="topicCode" data-value="5538, 5571, 5655, 5657, 5801, 5808, 42111, 42136, 42139, 44012, 44013" data-type="array"></span>
            <span class="hide tagmanagervalue" data-attribute="category" data-value="Research" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="journalClub" data-value="No" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="contentStatus" data-value="Free" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="articlePubState" data-value="Final" data-type="string"></span>
            <span class="hide tagmanagervalue" data-attribute="contentMedium" data-value="Article" data-type="string"></span>


        <div class="meta-article-type-wrap">
            <div class="meta-article-type thm-col">Original Contribution </div>
        </div>
        <div class="meta-date">July 17, 2002</div>
        <div class="meta-article-title-wrap">
            
            <h1 class="meta-article-title ">Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women<span class="subtitle"><span class="colon-for-citation-subtitle">: </span>Principal Results From the Women's Health Initiative Randomized Controlled Trial</span></h1>

            
        </div>
            <div class="meta-authors">
                <span class="wi-fullname brand-fg"><a href="/searchresults?author=Writing+Group+for+the+Women%27s+Health+Initiative+Investigators&q=Writing+Group+for+the+Women%27s+Health+Initiative+Investigators" rel=nofollow target="_blank">Writing Group for the Women's Health Initiative Investigators<sup></sup></a></span>
            </div>
            <div class="meta-author">
                <a class="meta-author-title is-b stats-meta-author-toggle" data-tog-target=".meta-author-content">Author Affiliations</a>


                <div class="meta-author-content">



                            <div class="meta-author-notes"><p class="para"><strong>Writing Group for the Women's Health Initiative Investigators:</strong> Jacques E. Rossouw, MBChB, MD, National Heart, Lung, and Blood Institute, Bethesda, Md; Garnet L. Anderson, PhD, Ross L. Prentice, PhD, Andrea Z. LaCroix, PhD, and Charles Kooperberg, PhD, Fred Hutchinson Cancer Research Center, Seattle, Wash; Marcia L. Stefanick, PhD, Stanford University Clinical Center, Stanford, Calif; Rebecca D. Jackson, MD, Ohio State University Clinical Center, Columbus; Shirley A. A. Beresford, PhD, Fred Hutchinson Cancer Research Center, Seattle, Wash; Barbara V. Howard, PhD, MedStar Research Institute, Washington, DC; Karen C. Johnson, MD, MPH, University of Tennessee, Memphis; Jane Morley Kotchen, MD, Medical College of Wisconsin, Milwaukee; Judith Ockene, PhD, University of Massachusetts Medical School, Worcester.</p></div>
                </div>
            </div>
        <div class="meta-citation-wrap">
            <span class="meta-citation-journal-name">JAMA. </span><span class="meta-citation"> 2002;288(3):321-333. doi:10.1001/jama.288.3.321</span>
        </div>

 
    </div>
    <div class="widget-EditorsChoice widget-instance-AMA_EditorsChoice_Links">
        
 
    </div>
    <div class="widget-LinkedContentToolbar widget-instance-AMA_LinkedContentToolbar">
        
<div class="linked-content-toolbar">
    
    <div class="hidden js-search-open-multimedia-by-default" showContentByDefault="False"></div>
    <div class="linked-content-controls">
        <a class="linked-content-trigger td-n stats-graphical-abstract" href="#graphical-abstract-tab">
            <i class="icon-visual-abstract"><span class="sr-t">visual abstract icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Visual <div>Abstract</div></div>
        </a>
        <a class="linked-content-trigger td-n stats-editorial-comment" href="#editorial-comment-tab">
            <i class="icon-document"><span class="sr-t">editorial comment icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Editorial <div>Comment</div></div>
        </a>
        <a class="linked-content-trigger td-n stats-related-articles" href="#related-articles-tab">
            <i class="icon-related"><span class="sr-t">related articles icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Related <div>Articles</div></div>
        </a>
        <a class="linked-content-trigger td-n stats-author-interviews" href="#author-interviews-tab">
            <i class="icon-author_interview"><span class="sr-t">author interview icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Interviews</div>
        </a>
        <a class="linked-content-trigger td-n stats-more-multimedia" href="#more-multimedia-tab">
            <i class="icon-multimedia"><span class="sr-t">multimedia icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Multimedia</div>
        </a>
        <a class="linked-content-trigger td-n stats-listen-to-this-article" href="#listen-to-this-article-tab">
            <i class="icon-audio"><span class="sr-t">audio icon</span></i>
            <div class="trigger-text d-ib va-m ta-l fw-5">Listen to <div>this article</div></div>
        </a>
    </div>

    
<div class="linked-content-tabs">
    <div id="graphical-abstract-tab" class="linked-content-tab graphical-abstract-tab">
    <div class="widget-SectionDisplay widget-instance-AMA_GraphicalAbstract_Tab">
        
 
    </div>

    </div>

    
    <div id="editorial-comment-tab" class="linked-content-tab editorial-comment-tab">
    <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_EditorialComments">
        
    <ul class="article-abstract-links related-abstract-content">
            <li class="article-link related-abstract-article">

                    <a class="related-article-title" href="https://jamanetwork.com/journals/jama/fullarticle/195112">
                            <div class="related-article-type">Editorial</div>
                        <div class="related-article-title sb-tc">Failure of Estrogen Plus Progestin Therapy for Prevention</div>
                    </a>
                    <div class="related-article-authors">Suzanne W. Fletcher, MD, MSc; Graham A. Colditz, MD, DrPH</div>
                                    <div class="related-article-journal-name">JAMA</div>
            </li>
    </ul>
 
    </div>

    </div>

    
    <div id="related-articles-tab" class="linked-content-tab related-article-tab">
    <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_RelatedArticle">
        
 
    </div>
    <div class="widget-ArticleLinks widget-instance-AMA_LinkedContentToolbar_RelatedEditorsChoices">
        
 
    </div>

    </div>

    
    <div id="author-interviews-tab" class="linked-content-tab linked-author-interviews-tab">
    <div class="widget-AudioPlayer widget-instance-AMA_LinkedContentToolbar_PlatformAudioPlayer_AuthorInterviews">
         
    </div>

    </div>

    
    <div id="listen-to-this-article-tab" class="linked-content-tab linked-listen-to-this-article-tab">
    <div class="widget-AudioPlayer widget-instance-AMA_LinkedContentToolbar_PlatformAudioPlayer_ListenToThisArticle">
         
    </div>

    </div>

    
    <div id="more-multimedia-tab" class="linked-content-tab more-multimedia-tab">

    </div>
</div>
</div> 
    </div>

            <div class="widget-ArticleFulltext widget-instance-AMA_Article_FullText_Widget">
        <div class="article-full-text" data-userHasAccess="True">
    

            <a class="article-section-id-anchor" id="25024139"></a>
                        <div class="h3 cb section-type-abstract decorated-hed ">

                            <div class="heading-text thm-col sb-sc">
                                Abstract
                            </div>
                        </div>
<p><strong>Context</strong>Despite decades of accumulated observational evidence, the balance of
risks and benefits for hormone use in healthy postmenopausal women remains
uncertain.</p><p><strong>Objective</strong>To assess the major health benefits and risks of the most commonly used
combined hormone preparation in the United States.</p><p><strong>Design</strong>Estrogen plus progestin component of the Women's Health Initiative,
a randomized controlled primary prevention trial (planned duration, 8.5 years)
in which 16608 postmenopausal women aged 50-79 years with an intact uterus
at baseline were recruited by 40 US clinical centers in 1993-1998.</p><p><strong>Interventions</strong>Participants received conjugated equine estrogens, 0.625 mg/d, plus
medroxyprogesterone acetate, 2.5 mg/d, in 1 tablet (n = 8506) or placebo (n
= 8102).</p><p><strong>Main Outcomes Measures</strong>The primary outcome was coronary heart disease (CHD) (nonfatal myocardial
infarction and CHD death), with invasive breast cancer as the primary adverse
outcome. A global index summarizing the balance of risks and benefits included
the 2 primary outcomes plus stroke, pulmonary embolism (PE), endometrial cancer,
colorectal cancer, hip fracture, and death due to other causes.</p><p><strong>Results</strong>On May 31, 2002, after a mean of 5.2 years of follow-up, the data and
safety monitoring board recommended stopping the trial of estrogen plus progestin
vs placebo because the test statistic for invasive breast cancer exceeded
the stopping boundary for this adverse effect and the global index statistic
supported risks exceeding benefits. This report includes data on the major
clinical outcomes through April 30, 2002. Estimated hazard ratios (HRs) (nominal
95% confidence intervals [CIs]) were as follows: CHD, 1.29 (1.02-1.63) with
286 cases; breast cancer, 1.26 (1.00-1.59) with 290 cases; stroke, 1.41 (1.07-1.85)
with 212 cases; PE, 2.13 (1.39-3.25) with 101 cases; colorectal cancer, 0.63
(0.43-0.92) with 112 cases; endometrial cancer, 0.83 (0.47-1.47) with 47 cases;
hip fracture, 0.66 (0.45-0.98) with 106 cases; and death due to other causes,
0.92 (0.74-1.14) with 331 cases. Corresponding HRs (nominal 95% CIs) for composite
outcomes were 1.22 (1.09-1.36) for total cardiovascular disease (arterial
and venous disease), 1.03 (0.90-1.17) for total cancer, 0.76 (0.69-0.85) for
combined fractures, 0.98 (0.82-1.18) for total mortality, and 1.15 (1.03-1.28)
for the global index. Absolute excess risks per 10000 person-years attributable
to estrogen plus progestin were 7 more CHD events, 8 more strokes, 8 more
PEs, and 8 more invasive breast cancers, while absolute risk reductions per
10000 person-years were 6 fewer colorectal cancers and 5 fewer hip fractures.
The absolute excess risk of events included in the global index was 19 per
10000 person-years.</p><p><strong>Conclusions</strong>Overall health risks exceeded benefits from use of combined estrogen
plus progestin for an average 5.2-year follow-up among healthy postmenopausal
US women. All-cause mortality was not affected during the trial. The risk-benefit
profile found in this trial is not consistent with the requirements for a
viable intervention for primary prevention of chronic diseases, and the results
indicate that this regimen should not be initiated or continued for primary
prevention of CHD.</p>            <div class="movable-ad-target bta"> </div>
            <a class="article-section-id-anchor" id="25024143"></a>
<p class="para">The Women's Health Initiative (WHI) focuses on defining the risks and
benefits of strategies that could potentially reduce the incidence of heart
disease, breast and colorectal cancer, and fractures in postmenopausal women.
Between 1993 and 1998, the WHI enrolled 161809 postmenopausal women
in the age range of 50 to 79 years into a set of clinical trials (trials of
low-fat dietary pattern, calcium and vitamin D supplementation, and 2 trials
of postmenopausal hormone use) and an observational study at 40 clinical centers
in the United States.<sup><a href="#REF-JOC21036-1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> This article reports
principal results for the trial of combined estrogen and progestin in women
with a uterus. The trial was stopped early based on health risks that exceeded
health benefits over an average follow-up of 5.2 years. A parallel trial of
estrogen alone in women who have had a hysterectomy is being continued, and
the planned end of this trial is March 2005, by which time the average follow-up
will be about 8.5 years.</p>            <a class="article-section-id-anchor" id="25024146"></a>
<p class="para">The WHI clinical trials were designed in 1991-1992 using the accumulated
evidence at that time. The primary outcome for the trial of estrogen plus
progestin was designated as coronary heart disease (CHD). Potential cardioprotection
was based on generally supportive data on lipid levels in intermediate outcome
clinical trials, trials in nonhuman primates, and a large body of observational
studies suggesting a 40% to 50% reduction in risk among users of either estrogen
alone or, less frequently, combined estrogen and progestin.<sup><a href="#REF-JOC21036-2" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">2</a></sup><sup>-<a href="#REF-JOC21036-2" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">5</a></sup>
Hip fracture was designated as a secondary outcome, supported by observational
data as well as clinical trials showing benefit for bone mineral density.<sup><a href="#REF-JOC21036-6" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">6</a></sup><sup>,<a href="#REF-JOC21036-7" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">7</a></sup> Invasive breast cancer was designated
as a primary adverse outcome based on observational data.<sup><a href="#REF-JOC21036-3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">3</a></sup><sup>,<a href="#REF-JOC21036-8" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">8</a></sup>
Additional clinical outcomes chosen as secondary outcomes that may plausibly
be affected by hormone therapy include other cardiovascular diseases; endometrial,
colorectal, and other cancers; and other fractures.<sup><a href="#REF-JOC21036-3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">3</a></sup><sup>,<a href="#REF-JOC21036-6" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">6</a></sup><sup>,<a href="#REF-JOC21036-9" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">9</a></sup></p>            <a class="article-section-id-anchor" id="25024147"></a>
<p class="para">The effect of hormones on overall health was an important consideration
in the design and conduct of the WHI clinical trial. In an attempt to summarize
important aspects of health benefits vs risks, a global index was defined
as the earliest occurrence of CHD, invasive breast cancer, stroke, pulmonary
embolism (PE), endometrial cancer, colorectal cancer, hip fracture, or death
due to other causes. Compared with total mortality, which may be too insensitive,
this index assigns additional weight to the 7 listed diseases. Procedures
for monitoring the trial involved semiannual comparisons of the estrogen plus
progestin and placebo groups with respect to each of the elements of the global
index and to the overall global index.</p>            <a class="article-section-id-anchor" id="25024148"></a>
<p class="para">This report pertains primarily to estrogen plus progestin use among
healthy postmenopausal women, since only 7.7% of participating women reported
having had prior cardiovascular disease. During the course of the WHI trial,
the Heart and Estrogen/progestin Replacement Study (HERS) reported its principal
results.<sup><a href="#REF-JOC21036-10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup> HERS was another blinded, randomized
controlled trial comparing the same regimen of estrogen plus progestin with
placebo among women with a uterus; however, in HERS, all 2763 participating
women had documented CHD prior to randomization. The HERS findings of no overall
effect on CHD but an apparent increased risk in the first year after randomization
seemed surprising given preceding observational studies of hormone use in
women with CHD.<sup><a href="#REF-JOC21036-3" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">3</a></sup> Subsequent to HERS, some investigators
reanalyzed their observational study data and were able to detect an early
elevation in CHD risk among women with prior CHD<sup><a href="#REF-JOC21036-11" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">11</a></sup><sup>-<a href="#REF-JOC21036-11" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">13</a></sup>
but not in ostensibly healthy women,<sup><a href="#REF-JOC21036-14" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">14</a></sup> prompting
speculation that any early adverse effect of hormones on CHD incidence was
confined to women who have experienced prior CHD events.</p>            <a class="article-section-id-anchor" id="25024149"></a>
<p class="para">The WHI is the first randomized trial to directly address whether estrogen
plus progestin has a favorable or unfavorable effect on CHD incidence and
on overall risks and benefits in predominantly healthy women.</p>            <a class="article-section-id-anchor" id="25024150"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Methods
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024151"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Study Population
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024152"></a>
<p class="para">Detailed eligibility criteria and recruitment methods have been published.<sup><a href="#REF-JOC21036-1" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">1</a></sup> Briefly, most women were recruited by population-based
direct mailing campaigns to age-eligible women, in conjunction with media
awareness programs. Eligibility was defined as age 50 to 79 years at initial
screening, postmenopausal, likelihood of residence in the area for 3 years,
and provision of written informed consent. A woman was considered postmenopausal
if she had experienced no vaginal bleeding for 6 months (12 months for 50-
to 54-year-olds), had had a hysterectomy, or had ever used postmenopausal
hormones. Major exclusions were related to competing risks (any medical condition
likely to be associated with a predicted survival of &lt;3 years), safety
(eg, prior breast cancer, other prior cancer within the last 10 years except
nonmelanoma skin cancer, low hematocrit or platelet counts), and adherence
and retention concerns (eg, alcoholism, dementia).</p>            <a class="article-section-id-anchor" id="25024153"></a>
<p class="para">A 3-month washout period was required before baseline evaluation of
women using postmenopausal hormones at initial screening. Women with an intact
uterus at initial screening were eligible for the trial of combined postmenopausal
hormones, while women with a prior hysterectomy were eligible for the trial
of unopposed estrogen. This report is limited to the 16608 women with
an intact uterus at baseline who were enrolled in the trial component of estrogen
plus progestin vs placebo. The protocol and consent forms were approved by
the institutional review boards for all participating institutions (see Acknowledgment).</p>            <a class="article-section-id-anchor" id="25024154"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Study Regimens, Randomization, and Blinding
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024155"></a>
<p class="para">Combined estrogen and progestin was provided in 1 daily tablet containing
conjugated equine estrogen (CEE), 0.625 mg, and medroxyprogesterone acetate
(MPA), 2.5 mg (Prempro, Wyeth Ayerst, Philadelphia, Pa). A matching placebo
was provided to the control group. Eligible women were randomly assigned to
receive estrogen plus progestin or placebo after eligibility was established
and baseline assessments made (<a href="#joc21036f1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 1</a>).
The randomization procedure was developed at the WHI Clinical Coordinating
Center and implemented locally through a distributed study database, using
a randomized permuted block algorithm, stratified by clinical center site
and age group. All study medication bottles had a unique bottle number and
bar code to allow for blinded dispensing.</p>            <a class="article-section-id-anchor" id="25024157"></a>
<p class="para">Initially, the design allowed women with a uterus to be randomized to
receive unopposed estrogen, estrogen plus progestin, or placebo. After the
release of the Postmenopausal Estrogen/Progestin Intervention (PEPI) trial
results<sup><a href="#REF-JOC21036-15" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">15</a></sup> indicating that long-term adherence
to unopposed estrogen was not feasible in women with a uterus, the WHI protocol
was changed to randomize women with a uterus to only estrogen plus progestin
or placebo in equal proportions. The 331 women previously randomized to unopposed
estrogen were unblinded and reassigned to estrogen plus progestin. These women
are included in the estrogen plus progestin group in this report, resulting
in 8506 participants in the estrogen plus progestin group vs 8102 in the placebo
group. Analysis of the data excluding the women randomized before this protocol
change did not affect the results. Considerable effort was made to maintain
blinding of other participants and clinic staff. When required for safety
or symptom management, an unblinding officer provided the clinic gynecologist,
who was not involved with study outcomes activities, with the treatment assignment.</p>            <a class="article-section-id-anchor" id="25024158"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Follow-up
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024159"></a>
<p class="para">Study participants were contacted by telephone 6 weeks after randomization
to assess symptoms and reinforce adherence. Follow-up for clinical events
occurred every 6 months, with annual in-clinic visits required. At each semiannual
contact, a standardized interview collected information on designated symptoms
and safety concerns, and initial reports of outcome events were obtained using
a self-administered questionnaire. Adherence to study interventions was assessed
by weighing of returned bottles. The study protocol required annual mammograms
and clinical breast examinations; study medications were withheld if safety
procedures were not performed, but these participants continued to be followed
up. Electrocardiograms were collected at baseline and at follow-up years 3
and 6.</p>            <a class="article-section-id-anchor" id="25024160"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Data Collection, Management, and Quality Assurance
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024161"></a>
<p class="para">All data were collected on standardized study forms by certified staff
according to documented study procedures. Study data were entered into a local
clinical center database developed and maintained by the Clinical Coordinating
Center and provided to each site in the form of a local area network connected
to the Clinical Coordinating Center through a wide area network. Data quality
was ensured through standard data entry mechanisms, routine reporting and
database checks, random chart audits, and routine site visits.</p>            <a class="article-section-id-anchor" id="25024162"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Maintenance/Discontinuation of Study Medications
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024163"></a>
<p class="para">During the trial, some flexibility of the dosages of both estrogen and
progestin was allowed to manage symptoms such as breast tenderness and vaginal
bleeding. Vaginal bleeding was managed according to an algorithm that accounted
for the time since randomization, severity of the bleeding, treatment assignment,
and endometrial histology. Women who had a hysterectomy after randomization
for indications other than cancer were switched to unopposed estrogen or the
corresponding placebo without unblinding. These women are included in the
original randomization group for analyses.</p>            <a class="article-section-id-anchor" id="25024164"></a>
<p class="para">Permanent discontinuation of study medication was required by protocol
for women who developed breast cancer, endometrial pathologic state (hyperplasia
not responsive to treatment, atypia, or cancer), deep vein thrombosis (DVT)
or PE, malignant melanoma, meningioma, triglyceride level greater than 1000
mg/dL (11.3 mmol/L), or prescription of estrogen, testosterone, or selective
estrogen-receptor modulators by their personal physician. Medications were
temporarily discontinued in participants who had acute myocardial infarction
(MI), stroke, fracture, or major injury involving hospitalization, surgery
involving use of anesthesia, any illness resulting in immobilization for more
than 1 week, or any other severe illness in which hormone use is temporarily
inappropriate.</p>            <a class="article-section-id-anchor" id="25024165"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Outcome Ascertainment
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024166"></a>
<p class="para"><strong>Cardiovascular Disease</strong> Coronary heart disease was defined as acute MI requiring overnight hospitalization,
silent MI determined from serial electrocardiograms (ECGs), or CHD death.
The diagnosis of acute MI was established according to an algorithm adapted
from standardized criteria<sup><a href="#REF-JOC21036-16" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">16</a></sup> that included
cardiac pain, cardiac enzyme and troponin levels, and ECG readings. The primary
analyses included both definite and probable MIs as defined by the algorithm.
Myocardial infarction occurring during surgery and aborted MIs were included.
An aborted MI was defined as chest pain and ECG evidence of acute MI at presentation,
an intervention (eg, thrombolysis) followed by resolution of ECG changes,
and all cardiac enzyme levels within normal ranges. Silent MI was diagnosed
by comparing baseline and follow-up ECGs at 3 and 6 years after randomization.
Coronary death was defined as death consistent with CHD as underlying cause
plus 1 or more of the following: preterminal hospitalization with MI within
28 days of death, previous angina or MI and no potentially lethal noncoronary
disease, death resulting from a procedure related to coronary artery disease,
or death certificate consistent with CHD as the underlying cause. Stroke diagnosis
was based on rapid onset of a neurologic deficit lasting more than 24 hours,
supported by imaging studies when available. Pulmonary embolism and DVT required
clinical symptoms supported by relevant diagnostic studies.</p>            <a class="article-section-id-anchor" id="25024167"></a>
<p class="para"><strong>Cancer</strong> Breast, colorectal, endometrial, and other cancers were confirmed by
pathological reports when available. Current data indicate that at least 98%
of breast, colorectal, and endometrial cancers and 92% of other cancers were
documented with pathological reports.</p>            <a class="article-section-id-anchor" id="25024168"></a>
<p class="para"><strong>Fractures</strong> Reports of hip, vertebral, and other osteoporotic fractures (including
all fractures except those of the ribs, chest/sternum, skull/face, fingers,
toes, and cervical vertebrae) were routinely ascertained. All fracture outcomes
were verified by radiology reports. Study radiographs were not obtained to
ascertain subclinical vertebral fractures.</p>            <a class="article-section-id-anchor" id="25024169"></a>
<p class="para">This report is based on outcomes adjudicated by clinical center physician
adjudicators, as used for trial-monitoring purposes. Clinical center physician
adjudicators were centrally trained and blinded to treatment assignment and
participants' symptoms. Future communications will report results based on
centrally adjudicated outcomes and will include a broader range of outcomes
with more extensive explanatory analyses. Since this report is presented before
the planned study closeout, outcome information is still being collected and
adjudicated. Local adjudication is complete for approximately 96% of the designated
self-reported events. To date, agreement rates between local and central adjudication
are: MI, 84%; revascularization procedures, 97%; PE, 89%; DVT, 84%; stroke,
94%; invasive breast cancer, 98%; endometrial cancer, 96%; colorectal cancer,
98%; hip fracture, 95%; and specific cause of death, 82%. When related cardiovascular
conditions are combined (eg, when unstable angina or congestive heart failure
is grouped with MI), agreement rates exceed 94% for cardiovascular disease
and 90% for specific cause of death.</p>            <a class="article-section-id-anchor" id="25024170"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Statistical Analyses
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024171"></a>
<p class="para">All primary analyses use time-to-event methods and are based on the
intention-to-treat principle. For a given outcome, the time of event was defined
as the number of days from randomization to the first postrandomization diagnosis,
as determined by the local adjudicator. For silent MIs, the date of the follow-up
ECG applied. Participants without a diagnosis were censored for that event
at the time of last follow-up contact. Primary outcome comparisons are presented
as hazard ratios (HRs) and 95% confidence intervals (CIs) from Cox proportional
hazards analyses,<sup><a href="#REF-JOC21036-17" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">17</a></sup> stratified by clinical
center, age, prior disease, and randomization status in the low-fat diet trial.</p>            <a class="article-section-id-anchor" id="25024172"></a>
<p class="para">Two forms of CIs are presented, nominal and adjusted. Nominal 95% CIs
describe the variability in the estimates that would arise from a simple trial
for a single outcome. Although traditional, these CIs do not account for the
multiple statistical testing issues (across time and across outcome categories)
that occurred in this trial, so the probability is greater than .05 that at
least 1 of these CIs will exclude unity under an overall null hypothesis.
The adjusted 95% CIs presented herein use group sequential methods to correct
for multiple analyses over time. A Bonferroni correction for 7 outcomes as
specified in the monitoring plan (described herein) was applied to all clinical
outcomes other than CHD and breast cancer, the designated primary and primary
adverse effect outcomes, and the global index. The adjusted CIs are closely
related to the monitoring procedures and, as such, represent a conservative
assessment of the evidence. This report focuses primarily on results using
the unadjusted statistics and also relies on consistency across diagnostic
categories, supportive data from other studies, and biologic plausibility
for interpretation of the findings.</p>            <a class="article-section-id-anchor" id="25024173"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Data and Safety Monitoring
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024174"></a>
<p class="para">Trial monitoring guidelines for early stopping considerations were based
on O'Brien-Fleming boundaries<sup><a href="#REF-JOC21036-18" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">18</a></sup> using asymmetric
upper and lower boundaries: a 1-sided, .025-level upper boundary for benefit
and 1-sided, .05-level lower boundaries for adverse effects. The adverse-effect
boundaries were further adjusted with a Bonferroni correction for the 7 major
outcomes other than breast cancer that were specifically monitored (CHD, stroke,
PE, colorectal cancer, endometrial cancer, hip fracture, and death due to
other causes). The global index of monitored outcomes played a supportive
role as a summary measure of the overall balance of risks and benefits. Trial
monitoring for early stopping considerations was conducted semiannually by
an independent data and safety monitoring board (DSMB). Aspects of the monitoring
plan have been published.<sup><a href="#REF-JOC21036-19" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">19</a></sup></p>            <a class="article-section-id-anchor" id="25024175"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Results
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024176"></a>
<p class="para"><strong>Trial Monitoring and Early Stopping</strong> Formal monitoring began in the fall of 1997 with the expectation of
final analysis in 2005 after an average of approximately 8.5 years of follow-up.
Late in 1999, with 5 interim analyses completed, the DSMB observed small but
consistent early adverse effects in cardiovascular outcomes and in the global
index. None of the disease-specific boundaries had been crossed. In the spring
of 2000 and again in the spring of 2001, at the direction of the DSMB, hormone
trial participants were given information indicating that increases in MI,
stroke, and PE/DVT had been observed and that the trial continued because
the balance of risks and benefits remained uncertain.</p>            <a class="article-section-id-anchor" id="25024177"></a>
<p class="para">In reviewing the data for the 10th interim analyses on May 31, 2002,
the DSMB found that the adverse effects in cardiovascular diseases persisted,
although these results were still within the monitoring boundaries. However,
the design-specified weighted log-rank test statistic for breast cancer (<em>z</em> = 3.19) crossed the designated boundary (<em>z</em> = 2.32) and the global index was supportive of
a finding of overall harm (<em>z</em> = 1.62). Updated
analyses including 2 months of additional data, available by the time of the
meeting, did not appreciably change the overall results. On the basis of these
data, the DSMB concluded that the evidence for breast cancer harm, along with
evidence for some increase in CHD, stroke, and PE, outweighed the evidence
of benefit for fractures and possible benefit for colon cancer over the average
5.2-year follow-up period. Therefore, the DSMB recommended early stopping
of the estrogen plus progestin component of the trial. Because the balance
of risks and benefits in the unopposed-estrogen component remains uncertain,
the DSMB recommended continuation of that component of the WHI. Individual
trial participants have been informed.</p>            <a class="article-section-id-anchor" id="25024178"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Baseline Characteristics
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024179"></a>
<p class="para">There were no substantive differences between study groups at baseline;
8506 women were randomized into the estrogen plus progestin group and 8102
into the placebo group (<a href="#JOC21036T1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 1a</a>).
The mean (SD) age was 63.3 (7.1) years. Two thirds of the women who reported
prior or current hormone use had taken combined hormones and one third had
used unopposed estrogen.</p>            <a class="article-section-id-anchor" id="25024182"></a>
<p class="para">Prevalence of prior cardiovascular disease was low and levels of cardiovascular
risk factors were consistent with a generally healthy population of postmenopausal
women. An assessment of commonly studied breast cancer risk factors, both
individually and combined using the Gail model,<sup><a href="#REF-JOC21036-20" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">20</a></sup>
indicate that the cohort in general was not at increased risk of breast cancer.</p>            <a class="article-section-id-anchor" id="25024183"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Follow-up, Adherence, and Unblinding
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024184"></a>
<p class="para">Vital status is known for 16025 randomized participants (96.5%),
including 449 (2.7%) known to be deceased. A total of 583 (3.5%) participants
were lost to follow-up or stopped providing outcomes information for more
than 18 months. The remaining 15576 (93.8%) provided recent outcome
information (<a href="#joc21036f1" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 1</a>).</p>            <a class="article-section-id-anchor" id="25024185"></a>
<p class="para">At the time of this report, all women had been enrolled for at least
3.5 years, with an average follow-up of 5.2 years and a maximum of 8.5 years.
A substantial number of women had stopped taking study drugs at some time
(42% of estrogen plus progestin and 38% of placebo). Dropout rates over time
(<a href="#joc21036f2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 2</a>) exceeded design projections,
particularly early on, but compare favorably with community-based adherence
to postmenopausal hormones.<sup><a href="#REF-JOC21036-21" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">21</a></sup> Some women in
both groups initiated hormone use through their own clinician (6.2% in the
estrogen plus progestin group and 10.7% in the placebo group cumulatively
by the sixth year). These "drop-in" rates were also greater than expected.</p>            <a class="article-section-id-anchor" id="25024187"></a>
<p class="para">At the time of this report, clinic gynecologists had been unblinded
to treatment assignment for 3444 women in the estrogen plus progestin group
and 548 women in the placebo group, primarily to manage persistent vaginal
bleeding. During the trial, 248 women in the estrogen plus progestin group
and 183 in the placebo group had a hysterectomy.</p>            <a class="article-section-id-anchor" id="25024188"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Intermediate Cardiovascular Disease End Points
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024189"></a>
<p class="para">Blood lipid levels, assessed in an 8.6% subsample of fasting blood specimens
collected from women at baseline and year 1, showed greater reductions in
low-density lipoprotein cholesterol (12.7%) and increases in high-density
lipoprotein cholesterol (7.3%) and triglycerides (6.9%) with estrogen plus
progestin relative to placebo (data not shown), consistent with HERS and PEPI.<sup><a href="#REF-JOC21036-10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup><sup>,<a href="#REF-JOC21036-22" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">22</a></sup> Systolic blood pressure was, on average,
1.0 mm Hg higher in women taking estrogen plus progestin at 1 year, rising
to 1.5 mm Hg at 2 years and beyond (data not shown). Diastolic blood pressures
did not differ.</p>            <a class="article-section-id-anchor" id="25024190"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Clinical Outcomes
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024191"></a>
<p class="para"><strong>Cardiovascular Disease</strong> Overall CHD rates were low (<a href="#JOC21036T2" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table
2</a>). The rate of women experiencing CHD events was increased by 29%
for women taking estrogen plus progestin relative to placebo (37 vs 30 per
10000 person-years), reaching nominal statistical significance (at the
.05 level). Most of the excess was in nonfatal MI. No significant differences
were observed in CHD deaths or revascularization procedures (coronary artery
bypass grafting or percutaneous transluminal coronary angioplasty). Stroke
rates were also higher in women receiving estrogen plus progestin (41% increase;
29 vs 21 per 10000 person-years), with most of the elevation occurring
in nonfatal events. Women in the estrogen plus progestin group had 2-fold
greater rates of venous thromboembolism (VTE), as well as DVT and PE individually,
with almost all associated CIs excluding 1. Rates of VTE were 34 and 16 per
10000 person-years in the estrogen plus progestin and placebo groups,
respectively. Total cardiovascular disease, including other events requiring
hospitalization, was increased by 22% in the estrogen plus progestin group.</p>            <a class="article-section-id-anchor" id="25024193"></a>
<p class="para"><strong>Cancer</strong> The invasive breast cancer rates in the placebo group were consistent
with design expectations. The 26% increase (38 vs 30 per 10000 person-years)
observed in the estrogen plus progestin group almost reached nominal statistical
significance and, as noted herein, the weighted test statistic used for monitoring
was highly significant. No significant difference was observed for in situ
breast cancers. Follow-up rates for mammography were comparable in the estrogen
plus progestin and placebo groups. Colorectal cancer rates were reduced by
37% (10 vs 16 per 10000 person-years), also reaching nominal statistical
significance. Endometrial cancer incidence was not affected, nor was lung
cancer incidence (54 vs 50; HR, 1.04; 95% CI, 0.71-1.53) or total cancer incidence.</p>            <a class="article-section-id-anchor" id="25024194"></a>
<p class="para"><strong>Fractures</strong> This cohort experienced low hip fracture rates (10 per 10000 person-years
in the estrogen plus progestin group vs 15 per 10000 person-years in
the placebo group). Estrogen plus progestin reduced the observed hip and clinical
vertebral fracture rates by one third compared with placebo, both nominally
significantly. The reductions in other osteoporotic fractures (23%) and total
fractures (24%) were statistically significant (all associated CIs exclude
1).</p>            <a class="article-section-id-anchor" id="25024195"></a>
<p class="para">The global index showed a nominally significant 15% increase in the
estrogen plus progestin group (170 vs 151 per 10000 person-years). There
were no differences in mortality or cause of death between groups (<a href="#JOC21036T3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 3</a>).</p>            <a class="article-section-id-anchor" id="25024198"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Time Trends
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024199"></a>
<p class="para">The Kaplan Meier estimates of cumulative hazards (<a href="#joc21036f3" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 3</a>) for CHD indicate that the difference between treatment
groups began to develop soon after randomization. These curves provide little
evidence of convergence through 6 years of follow-up. The cumulative hazards
for stroke begin to diverge between 1 and 2 years after randomization, and
this difference persists beyond the fifth year. For PE, the curves separate
soon after randomization and show continuing adverse effects throughout the
observation period. For breast cancer, the cumulative hazard functions are
comparable through the first 4 years, at which point the curve for estrogen
plus progestin begins to rise more rapidly than that for placebo. Curves for
colorectal cancer show benefit beginning at 3 years, and curves for hip fracture
show increasing cumulative benefit over time. The difference in hazard rates
for the global index (<a href="#joc21036f4" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Figure 4</a>)
suggests a gradual increase in adverse effects compared with benefits for
estrogen plus progestin through year 5, with a possible narrowing of the difference
by year 6; however, HR estimates tend to be unstable beyond 6 years after
randomization. Total mortality rates are indistinguishable between estrogen
plus progestin and placebo.</p>            <a class="article-section-id-anchor" id="25024202"></a>
<p class="para">Tests for linear trends with time since randomization, based on a Cox
proportional hazards model with a time-dependent covariate, detected no trend
with time for CHD, stroke, colorectal cancer, hip fracture, total mortality,
or the global index (<a href="#JOC21036T4" class="figure-link section-jump-link" data-tab-toggle=".tab-nav-figure-table">Table 4</a>).
There was some evidence for an increasing risk of breast cancer over time
with estrogen plus progestin (<em>z</em> = 2.56 compared with
a nominal <em>z</em> score for statistical significance of
1.96) and a decreasing risk of VTE with time (<em>z</em> = 2.45).
These results must be viewed cautiously because the number of events in each
interval is modest, the data in later years are still incomplete, and later
year comparisons are limited to women still at risk of their first event for
that outcome.</p>            <a class="article-section-id-anchor" id="25024205"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Subgroup Analyses
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024206"></a>
<p class="para"><strong>Cardiovascular Disease</strong> A small subset of women (n = 400; average follow-up, 57.4 months) in
WHI reported conditions at baseline that would have made them eligible for
HERS, ie, prior MI or revascularization procedures. Among these women with
established coronary disease, the HR for subsequent CHD for estrogen plus
progestin relative to placebo was 1.28 (95% CI, 0.64-2.56) with 19 vs 16 events.
The remaining women, those without prior CHD, had an identical HR for CHD
(145 vs 106; HR, 1.28; 95% CI, 1.00-1.65). Few women with a history of VTE
were enrolled, but these data suggest a possibility that these women may be
at greater risk of future VTE events when taking estrogen plus progestin (7
vs 1; HR, 4.90; 95% CI, 0.58-41.06) than those without a history of VTE (144
vs 66; HR, 2.06; 95% CI, 1.54-2.76). For stroke, prior history did not confer
additional risk (1 vs 5 in women with prior stroke; HR, 0.46; 95% CI, 0.05-4.51;
126 vs 80 with no prior stroke; HR, 1.47; 95% CI, 1.11-1.95). No noteworthy
interactions with age, race/ethnicity, body mass index, prior hormone use,
smoking status, blood pressure, diabetes, aspirin use, or statin use were
found for the effect of estrogen plus progestin on CHD, stroke, or VTE.</p>            <a class="article-section-id-anchor" id="25024207"></a>
<p class="para"><strong>Breast Cancer</strong> Women reporting prior postmenopausal hormone use had higher HRs for
breast cancer associated with estrogen plus progestin use than those who never
used postmenopausal hormones (among never users, 114 vs 102; HR, 1.06; 95%
CI, 0.81-1.38; for women with &lt;5 years of prior use, 32 vs 15; HR, 2.13;
95% CI, 1.15-3.94; for women with 5-10 years of prior use, 11 vs 2; HR, 4.61;
95% CI, 1.01-21.02; and for women with 10 years of prior use, 9 vs 5;
HR, 1.81; 95% CI, 0.60-5.43; test for trend, <em>z</em> =
2.17). No interactions between estrogen plus progestin and age, race/ethnicity,
family history, parity, age at first birth, body mass index, or Gail-model
risk score were observed for invasive breast cancer.</p>            <a class="article-section-id-anchor" id="25024208"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Further Analyses
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024209"></a>
<p class="para">Because a number of women stopped study medications during follow-up,
several analyses were performed to examine the sensitivity of the principal
HR estimates to actual use of study medications. Analyses that censored a
woman's event history 6 months after becoming nonadherent (using &lt;80% of
or stopping study drugs) produced the largest changes to estimated effect
sizes. This approach increased HRs to 1.51 for CHD, to 1.49 for breast cancer,
to 1.67 for stroke, and to 3.29 for VTE. Analyses attributing events to actual
hormone use ("as treated," allowing for a 6-month lag) produced more modest
changes to these estimates. Analyses excluding women randomized during the
period when the unopposed-estrogen component was open to women with a uterus
and analyses stratifying by enrollment period did not substantially affect
the results. These analyses suggest that the intention-to-treat estimates
of HRs may somewhat underestimate the effect sizes relative to what would
be observed with full adherence to study medications.</p>            <a class="article-section-id-anchor" id="25024210"></a>
                        <div class="h3 cb section-type-section  ">

                            <div class="heading-text thm-col sb-sc">
                                Comment
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024211"></a>
<p class="para">The WHI provides evidence from a large randomized trial that addresses
the important issue of whether most women with an intact uterus in the decades
of life following menopause should consider hormone therapy to prevent chronic
disease. The WHI enrolled a cohort of mostly healthy, ethnically diverse women,
spanning a large age range (50-79 years at baseline). It is noteworthy that
the increased risks for cardiovascular disease and invasive breast cancer
were present across racial/ethnic and age strata and were not influenced by
the antecedent risk status or prior disease. Hence, the results are likely
to be generally applicable to healthy women in this age range. At the time
the trial was stopped, the increases in numbers of invasive breast cancers,
CHD, stroke, and PE made approximately equal contributions to harm in the
estrogen plus progestin group compared with placebo, which were not counterbalanced
by the smaller reductions in numbers of hip fractures and colorectal cancers.</p>            <a class="article-section-id-anchor" id="25024212"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Cardiovascular Disease
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024213"></a>
<p class="para">Even though the trial was stopped early for harm from breast cancer,
a sufficient number of CHD events had occurred by 5.2 years of average follow-up
to suggest that continuation to the planned end would have been unlikely to
yield a favorable result for the primary outcome of CHD. Even if there were
a reversal of direction toward benefit of a magnitude seen in the observational
studies (ie, a risk reduction of 55%) during the remaining years, conditional
power analyses indicate that less than 10% power remained for showing potential
benefit if the trial continued.</p>            <a class="article-section-id-anchor" id="25024214"></a>
<p class="para">The WHI finding that estrogen plus progestin does not confer benefit
for preventing CHD among women with a uterus concurs with HERS findings among
women with clinically apparent CHD,<sup><a href="#REF-JOC21036-10" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">10</a></sup> with
the Estrogen Replacement for Atherosclerosis trial, in which estrogen plus
progestin did not inhibit progression,<sup><a href="#REF-JOC21036-23" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">23</a></sup> and
with a trial in women with unstable angina that did not observe a reduction
in ischemic events.<sup><a href="#REF-JOC21036-24" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">24</a></sup> The finding of an increased
risk after initiation of treatment in WHI is similar to HERS. In HERS, after
4.1 and 6.8 years of follow-up, hormone therapy did not increase or decrease
risk of cardiovascular events in women with CHD.<sup><a href="#REF-JOC21036-25" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">25</a></sup>
The WHI extends these findings to include a wider range of women, including
younger women and those without clinically apparent CHD, and indicates that
the risk may persist for some years.</p>            <a class="article-section-id-anchor" id="25024215"></a>
<p class="para">Unlike CHD, the excess risk of stroke in the estrogen plus progestin
group was not present in the first year but appeared during the second year
and persisted through the fifth year. Preliminary analyses indicate that the
modest difference in blood pressure between groups does not contribute much
to an explanation of the increase in strokes (data not shown). The findings
in WHI for stroke are consistent with but somewhat more extreme than those
of HERS, which reported a nonsignificant 23% increase in the treatment group.<sup><a href="#REF-JOC21036-26" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">26</a></sup> The results were also more extreme than those of
the Women's Estrogen and Stroke Trial of estradiol (without progestin) in
women with prior stroke, which found no effect of estrogen on recurrent strokes
overall but some increase in the first 6 months.<sup><a href="#REF-JOC21036-27" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">27</a></sup>
Trials of the effect of estradiol on carotid intima-media thickness have yielded
conflicting results.<sup><a href="#REF-JOC21036-28" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">28</a></sup><sup>,<a href="#REF-JOC21036-29" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">29</a></sup> At least
1 observational study has suggested that that use of estrogen plus progestin
is associated with higher risk of stroke than estrogen alone.<sup><a href="#REF-JOC21036-14" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">14</a></sup>
In WHI, there was no indication that excess strokes due to estrogen plus progestin
were more likely to occur in older women, in women with prior stroke history,
by race/ethnicity, or in women with high blood pressure at baseline. Therefore,
it appears that estrogen plus progestin increases the risk of strokes in apparently
healthy women.</p>            <a class="article-section-id-anchor" id="25024216"></a>
<p class="para">Venous thromboembolism is an expected complication of postmenopausal
hormones, and the pattern over time in WHI is consistent with the findings
from HERS and several observational studies.<sup><a href="#REF-JOC21036-30" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">30</a></sup><sup>,<a href="#REF-JOC21036-31" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">31</a></sup></p>            <a class="article-section-id-anchor" id="25024217"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Cancer
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024218"></a>
<p class="para">The WHI is the first randomized controlled trial to confirm that combined
estrogen plus progestin does increase the risk of incident breast cancer and
to quantify the degree of risk. The WHI could not address the risk of death
due to breast cancer because with the relatively short follow-up time, few
women in the WHI have thus far died as a result of breast cancer (3 in the
active treatment group and 2 in the placebo group). The risk of breast cancer
emerged several years after randomization. After an average follow-up of about
5 years, the adverse effect on breast cancer had crossed the monitoring boundary.
The 26% excess of breast cancer is consistent with estimates from pooled epidemiological
data, which reported a 15% increase for estrogen plus progestin use for less
than 5 years and a 53% increase for use for more than 5 years.<sup><a href="#REF-JOC21036-32" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">32</a></sup>
It is also consistent with the (nonsignificant) 27% increase found after 6.8
years of follow-up in HERS.<sup><a href="#REF-JOC21036-33" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">33</a></sup></p>            <a class="article-section-id-anchor" id="25024219"></a>
<p class="para">With more common use of estrogen plus progestin, several epidemiological
studies have reported that estrogen plus progestin appears to be associated
with greater risk of breast cancer than estrogen alone.<sup><a href="#REF-JOC21036-34" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">34</a></sup><sup>-<a href="#REF-JOC21036-34" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">37</a></sup>
In the PEPI trial, women in the 3 estrogen plus progestin groups had much
greater increases in mammographic density (a predictor of breast cancer) than
women in the estrogen or placebo groups.<sup><a href="#REF-JOC21036-38" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">38</a></sup>
In WHI, the HR for estrogen plus progestin was not higher in women with a
family history or other risk factors for breast cancer, except for reported
prior use of postmenopausal hormones. This may suggest a cumulative effect
of years of exposure to postmenopausal hormones.</p>            <a class="article-section-id-anchor" id="25024220"></a>
<p class="para">Endometrial cancer rates were low and were not increased by 5 years
of estrogen plus progestin exposure. Close monitoring for bleeding and treatment
of hyperplasia may contribute to the absence of increased risk of endometrial
cancer.</p>            <a class="article-section-id-anchor" id="25024221"></a>
<p class="para">The reduction in colorectal cancer in the hormone group is consistent
with observational studies, which have suggested fairly consistently that
users of postmenopausal hormones may be at lower risk of colorectal cancer.<sup><a href="#REF-JOC21036-39" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">39</a></sup> The mechanisms by which hormone use might reduce
risk are unclear. Results from other trials of postmenopausal hormones will
help resolve the effects of hormones on colorectal cancer.<sup><a href="#REF-JOC21036-40" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">40</a></sup></p>            <a class="article-section-id-anchor" id="25024222"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Fractures
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024223"></a>
<p class="para">The reductions in clinical vertebral fractures, other osteoporotic fractures,
and combined fractures supported the benefit for hip fractures found in this
trial. These findings are consistent with the observational data and limited
data from clinical trials<sup><a href="#REF-JOC21036-41" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">41</a></sup> and are also consistent
with the known ability of estrogen (with or without progestin) to maintain
bone mineral density.<sup><a href="#REF-JOC21036-42" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">42</a></sup> The WHI is the first
trial with definitive data supporting the ability of postmenopausal hormones
to prevent fractures at the hip, vertebrae, and other sites.</p>            <a class="article-section-id-anchor" id="25024224"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Overall Risks and Benefits
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024225"></a>
<p class="para">At the end of the trial, the global index indicated that there were
more harmful than beneficial outcomes in the estrogen plus progestin group
vs the placebo group. The monitored outcomes included in the global index
were selected to represent diseases of serious import that estrogen plus progestin
treatment might affect, and do not include a variety of other conditions and
measures that may be affected in unfavorable or favorable ways (eg, gallbladder
disease, diabetes, quality of life, and cognitive function). The data on these
and other outcomes will be the subject of future publications. All-cause mortality
was balanced between the groups; however, longer follow-up may be needed to
assess the impact of the incident diseases on total mortality.</p>            <a class="article-section-id-anchor" id="25024226"></a>
<p class="para">The absolute excess risk (or risk reduction) attributable to estrogen
plus progestin was low. Over 1 year, 10000 women taking estrogen plus
progestin compared with placebo might experience 7 more CHD events, 8 more
strokes, 8 more PEs, 8 more invasive breast cancers, 6 fewer colorectal cancers,
and 5 fewer hip fractures. Combining all the monitored outcomes, women taking
estrogen plus progestin might expect 19 more events per year per 10000
women than women taking placebo. Over a longer period, more typical of the
duration of treatment that would be needed to prevent chronic disease, the
absolute numbers of excess outcomes would increase proportionately.</p>            <a class="article-section-id-anchor" id="25024227"></a>
<p class="para">During the 5.2 years of this trial, the number of women experiencing
a global index event was about 100 more per 10000 women taking estrogen
plus progestin than taking placebo. If the current findings can be extrapolated
to an even longer treatment duration, the absolute risks and benefits associated
with estrogen plus progestin for each of these conditions could be substantial
and on a population basis could account for tens of thousands of conditions
caused, or prevented, by hormone use.</p>            <a class="article-section-id-anchor" id="25024228"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Limitations
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024230"></a>
<p class="para">This trial tested only 1 drug regimen, CEE, 0.625 mg/d, plus MPA, 2.5
mg/d, in postmenopausal women with an intact uterus. The results do not necessarily
apply to lower dosages of these drugs, to other formulations of oral estrogens
and progestins, or to estrogens and progestins administered through the transdermal
route. It remains possible that transdermal estradiol with progesterone, which
more closely mimics the normal physiology and metabolism of endogenous sex
hormones, may provide a different risk-benefit profile. The WHI findings for
CHD and VTE are supported by findings from HERS, but there is no other evidence
from clinical trials for breast cancer and colorectal cancer, and only limited
data from trials concerning fractures.</p>            <a class="article-section-id-anchor" id="25024232"></a>
<p class="para">Importantly, this trial could not distinguish the effects of estrogen
from those of progestin. The effects of progestin may be important for breast
cancer and atherosclerotic diseases, including CHD and stroke. Per protocol,
in a separate and adequately powered trial, WHI is testing the hypothesis
of whether oral estrogen will prevent CHD in 10739 women who have had
a hysterectomy. The monitoring of this trial is similar to that for the trial
of estrogen plus progestin. At an average follow-up of 5.2 years, the DSMB
has recommended that this trial continue because the balance of overall risks
and benefits remains uncertain. These results are expected to be available
in 2005, at the planned termination.</p>            <a class="article-section-id-anchor" id="25024233"></a>
<p class="para">The relatively high rates of discontinuation in the active treatment
arm (42%) and crossover to active treatment in the placebo arm (10.7%) are
a limitation of the study; however, the lack of adherence would tend to decrease
the observed treatment effects. Thus, the results presented here may underestimate
the magnitude of both adverse effects on cardiovascular disease and breast
cancer and the beneficial effects on fractures and colorectal cancer among
women who adhere to treatment.</p>            <a class="article-section-id-anchor" id="25024234"></a>
<p class="para">The fact that the trial was stopped early decreases the precision of
estimates of long-term treatment effects. A longer intervention period might
have shown more pronounced benefit for fractures and might have yielded a
more precise test of the hypothesis that treatment reduces colorectal cancer.
Nonetheless, it appears unlikely that benefit for CHD would have emerged by
continuing the trial to its planned termination. The trial results indicate
that treatment for up to 5.2 years is not beneficial overall and that there
is early harm for CHD, continuing harm for stroke and VTE, and increasing
harm for breast cancer with increasing duration of treatment. This risk-benefit
profile is not consistent with the requirements for a viable intervention
for the primary prevention of chronic diseases.</p>            <a class="article-section-id-anchor" id="25024235"></a>
                        <div class="h4 cb section-type-section  ">

                            <div class="heading-text ">
                                Implications
                            </div>
                        </div>
            <a class="article-section-id-anchor" id="25024236"></a>
<p class="para">The WHI trial results provide the first definitive data on which to
base treatment recommendations for healthy postmenopausal women with an intact
uterus. This trial did not address the short-term risks and benefits of hormones
given for the treatment of menopausal symptoms. On the basis of HERS and other
secondary prevention trials, the American Heart Association recommended against
initiating postmenopausal hormones for the secondary prevention of cardiovascular
disease.<sup><a href="#REF-JOC21036-43" class="ref-link section-jump-link" data-tab-toggle=".tab-nav-references">43</a></sup> The American Heart Association made
no firm recommendation for primary prevention while awaiting the results from
randomized clinical trials such as WHI, and stated that continuation of the
treatment should be considered on the basis of established noncoronary benefits
and risks, possible coronary benefits and risks, and patient preference.</p>            <a class="article-section-id-anchor" id="25024237"></a>
<p class="para">Results from WHI indicate that the combined postmenopausal hormones
CEE, 0.625 mg/d, plus MPA, 2.5 mg/d, should not be initiated or continued
for the primary prevention of CHD. In addition, the substantial risks for
cardiovascular disease and breast cancer must be weighed against the benefit
for fracture in selecting from the available agents to prevent osteoporosis.</p>            <a class="article-section-id-anchor" id="25024238"></a>
                        <div class="h3 cb section-type-references  ">

                            <div class="heading-text thm-col sb-sc">
                                References
                            </div>
                        </div>
<div class="references"><div class="reference"><a class="reference-number" id="ref-joc21036-1">1.</a><div class="reference-content">The Women's Health Initiative Study Group.Design of the Women's Health Initiative clinical trial and observational
study.<I xmlns:helper="urn:XsltStringHelper">Control Clin Trials.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1998;19:61-109.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Design%20of%20the%20Women%27s%20Health%20Initiative%20clinical%20trial%20and%20observational%20study.&amp;publication_year=&amp;journal=Control%20Clin%20Trials.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-2">2.</a><div class="reference-content">StampferM, ColditzG.Estrogen replacement therapy and coronary heart disease: a quantitative
assessment of the epidemiologic evidence.<I xmlns:helper="urn:XsltStringHelper">Prev Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1991;20:47-63.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Estrogen%20replacement%20therapy%20and%20coronary%20heart%20disease%3A%20a%20quantitative%20assessment%20of%20the%20epidemiologic%20evidence.&amp;author=M%20Stampfer&amp;author=G%20Colditz&amp;publication_year=&amp;journal=Prev%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-3">3.</a><div class="reference-content">GradyD, RuebenSB, PettitiDB.
    et al.Hormone therapy to prevent disease and prolong life in postmenopausal
women.<I xmlns:helper="urn:XsltStringHelper">Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1992;117:1016-1037.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Hormone%20therapy%20to%20prevent%20disease%20and%20prolong%20life%20in%20postmenopausal%20women.&amp;author=D%20Grady&amp;author=SB%20Rueben&amp;author=DB%20Pettiti&amp;publication_year=&amp;journal=Ann%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-4">4.</a><div class="reference-content">RijpkemaAH, van der SandenAA, RuijsAH.Effects of postmenopausal estrogen-progesterone therapy on serum lipids
and lipoproteins: a review.<I xmlns:helper="urn:XsltStringHelper">Maturitas.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;12:259-285.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20postmenopausal%20estrogen-progesterone%20therapy%20on%20serum%20lipids%20and%20lipoproteins%3A%20a%20review.&amp;author=AH%20Rijpkema&amp;author=AA%20van der Sanden&amp;author=AH%20Ruijs&amp;publication_year=&amp;journal=Maturitas.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-5">5.</a><div class="reference-content">AdamsMR, KaplanJR, ManuckSB.
    et al.Inhibition of coronary artery atherosclerosis by 17-beta estradiol
in ovariectomized monkeys: lack of an effect of added progesterone.<I xmlns:helper="urn:XsltStringHelper">Arteriosclerosis.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;10:1051-1057.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Inhibition%20of%20coronary%20artery%20atherosclerosis%20by%2017-beta%20estradiol%20in%20ovariectomized%20monkeys%3A%20lack%20of%20an%20effect%20of%20added%20progesterone.&amp;author=MR%20Adams&amp;author=JR%20Kaplan&amp;author=SB%20Manuck&amp;publication_year=&amp;journal=Arteriosclerosis.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-6">6.</a><div class="reference-content">WeissNS, UreCL, BallardJH, WilliamsAR, DalingJR.Decreased risk of fractures of the hip and lower forearm with postmenopausal
use of estrogen.<I xmlns:helper="urn:XsltStringHelper">N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1980;303:1195-1198.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Decreased%20risk%20of%20fractures%20of%20the%20hip%20and%20lower%20forearm%20with%20postmenopausal%20use%20of%20estrogen.&amp;author=NS%20Weiss&amp;author=CL%20Ure&amp;author=JH%20Ballard&amp;author=AR%20Williams&amp;author=JR%20Daling&amp;publication_year=&amp;journal=N%20Engl%20J%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-7">7.</a><div class="reference-content">GenantHK, BaylinkDJ, GallagherJC, HarrisST, SteigerP, HerberM.Effect of estrone sulfate on postmenopausal bone loss.<I xmlns:helper="urn:XsltStringHelper">Obstet Gynecol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1990;76:579-584.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20estrone%20sulfate%20on%20postmenopausal%20bone%20loss.&amp;author=HK%20Genant&amp;author=DJ%20Baylink&amp;author=JC%20Gallagher&amp;author=ST%20Harris&amp;author=P%20Steiger&amp;author=M%20Herber&amp;publication_year=&amp;journal=Obstet%20Gynecol.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-8">8.</a><div class="reference-content">SteinbergKA, ThackerSB, SmithSJ.
    et al.A meta-analysis of the effect of estrogen replacement therapy on the
risk of breast cancer.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1991;265:1985-1990.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20meta-analysis%20of%20the%20effect%20of%20estrogen%20replacement%20therapy%20on%20the%20risk%20of%20breast%20cancer.&amp;author=KA%20Steinberg&amp;author=SB%20Thacker&amp;author=SJ%20Smith&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-9">9.</a><div class="reference-content">Gerhardsson deVM, LondonS.Reproductive factors, exogenous female hormones, and colorectal cancer
by subsite.<I xmlns:helper="urn:XsltStringHelper">Cancer Causes Control.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1992;3:355-360.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Reproductive%20factors%2C%20exogenous%20female%20hormones%2C%20and%20colorectal%20cancer%20by%20subsite.&amp;author=VM%20Gerhardsson de&amp;author=S%20London&amp;publication_year=&amp;journal=Cancer%20Causes%20Control.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-10">10.</a><div class="reference-content">HulleyS, GradyD, BushT.
    et al.Randomized trial of estrogen plus progestin for secondary prevention
of coronary heart disease in postmenopausal women.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1998;280:605-613.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Randomized%20trial%20of%20estrogen%20plus%20progestin%20for%20secondary%20prevention%20of%20coronary%20heart%20disease%20in%20postmenopausal%20women.&amp;author=S%20Hulley&amp;author=D%20Grady&amp;author=T%20Bush&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-11">11.</a><div class="reference-content">GrodsteinF, MansonJE, StampferMJ.Postmenopausal hormone use and secondary prevention of coronary events
in the Nurses' Health Study.<I xmlns:helper="urn:XsltStringHelper">Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;135:1-8.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Postmenopausal%20hormone%20use%20and%20secondary%20prevention%20of%20coronary%20events%20in%20the%20Nurses%27%20Health%20Study.&amp;author=F%20Grodstein&amp;author=JE%20Manson&amp;author=MJ%20Stampfer&amp;publication_year=&amp;journal=Ann%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-12">12.</a><div class="reference-content">AlexanderKP, NewbyLK, HellkampAS.
    et al.Initiation of hormone replacement therapy after acute myocardial infarction
is associated with more cardiac events during follow-up.<I xmlns:helper="urn:XsltStringHelper">J Am Coll Cardiol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;38:1-7.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Initiation%20of%20hormone%20replacement%20therapy%20after%20acute%20myocardial%20infarction%20is%20associated%20with%20more%20cardiac%20events%20during%20follow-up.&amp;author=KP%20Alexander&amp;author=LK%20Newby&amp;author=AS%20Hellkamp&amp;publication_year=&amp;journal=J%20Am%20Coll%20Cardiol.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-13">13.</a><div class="reference-content">HeckbertSR, KaplanRC, WeissNS.
    et al.Risk of recurrent coronary events in relation to use and recent initiation
of postmenopausal hormone therapy.<I xmlns:helper="urn:XsltStringHelper">Arch Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;161:1709-1173.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Risk%20of%20recurrent%20coronary%20events%20in%20relation%20to%20use%20and%20recent%20initiation%20of%20postmenopausal%20hormone%20therapy.&amp;author=SR%20Heckbert&amp;author=RC%20Kaplan&amp;author=NS%20Weiss&amp;publication_year=&amp;journal=Arch%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-14">14.</a><div class="reference-content">GrodsteinF, MansonJE, ColditzGA, WillitWC, SpeizerFE, StampferMJ.A prospective, observational study of postmenopausal hormone therapy
and primary prevention of cardiovascular disease.<I xmlns:helper="urn:XsltStringHelper">Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;133:933-941.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20prospective%2C%20observational%20study%20of%20postmenopausal%20hormone%20therapy%20and%20primary%20prevention%20of%20cardiovascular%20disease.&amp;author=F%20Grodstein&amp;author=JE%20Manson&amp;author=GA%20Colditz&amp;author=WC%20Willit&amp;author=FE%20Speizer&amp;author=MJ%20Stampfer&amp;publication_year=&amp;journal=Ann%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-15">15.</a><div class="reference-content">The Writing Group for the PEPI Trial.Effects of hormone replacement therapy on endometrial histology in
postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions
(PEPI) Trial.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1996;275:370-375.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20hormone%20replacement%20therapy%20on%20endometrial%20histology%20in%20postmenopausal%20women%3A%20the%20Postmenopausal%20Estrogen%2FProgestin%20Interventions%20%28PEPI%29%20Trial.&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-16">16.</a><div class="reference-content">IvesDG, FitzpatrickAL, BildDE.
    et al.Surveillance and ascertainment of cardiovascular events: the Cardiovascular
Health Study.<I xmlns:helper="urn:XsltStringHelper">Ann Epidemiol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1995;5:275-285.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Surveillance%20and%20ascertainment%20of%20cardiovascular%20events%3A%20the%20Cardiovascular%20Health%20Study.&amp;author=DG%20Ives&amp;author=AL%20Fitzpatrick&amp;author=DE%20Bild&amp;publication_year=&amp;journal=Ann%20Epidemiol.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-17">17.</a><div class="reference-content">CoxDR.Regression analysis and life tables.<I xmlns:helper="urn:XsltStringHelper">J R Stat Soc.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1972;34:187-220.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Regression%20analysis%20and%20life%20tables.&amp;author=DR%20Cox&amp;publication_year=&amp;journal=J%20R%20Stat%20Soc.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-18">18.</a><div class="reference-content">O'BrienPC, FlemingRT.A multiple testing procedure for clinical trials.<I xmlns:helper="urn:XsltStringHelper">Biometrics.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1979;35:549-556.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20multiple%20testing%20procedure%20for%20clinical%20trials.&amp;author=PC%20O'Brien&amp;author=RT%20Fleming&amp;publication_year=&amp;journal=Biometrics.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-19">19.</a><div class="reference-content">FreedmanLS, AndersonG, KipnisV.
    et al.Approaches to monitoring the results of long-term disease prevention
trials: examples from the Women's Health Initiative.<I xmlns:helper="urn:XsltStringHelper">Control Clin Trials.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1996;17:509-525.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Approaches%20to%20monitoring%20the%20results%20of%20long-term%20disease%20prevention%20trials%3A%20examples%20from%20the%20Women%27s%20Health%20Initiative.&amp;author=LS%20Freedman&amp;author=G%20Anderson&amp;author=V%20Kipnis&amp;publication_year=&amp;journal=Control%20Clin%20Trials.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-20">20.</a><div class="reference-content">GailMH, BrintonLA, ByarDP.
    et al.Projecting individualized probabilities of developing breast cancer
for white females who are being examined annually.<I xmlns:helper="urn:XsltStringHelper">J Natl Cancer Inst.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1989;81:1879-1886.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Projecting%20individualized%20probabilities%20of%20developing%20breast%20cancer%20for%20white%20females%20who%20are%20being%20examined%20annually.&amp;author=MH%20Gail&amp;author=LA%20Brinton&amp;author=DP%20Byar&amp;publication_year=&amp;journal=J%20Natl%20Cancer%20Inst.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-21">21.</a><div class="reference-content">PilonD, CastillouxAM, LelorierJ.Estrogen replacement therapy: determinants of persistence with treatment.<I xmlns:helper="urn:XsltStringHelper">Obstet Gynecol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;97:97-100.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Estrogen%20replacement%20therapy%3A%20determinants%20of%20persistence%20with%20treatment.&amp;author=D%20Pilon&amp;author=AM%20Castilloux&amp;author=J%20Lelorier&amp;publication_year=&amp;journal=Obstet%20Gynecol.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-22">22.</a><div class="reference-content">Writing Group for the PEPI Trial.Effects of estrogen or estrogen/progestin regimens on heart disease
risk factors in postmenopausal women.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1995;273:199-208.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20estrogen%20or%20estrogen%2Fprogestin%20regimens%20on%20heart%20disease%20risk%20factors%20in%20postmenopausal%20women.&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-23">23.</a><div class="reference-content">HerringtonDM, ReboussinDM, BrosnihanKB.
    et al.Effects of estrogen replacement on the progression of coronary artery
atherosclerosis.<I xmlns:helper="urn:XsltStringHelper">N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;343:522-529.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20estrogen%20replacement%20on%20the%20progression%20of%20coronary%20artery%20atherosclerosis.&amp;author=DM%20Herrington&amp;author=DM%20Reboussin&amp;author=KB%20Brosnihan&amp;publication_year=&amp;journal=N%20Engl%20J%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-24">24.</a><div class="reference-content">SchulmanSP, ThiemannDR, OuyangP.
    et al.Effects of acute hormone therapy on recurrent ischemia in postmenopausal
women with unstable angina.<I xmlns:helper="urn:XsltStringHelper">J Am Coll Cardiol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;39:231-237.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20acute%20hormone%20therapy%20on%20recurrent%20ischemia%20in%20postmenopausal%20women%20with%20unstable%20angina.&amp;author=SP%20Schulman&amp;author=DR%20Thiemann&amp;author=P%20Ouyang&amp;publication_year=&amp;journal=J%20Am%20Coll%20Cardiol.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-25">25.</a><div class="reference-content">GradyD, HerringtonD, BittnerV.
    et al.for the HERS Research Group.Cardiovascular disease outcomes during 6.8 years of hormone therapy:
Heart and Estrogen/progestin Replacement Study Follow-up (HERS II).<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;288:49-57.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Cardiovascular%20disease%20outcomes%20during%206.8%20years%20of%20hormone%20therapy%3A%20Heart%20and%20Estrogen%2Fprogestin%20Replacement%20Study%20Follow-up%20%28HERS%20II%29.&amp;author=D%20Grady&amp;author=D%20Herrington&amp;author=V%20Bittner&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-26">26.</a><div class="reference-content">SimonJA, HsiaJ, CauleyJA.
    et al.Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin
Replacement Study (HERS).<I xmlns:helper="urn:XsltStringHelper">Circulation.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;103:638-642.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Postmenopausal%20hormone%20therapy%20and%20risk%20of%20stroke%3A%20the%20Heart%20and%20Estrogen-progestin%20Replacement%20Study%20%28HERS%29.&amp;author=JA%20Simon&amp;author=J%20Hsia&amp;author=JA%20Cauley&amp;publication_year=&amp;journal=Circulation.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-27">27.</a><div class="reference-content">ViscoliCM, BrassLM, KernanWN, SarrelPM, SuissaS, HorwitzRI.A clinical trial of estrogen-replacement therapy after ischemic stroke.<I xmlns:helper="urn:XsltStringHelper">N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;345:1243-1249.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=A%20clinical%20trial%20of%20estrogen-replacement%20therapy%20after%20ischemic%20stroke.&amp;author=CM%20Viscoli&amp;author=LM%20Brass&amp;author=WN%20Kernan&amp;author=PM%20Sarrel&amp;author=S%20Suissa&amp;author=RI%20Horwitz&amp;publication_year=&amp;journal=N%20Engl%20J%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-28">28.</a><div class="reference-content">HodisHN, MackWJ, LoboRA.
    et al.Estrogen in the prevention of atherosclerosis: a randomized, double-blind
controlled trial.<I xmlns:helper="urn:XsltStringHelper">Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;135:939-953.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Estrogen%20in%20the%20prevention%20of%20atherosclerosis%3A%20a%20randomized%2C%20double-blind%20controlled%20trial.&amp;author=HN%20Hodis&amp;author=WJ%20Mack&amp;author=RA%20Lobo&amp;publication_year=&amp;journal=Ann%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-29">29.</a><div class="reference-content">AngererP, StorkS, KothnyW, SchmittP, von SchackyC.Effect of oral postmenopausal hormone replacement on progression of
atherosclerosis: a randomized, controlled trial.<I xmlns:helper="urn:XsltStringHelper">Arterioscler Thromb Vasc Biol.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;21:262-268.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20oral%20postmenopausal%20hormone%20replacement%20on%20progression%20of%20atherosclerosis%3A%20a%20randomized%2C%20controlled%20trial.&amp;author=P%20Angerer&amp;author=S%20Stork&amp;author=W%20Kothny&amp;author=P%20Schmitt&amp;author=C%20von Schacky&amp;publication_year=&amp;journal=Arterioscler%20Thromb%20Vasc%20Biol.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-30">30.</a><div class="reference-content">CastellsagueJ, Perez GutthannS, Garcia RodriguezLA.Recent epidemiological studies of the association between hormone replacement
therapy and venous thromboembolism: a review.<I xmlns:helper="urn:XsltStringHelper">Drug Saf.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1998;18:117-123.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Recent%20epidemiological%20studies%20of%20the%20association%20between%20hormone%20replacement%20therapy%20and%20venous%20thromboembolism%3A%20a%20review.&amp;author=J%20Castellsague&amp;author=S%20Perez Gutthann&amp;author=LA%20Garcia Rodriguez&amp;publication_year=&amp;journal=Drug%20Saf.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-31">31.</a><div class="reference-content">GradyD, WengerNK, HerringtonD.
    et al.Postmenopausal hormone therapy increases risk for venous thromboembolic
disease: the Heart and Estrogen/progestin Replacement Study.<I xmlns:helper="urn:XsltStringHelper">Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;132:689-696.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Postmenopausal%20hormone%20therapy%20increases%20risk%20for%20venous%20thromboembolic%20disease%3A%20the%20Heart%20and%20Estrogen%2Fprogestin%20Replacement%20Study.&amp;author=D%20Grady&amp;author=NK%20Wenger&amp;author=D%20Herrington&amp;publication_year=&amp;journal=Ann%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-32">32.</a><div class="reference-content">Collaborative Group on Hormonal Factors in Breast Cancer.Breast cancer and hormone replacement therapy: collaborative reanalysis
of data from 51 epidemiological studies of 52,705 women with breast cancer
and 108,411 women without breast cancer.<I xmlns:helper="urn:XsltStringHelper">Lancet.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1997;350:1047-1059.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Breast%20cancer%20and%20hormone%20replacement%20therapy%3A%20collaborative%20reanalysis%20of%20data%20from%2051%20epidemiological%20studies%20of%2052%2C705%20women%20with%20breast%20cancer%20and%20108%2C411%20women%20without%20breast%20cancer.&amp;publication_year=&amp;journal=Lancet.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-33">33.</a><div class="reference-content">HulleyS, FurbergC, Barrett-ConnorE.
    et al.for the HERS Research Group.Noncardiovascular disease outcomes during 6.8 years of hormone therapy:
Heart and Estrogen/progestin Replacement Study Follow-up (HERS II).<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2002;288:58-66.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Noncardiovascular%20disease%20outcomes%20during%206.8%20years%20of%20hormone%20therapy%3A%20Heart%20and%20Estrogen%2Fprogestin%20Replacement%20Study%20Follow-up%20%28HERS%20II%29.&amp;author=S%20Hulley&amp;author=C%20Furberg&amp;author=E%20Barrett-Connor&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-34">34.</a><div class="reference-content">SchairerC, LubinJ, TroisiR, SturgeonS, BrintonL, HooverR.Menopausal estrogen and estrogen-progestin replacement therapy and
breast cancer risk.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;283:485-491.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Menopausal%20estrogen%20and%20estrogen-progestin%20replacement%20therapy%20and%20breast%20cancer%20risk.&amp;author=C%20Schairer&amp;author=J%20Lubin&amp;author=R%20Troisi&amp;author=S%20Sturgeon&amp;author=L%20Brinton&amp;author=R%20Hoover&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-35">35.</a><div class="reference-content">RossRK, Paganini-HillA, WanPC, PikeMC.Effect of hormone replacement therapy on breast cancer risk: estrogen
versus estrogen plus progestin.<I xmlns:helper="urn:XsltStringHelper">J Natl Cancer Inst.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2000;92:328-332.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effect%20of%20hormone%20replacement%20therapy%20on%20breast%20cancer%20risk%3A%20estrogen%20versus%20estrogen%20plus%20progestin.&amp;author=RK%20Ross&amp;author=A%20Paganini-Hill&amp;author=PC%20Wan&amp;author=MC%20Pike&amp;publication_year=&amp;journal=J%20Natl%20Cancer%20Inst.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-36">36.</a><div class="reference-content">ColditzGA, HankinsonSE, HunterDJ.
    et al.The use of estrogens and progestins and the risk of breast cancer in
postmenopausal women.<I xmlns:helper="urn:XsltStringHelper">N Engl J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1995;332:1589-1593.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=The%20use%20of%20estrogens%20and%20progestins%20and%20the%20risk%20of%20breast%20cancer%20in%20postmenopausal%20women.&amp;author=GA%20Colditz&amp;author=SE%20Hankinson&amp;author=DJ%20Hunter&amp;publication_year=&amp;journal=N%20Engl%20J%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-37">37.</a><div class="reference-content">MagnussonC, BaronJA, CorreiaN, BergstromR, AdamiH-O, PerssonI.Breast-cancer risk following long-term oestrogen and oestrogen-progestin-replacement
therapy.<I xmlns:helper="urn:XsltStringHelper">Int J Cancer.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;81:339-344.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Breast-cancer%20risk%20following%20long-term%20oestrogen%20and%20oestrogen-progestin-replacement%20therapy.&amp;author=C%20Magnusson&amp;author=JA%20Baron&amp;author=N%20Correia&amp;author=R%20Bergstrom&amp;author=H-O%20Adami&amp;author=I%20Persson&amp;publication_year=&amp;journal=Int%20J%20Cancer.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-38">38.</a><div class="reference-content">GreendaleGA, ReboussinBA, SieA.
    et al.Effects of estrogen and estrogen-progestin on mammographic parenchymal
density.<I xmlns:helper="urn:XsltStringHelper">Ann Intern Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;130:262-269.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20estrogen%20and%20estrogen-progestin%20on%20mammographic%20parenchymal%20density.&amp;author=GA%20Greendale&amp;author=BA%20Reboussin&amp;author=A%20Sie&amp;publication_year=&amp;journal=Ann%20Intern%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-39">39.</a><div class="reference-content">GrodsteinF, NewcombPA, StampferMJ.Postmenopausal hormone therapy and the risk of colorectal cancer: a
review and meta-analysis.<I xmlns:helper="urn:XsltStringHelper">Am J Med.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1999;106:574-582.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Postmenopausal%20hormone%20therapy%20and%20the%20risk%20of%20colorectal%20cancer%3A%20a%20review%20and%20meta-analysis.&amp;author=F%20Grodstein&amp;author=PA%20Newcomb&amp;author=MJ%20Stampfer&amp;publication_year=&amp;journal=Am%20J%20Med.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-40">40.</a><div class="reference-content">VickersMR, MeadeTW, WilkesHC.Hormone replacement therapy and cardiovascular disease: the case for
a randomized controlled trial.<I xmlns:helper="urn:XsltStringHelper">Ciba Found Symp.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1995;191:150-160.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Hormone%20replacement%20therapy%20and%20cardiovascular%20disease%3A%20the%20case%20for%20a%20randomized%20controlled%20trial.&amp;author=MR%20Vickers&amp;author=TW%20Meade&amp;author=HC%20Wilkes&amp;publication_year=&amp;journal=Ciba%20Found%20Symp.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-41">41.</a><div class="reference-content">TorgersonDJ, Bell-SeyerSE.Hormone replacement therapy and prevention of nonvertebral fractures:
a meta-analysis of randomized trials.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;285:2891-2897.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Hormone%20replacement%20therapy%20and%20prevention%20of%20nonvertebral%20fractures%3A%20a%20meta-analysis%20of%20randomized%20trials.&amp;author=DJ%20Torgerson&amp;author=SE%20Bell-Seyer&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-42">42.</a><div class="reference-content">Writing Group for the PEPI Trial.Effects of hormone therapy on bone mineral density: results from the
Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.<I xmlns:helper="urn:XsltStringHelper">JAMA.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">1996;275:1389-1396.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Effects%20of%20hormone%20therapy%20on%20bone%20mineral%20density%3A%20results%20from%20the%20Postmenopausal%20Estrogen%2FProgestin%20Interventions%20%28PEPI%29%20Trial.&amp;publication_year=&amp;journal=JAMA.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div><div class="reference"><a class="reference-number" id="ref-joc21036-43">43.</a><div class="reference-content">MoscaL, CollinsP, HerringtonDM.
    et al.Hormone replacement therapy and cardiovascular disease: a statement
for healthcare professionals from the American Heart Association.<I xmlns:helper="urn:XsltStringHelper">Circulation.</I><span class="ref-text" xmlns:helper="urn:XsltStringHelper">2001;104:499-503.</span><a class="google-scholar-ref-link" href="https://scholar.google.com/scholar_lookup?title=Hormone%20replacement%20therapy%20and%20cardiovascular%20disease%3A%20a%20statement%20for%20healthcare%20professionals%20from%20the%20American%20Heart%20Association.&amp;author=L%20Mosca&amp;author=P%20Collins&amp;author=DM%20Herrington&amp;publication_year=&amp;journal=Circulation.&amp;volume=&amp;pages=" target="_blank" xmlns:helper="urn:XsltStringHelper">Google Scholar</a></div></div></div>

</div>
 
    </div>

        <div class="movable-ad bta">
    <div class="widget-WidgetLoader widget-instance-AMA_AdTag_textbreak_bta_dual">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_textbreak_bta_dual" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:8,&quot;adSection&quot;:&quot;textbreak&quot;,&quot;adPosition&quot;:&quot;bta&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{}}"></div>
 
    </div>

        </div>
    </div> 

</div> 

<div class="hidden-jobs-ad hide">
    <div class="widget-WidgetLoader widget-instance-AMA_JobsAd">
        
<div class="SCM-SharedWidgets-AsyncJobsAdLoader" data-url="/AMA/JobsAd/AMA_JobsAd" data-params="{&quot;parameters&quot;:{&quot;SiteId&quot;:3},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

</div>



<script>
                var App = App || {};
                App.ArticleSplitScreen = App.ArticleSplitScreen || {};
                App.ArticleSplitScreen.siteName = 'jama';
                App.ArticleSplitScreen.siteId = 3;
                App.ArticleSplitScreen.journalId = 67;
                App.ArticleSplitScreen.adDisplay = 'ArticleContentsSkyBox';
                App.ArticleSplitScreen.adSection = "scholarly";
                App.ArticleSplitScreen.adPosition = "contab";
                App.ArticleSplitScreen.controlId = "AMA_AdTag_Contents_Skybox";
                App.ArticleSplitScreen.fromGoogle = "False";
                App.ArticleSplitScreen.slotLocationOverride = "50";

</script> 
    </div>


 
    </div>

    </section>


    <section id="secFooterControl" class="master-footer">
        

        <script>
            var App = App || {};

            function scmByClass(className) {
                return document.getElementsByClassName(className);
            }

            function scmById(id) {
                return document.getElementById(id);
            }

            function scmquery(selector) {
                return document.querySelector(selector);
            }

            function queryAll(selector) {
                return document.querySelectorAll(selector);
            }

            function isTrueString(string) {
                if (typeof string === 'string') {
                    return string.toLowerCase() === 'true';
                }

                return undefined;
            }

            function updateViewportDimensions() {
                var w = window, d = document, e = d.documentElement, g = d.getElementsByTagName('body')[0], x = w.innerWidth || e.clientWidth || g.clientWidth, y = w.innerHeight || e.clientHeight || g.clientHeight;
                return { width: x, height: y };
            }

            var viewport = updateViewportDimensions();

            var debounce = function (func, wait, immediate) {
                var timeout;
                return function () {
                    var context = this, args = arguments;
                    var later = function () {
                        timeout = null;
                        if (!immediate) func.apply(context, args);
                    };
                    var callNow = immediate && !timeout;
                    clearTimeout(timeout);
                    timeout = setTimeout(later, wait);
                    if (callNow) func.apply(context, args);
                };
            };

            (function (App) {
                App.mobileUpperBreakpoint = 767;
                App.mobileAltBreakpoint = 640;
                App.mobileMinBreakpoint = 547;
                App.tabletUpperBreakpoint = 1023;

                function setVariables() {
                    viewport = updateViewportDimensions();
                    App.isMobile = (viewport.width <= App.mobileUpperBreakpoint);
                    App.isMobileAlt = (viewport.width <= App.mobileAltBreakpoint);
                    App.isTablet = (viewport.width > App.mobileUpperBreakpoint && viewport.width <= App.tabletUpperBreakpoint);
                    App.isTabletDown = (viewport.width <= App.tabletUpperBreakpoint);
                    App.isDesktop = (viewport.width > App.tabletUpperBreakpoint);
                    App.activeViewport = App.isMobile ? 'small' : App.isTablet ? 'med' : 'large';
                }

                setVariables();

                App.cachedViewport = App.isMobile ? 'small' : App.isTablet ? 'med' : 'large';
                App.isAnyArticle = !!(scmByClass('widget-ArticleFullView').length || scmByClass('pg_abstract').length
                    || scmByClass('widget-MagazineView').length || scmByClass('widget-ChannelsMagazineView').length);
                App.isSplitScreen = !!scmByClass('widget-ArticleFullView').length;
                App.isAbstract = !!scmByClass('pg_abstract').length;
                App.isMag = !!(scmByClass('widget-MagazineView').length);
                App.isChannel = !!(scmByClass('channel-site').length);
                App.isChannelMag = !!(scmByClass('widget-ChannelsMagazineView').length);
                App.isFreeArticle = !!(scmquery('.widget-ArticleTopInfo .free-access') ||
                                        scmquery('.widget-ArticleTopInfo .open-access') ||
                                        scmquery('.widget-ArticleTopInfo .icon-free') || 
                                        scmquery('.widget-ChannelsMagazineView .free-access'));
                App.isTollFreeAccess = false;
                App.isIssue = !!scmByClass('pg_issue').length || !!scmByClass('pg_newonline').length || !!scmByClass('pg_currentissue').length || !!scmByClass('pg_pastissues').length;
                App.isNewOnline = !!scmByClass('pg_newonline').length;
                App.isCurrentIssue = !!scmByClass('pg_currentissue').length;
                App.isPastIssues = !!scmByClass('pg_pastissues').length;
                App.isJournal = !!scmByClass('pg_journal').length;
                App.isNetworkHome = !!scmByClass('pg_index').length;
                App.isSearch = !!scmByClass('pg_searchresults').length;
                App.isAdvancedSearch = !!scmByClass('pg_advancedsearch').length;
                App.isPlayer= !!scmByClass('pg_multimediaplayer').length;
                App.isSelfServe = !!scmByClass('pg_sspage').length;
                App.isCmsPage = !!scmByClass('pg_cmspage').length; 
                App.isMyAccount = !!scmByClass('pg_myaccount').length;
                App.supportsFlexbox = !!scmByClass('flexbox').length;
                App.isCollection = !!scmByClass('pg_collection').length;
                App.isPaidUser = isTrueString(scmById('hfAppIsPaidUser').getAttribute('value'));
                App.isMember = isTrueString(scmById('hfAppIsMember').getAttribute('value'));
                App.isIndividual = isTrueString(scmById('hfAppIsIndividual').getAttribute('value'));
                App.hasAccess = isTrueString(scmById('hfAppHasAccess').getAttribute('value'));
                App.isReferredFromGoogle = isTrueString(scmById('hfAppIsReferredFromGoogle').getAttribute('value'));
                var subscribedTo = scmById('hfAppSubscribedTo').getAttribute('value');
                App.userSubscribedTo = subscribedTo ? subscribedTo.split(',') : undefined;
                App.isLucy = isTrueString(scmById('hfAppIsLucy').getAttribute('value'));
                App.currentJournalCount = 26;
                App.isChannelPage = !!(scmByClass('channels-page'));
                App.updateAppVariables = debounce(function () {
                    setVariables();
                }, 50, false);
            })(App);
        </script>
        

        
<div class="footer-ad-wrapper">
    <div id="BodyContent_Footer_divAds" class="footer-ad desktop-only">
        
            <div class="widget-WidgetLoader widget-instance-AMA_AdTag_AnchorboardAd_btf">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_AnchorboardAd_btf" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:11,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;btf&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>
</div>
</div>

 
 <div class="ad-riser-wrap desktop-only">
     <div class="ad-riser--dismiss t-c">X</div>
         <div class="widget-WidgetLoader widget-instance-AMA_AdTag_Riser">
        
    <div class="SCM-SharedWidgets-AsyncAdLoader" data-url="/AMA/AdTag/AMA_AdTag_Riser" data-params="{&quot;parameters&quot;:{&quot;siteName&quot;:&quot;jama&quot;,&quot;siteId&quot;:3,&quot;journalId&quot;:67,&quot;adDisplay&quot;:12,&quot;adSection&quot;:&quot;scholarly&quot;,&quot;adPosition&quot;:&quot;Riser&quot;,&quot;fromGoogle&quot;:false},&quot;dynamicParameters&quot;:{&quot;localParams&quot;:&quot;[REPLACE_WITH_LOCAL]&quot;}}"></div>
 
    </div>

 </div>


<div class="footer-wrap">
    
    <footer class="footer" id="footer">
        
        <div id="footer-microsite" class="footer-microsite">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Left" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    @media (min-width: 1024px) {.split-screen .footer-microsite-contents {border-bottom:0 !important;}}
    .footer-microsite-contents {margin-bottom:1em;width:100%;}
    .footer-network-other .link-apps:before {width: 23px;}
    .footer-network-other .link-institutions-librarians:before {width: 23px;}
    .jn-ss-footer-border-top {border-top:1px solid #555;padding-top:15px;}
    .jn-ss-footer-border-bottom {border-bottom:1px solid #555;padding-bottom:10px;padding-right:3px;}
</style>
<div class="footer-heading-wrap">
<h3 id="BodyContent_Footer_h3SiteName" class="footer-heading is-b footer-microsite-heading" data-mobile-tog-target=".footer-microsite-links-wrap">JAMA</h3>
</div>
<div class="footer-microsite-links-wrap">
<div class="footer-microsite-contents  jn-ss-footer-border-bottom">
<h4 id="BodyContent_Footer_ContentHeader" class="footer-subheading">Content</h4>
<a href="/journals/jama">Home</a>
<a href="/journals/jama/newonline">New Online</a>
<a href="/journals/jama/currentissue">Current Issue</a>
</div>
<div class="footer-microsite-contents  jn-ss-footer-border-bottom">
<h4 class="footer-subheading">Podcasts</h4>
<a href="/journals/jama/pages/covid-19-interviews#audio">Coronavirus (COVID-19)&nbsp;Q&amp;A</a>
<a href="/journals/jama/pages/jama-clinical-reviews">Clinical Reviews</a>
<a href="/journals/jama/pages/jama-editors-summary">Editors' Summary</a>
<a href="/journals/jama/pages/jama-medical-news">Medical News</a>
<a href="/journals/jama/pages/jama-author-interviews">Author Interviews</a>
<a href="/journals/jama/pages/jamaevidence-jama-guide-to-statistics-and-methods">JAMAevidence: <em>JAMA Guide to Statistics and Methods</em></a>
<a href="/journals/jama/pages/jamaevidence-the-rational-clinical-examination">JAMAevidence: The Rational Clinical Examination</a>
<a href="/journals/jama/pages/jamaevidence-users-guides-to-the-medical-literature">JAMAevidence: Users' Guides to the Medical Literature</a>
</div>
<div class="footer-microsite-services cf">
<h4 id="BodyContent_Footer_ServiceHeader" class="footer-subheading">Journal Information</h4>
<a href="/journals/jama/pages/for-authors">For Authors</a>
<a href="/journals/jama/pages/jama-editors">JAMA Editors</a>
<a href="/journals/jama/editors-and-publishers">Editors &amp; Publishers</a>
<a href="/pages/rss">RSS</a>
<a href="/journals/jama/pages/contact-us">Contact Us</a>
</div>
<div class="footer-network-other  jn-ss-footer-border-bottom">
<a href="https://edhub.ama-assn.org/jn-learning" class="link-network-other is-b link-learning">JN Learning / CME</a>
<a href="https://store.jamanetwork.com" class="link-network-other is-b link-store" target="_blank">Store</a>
<a href="/pages/apps" class="link-network-other is-b link-mobile" target="_blank">Apps</a>
<a href="https://careers.jamanetwork.com/" class="link-network-other is-b link-jobs" target="_blank">Jobs</a>
<a href="/pages/resources-for-librarians" class="link-network-other is-b link-institutions-librarians" target="_blank">Institutions</a>
<a href="/pages/reprints-and-permissions" class="link-network-other is-b link-reprints-permissions">Reprints &amp; Permissions</a>
</div>
<div id="BodyContent_Footer_divSubscribe" class="footer-microsite-subscribe">
<img src="//cdn.jamanetwork.com/UI/app/img/covers/jama.jpg" class="subscribe-image" alt="Journal Cover">
<div class="subscribe-meta">
<h4 class="subscribe-heading footer-subheading">Subscribe</h4>
<a href="https://store.jamanetwork.com/productDetails.aspx?productcodeID=64" class="subscribe-submit btn">Go</a>
</div>
</div>
</div>





        </div>

        
        <div id="footer-network" class="footer-network">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Middle" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .footer-network-sites {width: 62.85542%;}
    .footer-network-info {width: 35.93976%}
    .jn-ss-subheading-mt {margin-top: 1.5em;}
    .jn-registered:after {content: "\00AE";font-size: 50%;vertical-align: top;}
    .jn-trademark:after {content: "\2122";font-size: 50%;vertical-align: top;}
</style>
<div class="footer-heading-wrap">
<h3 class="footer-heading is-b jn-registered" data-mobile-tog-target=".footer-network-links-wrap"><strong>JAMA</strong> Network</h3>
</div>
<div class="footer-network-links-wrap">
<div class="footer-network-sites">
<div class="internal">
<h4 id="BodyContent_Footer_JournalHeader" class="footer-subheading">Publications</h4>
<a href="/journals/jama">JAMA</a>
<a href="/journals/jamanetworkopen" target="_blank">JAMA Network Open</a>
<a href="/journals/jamacardiology">JAMA Cardiology</a>
<a href="/journals/jamadermatology">JAMA Dermatology</a>
<a href="/journals/jama-health-forum">JAMA Health Forum</a>
<a href="/journals/jamainternalmedicine">JAMA Internal Medicine</a>
<a href="/journals/jamaneurology">JAMA Neurology</a>
<a href="/journals/jamaoncology">JAMA Oncology</a>
<a href="/journals/jamaophthalmology">JAMA Ophthalmology</a>
<a href="/journals/jamaotolaryngology">JAMA OtolaryngologyHead &amp; Neck Surgery</a>
<a href="/journals/jamapediatrics">JAMA Pediatrics</a>
<a href="/journals/jamapsychiatry">JAMA Psychiatry</a>
<a href="/journals/jamasurgery">JAMA Surgery</a>
<a href="/journals/archneurpsyc">Archives of Neurology &amp; Psychiatry (1919-1959)</a>
</div>
<div class="external">
<h4 class="footer-subheading">Sites</h4>
<div id="BodyContent_Footer_ssFooterSiteMenu">
<div class="selfServe">
<a target="_blank" href="https://sites.jamanetwork.com/art-and-images-in-psychiatry/">Art and Images in Psychiatry</a>
<a target="_blank" href="/channels/ai">Artificial Intelligence (AI) Resource Center</a>
<a target="_blank" href="/journals/jama/pages/2023-most-viewed-jama">Best of the JAMA Network</a>
<a target="_blank" href="/channels/caring-for-the-critically-ill-patient">Caring for the Critically Ill Patient</a>
<a target="_blank" href="/journals/jama/pages/crosswords">Clinical Crosswords from JAMA</a>
<a target="_blank" href="/journals/jama/pages/coronavirus-alert">Coronavirus Resource Center</a>
<a target="_blank" href="https://ebm.jamanetwork.com/index.html">Evidence-Based Medicine: An Oral History</a>
<a target="_blank" href="/pages/fishbein-fellowship">Fishbein Fellowship</a>
<a target="_blank" href="/channels/genomics/">Genomics and Precision Health</a>
<a target="_blank" href="/channels/hypertension">Hypertension</a>
<a target="_blank" href="/channels/health-forum/archive">JAMA Forum Archive</a>
<a target="_blank" href="https://sites.jamanetwork.com/audio">JAMA Network Audio</a>
<a target="_blank" href="/pages/video">JAMA Network Video</a>
<a target="_blank" href="/pages/conferences">JAMA Network Conferences </a>
<a target="_blank" href="/pages/jama-summit">JAMA Summit </a>
<a target="_blank" href="/journals/jamasurgery/pages/statistics-and-methods">JAMA Surgery Guide to Statistics and Methods</a>
<a target="_blank" href="/channels/medical-news">Medical News</a>
<a target="_blank" href="/channels/monkeypox">Mpox (Monkeypox)</a>
<a target="_blank" href="https://sites.jamanetwork.com/research-ethics/">Research Ethics</a>
<a target="_blank" href="/pages/collections">Topics and Collections</a>
<a target="_blank" href="/pages/visual-abstracts">Visual Abstracts</a>
<a target="_blank" href="/channels/war">War and Health</a>
<a target="_blank" href="/channels/womens-health">Women's Health</a>
<h4 class="footer-subheading jn-ss-subheading-mt">Featured Articles</h4>
<a href="/journals/jama/fullarticle/2799240">Antiretroviral Drugs for HIV Treatment and Prevention in Adults - 2022 IAS-USA Recommendations</a>
<a href="/journals/jama/fullarticle/2781397">CONSERVE 2021 Guidelines for Reporting Trials Modified for the COVID-19 Pandemic</a>
<a href="/journals/jama/fullarticle/2808296">Creation and Adoption of Large Language Models in&nbsp;Medicine</a>
<a href="/journals/jamaoncology/fullarticle/2787350">Global Burden of Cancer, 2010-2019</a>
<a href="/journals/jama/fullarticle/2797443">Global Burden of Long COVID</a>
<a href="/journals/jamadermatology/fullarticle/2790344">Global Burden of Melanoma</a>
<a href="/journals/jamadermatology/fullarticle/2787350">Global Burden of Skin Diseases, 1990-2017</a>
<a href="/journals/jamaneurology/fullarticle/2793874">Global Disparities in Parkinson Disease</a>
<a href="/journals/jama/fullarticle/2799547">Guidelines for Reporting Outcomes in Trial Protocols: The SPIRIT-Outcomes 2022 Extension</a>
<a href="/journals/jamapsychiatry/fullarticle/2799486">Mass Violence and the Complex Spectrum of Mental Illness and Mental Functioning</a>
<a href="/journals/jamapsychiatry/fullarticle/2793903">Neuropsychiatry Sequelae of COVID-19</a>
<a href="/journals/jamaneurology/fullarticle/2810313">A New Framework for Dementia Nomenclature</a>
<a href="/journals/jama/fullarticle/2800656">Organization and Performance of US Health Systems</a>
<a href="/journals/jama-health-forum/fullarticle/2791195">Pharmacy Benefit Managers: History, Business Practices, Economics, and Policy</a>
<a href="/journals/jama-health-forum/fullarticle/2791195">Promoting EDI in Genetics Research</a>
<a href="/journals/jamacardiology/fullarticle/2781972">PTSD and Cardiovascular Disease</a>
<a href="/journals/jama/fullarticle/2810754">Red Blood Cell Transfusion: 2023 AABB International Guidelines</a>
<a href="/journals/jamapediatrics/fullarticle/2797600">Reimagining Childrens Rights in the US</a>
<a href="/journals/jama/fullarticle/2794049">Spirituality in Serious Illness and Health</a>
<a href="/journals/jama/fullarticle/2796374">The US Medicaid Program: Coverage, Financing, Reforms, and Implications for Health Equity</a>
<h4 class="footer-subheading jn-ss-subheading-mt">USPSTF Recommendation Statements</h4>
<a href="/journals/jama/fullarticle/2779985">Screening for Colorectal Cancer</a>
<a href="/journals/jama/fullarticle/2779190">Screening for Hypertension</a>
<a href="/journals/jama/fullarticle/2777244">Screening for Lung Cancer</a>
<a href="/journals/jama/fullarticle/2796244">Screening for Prediabetes and Type 2 Diabetes In Children</a>
<a href="/journals/jama/fullarticle/2783414">Screening for Prediabetes and Type 2 Diabetes In Adults</a>
<a href="/journals/jama/fullarticle/2795521">Statins for Primary Prevention of Cardiovascular Disease</a>
<a href="/journals/jama/fullarticle/2793446">Vitamin and Mineral Supplements for Primary Prevention of of Cardiovascular Disease and Cancer</a>
<h4 class="footer-subheading jn-ss-subheading-mt">Blogs</h4>
<a target="_blank" href="https://amastyleinsider.com/">AMA Style Insider</a>
</div>
</div>
</div>
</div>
<div id="footer-network-info" class="footer-network-info">
<div class="information-for-links">
<h4 id="BodyContent_Footer_InfoHeader" class="footer-subheading">Information</h4>
<a href="/pages/for-authors">For Authors</a>
<a href="/pages/resources-for-librarians">For Institutions &amp; Librarians</a>
<a href="/pages/advertisers">For Advertisers</a>
<a href="/pages/subscription-agents">For Subscription Agents</a>
<a href="https://careers.jamanetwork.com/" target="_blank">For Employers &amp; Job Seekers</a>
<a href="https://media.jamanetwork.com" rel="nofollow" target="_blank">For the Media</a>
<a href="/pages/equity-diversity-inclusion">Equity, Diversity, Inclusion</a>
<a href="/pages/commenting-policy">Online Commenting Policy</a>
<a href="/pages/access-at-jama-network">Public Access and Open Access Policy</a>
<a href="/pages/offensive-content-statement">Statement on Potentially Offensive Content</a>
</div>
<div class="services-links">
<h4 id="BodyContent_Footer_JAMANetworkProductsHeader" class="footer-subheading">JAMA Network Products</h4>
<a href="http://www.amamanualofstyle.com/" class="footer-service-link" target="_blank">AMA Manual of Style</a>
<a href="https://jamaevidence.mhmedical.com/" class="footer-service-link" target="_blank"><span class="jn-registered">JAMAevidence</span></a>
<a href="http://www.peerreviewcongress.org/" class="footer-service-link" target="_blank">Peer Review Congress</a>
</div>
<div class="learning-links">
<h4 id="BodyContent_Footer_LearningHeader" class="footer-subheading">JN Learning</h4>
<a href="https://edhub.ama-assn.org/jn-learning">Home</a>
<a href="https://edhub.ama-assn.org/jn-learning/state-cme">State CME</a>
<a href="https://edhub.ama-assn.org/jn-learning/pages/clinical-challenge-courses">Clinical Challenge CME</a>
<a href="https://edhub.ama-assn.org/jn-learning/course/288 ">Atrial Fibrillation Course</a>
<a href="https://edhub.ama-assn.org/jn-learning/course/294 ">Women's Health Course</a>
<a target="_blank" href="https://edhub.ama-assn.org/pages/auto-credit-reporting">CME / MOC Reporting Preferences</a>
<a href="https://edhub.ama-assn.org/jn-learning/pages/about-cme">About CME &amp; MOC</a>
</div>
</div>
</div>





        </div>
        
        <div id="footer-resources-wrap" class="footer-resources-wrap">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Right" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .footer-resources-wrap .footer-subheading {color: grey;display:block !important;font-size: 1.17647em;font-weight: 400;text-transform: uppercase;}
</style>
<div class="footer-heading-wrap">
<h3 class="footer-heading is-b footer-resources-heading" data-mobile-tog-target=".footer-resources">Help</h3>
</div>
<div class="footer-resources">
<a href="https://store.jamanetwork.com" class="footer-service-link" target="_blank">Subscriptions &amp; Renewals</a>
<a href="https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-alerts" class="footer-service-link" rel="nofollow">Manage Emails</a>
<a href="https://jamanetwork.com/oauthsignin?return_url=http%3A%2F%2Fjamanetwork.com%2Fmyaccount%23my-profile" class="footer-service-link" rel="nofollow">Update My Address</a>
<a href="https://support.jamanetwork.com/hc/en-us" class="footer-service-link">Support Center</a>
<a href="/myaccount " class="footer-service-link">My Account</a>
<h4 class="footer-subheading jn-ss-subheading-mt">JAMA Career Center</h4>
<a href="https://careers.jamanetwork.com/" class="footer-service-link" target="_blank">Physician Job Listings</a>
</div>








    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Socials" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .widget-instance-AMA_Journal_Home_Socials .iconsocial {display: inline-block !important;width: 34px;height: 34px;min-width: unset !important;margin: 0 2px !important;background-color: #fff;border-radius: 20px;border: 1px solid #191919;vertical-align: middle;}
    .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-black.svg);background-position: 7px 7px;background-repeat: no-repeat;background-size: 18px;}
    .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram:hover, .widget-instance-AMA_Journal_Home_Socials .iconsocial.instagram:focus {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-fill.png);border-color: #C13584;}
    .footer-resources-wrap .iconsocial {display: inline-block !important;width: 32px;height: 32px;min-width: unset !important;margin: 0 2px 0 3px !important;background-color: #fff;border-radius: 20px;border: 1px solid #191919;vertical-align: middle;}
    .footer-resources-wrap .iconsocial.instagram {background-image: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-black.svg);background-position: 6px 6px;background-repeat: no-repeat;background-size: 18px;}
    .footer-resources-wrap .iconsocial.instagram:hover, .footer-resources-wrap .iconsocial.instagram:focus {background-color: #C13584;border-color: #191919;}
    #load-instagram-image { background: url(https://cdn.jamanetwork.com/ImageLibrary/JamaNetwork/social/instagram-icon-fill.png) no-repeat -9999px -9999px; }
</style>
<div id="BodyContent_Footer_divSocial" class="social-links footer-social-links">
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.facebook.com/JAMAJournal/" class="social-link is-b facebook"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://twitter.com/JAMA_current" class="social-link is-b twitter"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.instagram.com/jamanetwork/?hl=en" class="iconsocial instagram"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.linkedin.com/company/jamanetwork/" class="social-link is-b linked-in"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.youtube.com/jamanetwork" class="social-link is-b you-tube"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://www.pinterest.com/jamanetwork/" class="social-link is-b pinterest"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="/rss/site_3/67.xml" class="social-link is-b rss"></a>
<a target="_blank" rel="nofollow" data-emailid="6d35777a-fc12-4d2d-9b49-81d031835d91" href="https://jamanetwork.com/journals/jama/pages/jama-editors-summary" class="social-link is-b podcast"></a>
<div id="load-instagram-image">&nbsp;</div>
</div>




<div id="BodyContent_Footer_divEmailUpdate" class="footer-email-updates">
                
                    <div class="widget-EmailListSignUp widget-instance-AMAv2_EmailListSignUp_Footer">
        <div class="email-signup">
    
    <div class="email-signup--text sb-pc">Get the latest from JAMA</div>
    <div class="email-signup--input-wrap is-b">
        <input type="text" name="email" class="email-signup--input" placeholder="Email address" title="Email address" />
        <a rel="nofollow" href="javascript:;" class="email-signup--submit sb-sc btn">Sign Up</a>
    </div>
    <div class="email-signup--link"> <a class="email-signup--privacy" href="/pages/privacy-policy">Privacy Policy</a> | <a class="email-signup--terms" href="/pages/terms-of-use">Terms of Use</a></div>
    <div class="email-signup--user-message"></div>
</div> 
    </div>
</div>
        </div>

        
        <div class="footer-bar" itemscope itemtype="https://schema.org/Organization">
            



    <input type="hidden" class="SelfServeContentId" value="v2_Footer_Bottom_Bar" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<style type="text/css">
    .nav-journals a.theme-jama-health-forum:before {background: #133763;}
    .jn-bottom-bar {color: #fff; float: left;font-size: 10px;padding: 13px 20px;width: 33.33%;}
    .jn-bottom-bar p {line-height: 2;}
    @media (max-width: 900px) {.jn-bottom-bar {float: none;width: 100%;}}
    .jn-footer-copyright {font-size:12px;line-height:1.5;margin-bottom:10px;}
    .jn-footer-pipe {margin:0 10px;}
    .footer-bar-jn-logo img {width: 230px;}
    @media (max-width: 900px) {.footer-bar-jn-logo img {width: 200px;}}
    [data-thm=umb] .jobs-ad--text h6 {color: #d71635 !important;}
    [data-thm=jama] .jobs-ad--text h6 {color: #d71635 !important;}
    [data-thm=jaman] .jobs-ad--text h6 {color: #ed0973 !important;}
    [data-thm=cardi] .jobs-ad--text h6 {color: #be1e32 !important;}
    [data-thm=derm] .jobs-ad--text h6 {color: #006f3b !important;}
    [data-thm=faci] .jobs-ad--text h6 {color: #ed1c24 !important;}
    [data-thm=jama-] .jobs-ad--text h6 {color: #fb5252 !important;}
    [data-thm=intem] .jobs-ad--text h6 {color: #006e96 !important;}
    [data-thm=neur] .jobs-ad--text h6 {color: #981b1e !important;}
    [data-thm=oncol] .jobs-ad--text h6 {color: #3b923f !important;}
    [data-thm=ophth] .jobs-ad--text h6 {color: #66bc29 !important;}
    [data-thm=otol] .jobs-ad--text h6 {color: #34b6e4 !important;}
    [data-thm=peds] .jobs-ad--text h6 {color: #0084c0 !important;}
    [data-thm=psych] .jobs-ad--text h6 {color: #005276 !important;}
    [data-thm=surg] .jobs-ad--text h6 {color: #f47920 !important;}
    .blockquote .para {margin: 0 0 1em 1em;}
    .jn-footer-copyright {display: block;}
    .inline-block {display: inline-block;}
    #selfserve-maintenance {display:block;margin:20px 0;max-height:none !important;min-height:200px;visibility:visible;}
</style>
<a class="footer-bar-jn-logo d-b no-mw mb1" href="/" title="JAMA Network Home"><img class="mw-100" src="https://cdn.jamanetwork.com/ImageLibrary/global/jn-signature-reversed-r.svg?versionId=81373" alt="Jama Network Logo"></a>
<div class="jn-bottom-bar">
<p>
<span class="jn-footer-copyright"> 2024 American Medical Association. <span class="inline-block">All rights reserved,</span> including those for text and data mining, AI training, <span class="inline-block">and similar technologies.</span></span>
<span class="inline-block"><a href="https://www.ama-assn.org/about/terms-use" rel="nofollow" class="p0">Terms of Use</a><span class="jn-footer-pipe">|</span></span>
<span class="inline-block"><a href="https://www.ama-assn.org/about/privacy-policy" rel="nofollow" class="p0">Privacy Policy</a><span class="jn-footer-pipe">|</span></span>
<span class="inline-block"><a href="https://www.ama-assn.org/about/accessibility-statement" rel="nofollow" class="p0">Accessibility Statement</a><span class="jn-footer-pipe">|</span></span>
<span class="inline-block"><a onclick="OneTrust.ToggleInfoDisplay()" rel="nofollow" class="p0" id="CookieFooter">Cookie Settings</a></span>
</p>
</div>
<!-- 
	#selfserve-maintenance {display:block;margin:20px 0;max-height:none !important;min-height:200px;visibility:visible;}
	-->





            <a class="footer-bar-sis no-mw relative nudge-down" href="https://www.silverchair.com" target="_blank"><img class="footer-bar-sis-img mt05 mw-100" width="600" height="70" src="//cdn.jamanetwork.com/UI/app/img/powered.png" alt="Silverchair Logo" /></a>
        </div>
    </footer>

</div>
<div class="ss-ui-only">
        <div class="widget-SelfServeContent widget-instance-AMA_SS_UI_Only">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SsUiOnly" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

.


</div>

 
    </div>

</div>

    </section>


        

        
        
        <div id="revealModal" class="reveal-modal" data-reveal>
            <div id="revealContent"></div>
            <a class="close-reveal-modal icon-close"></a>
        </div>

        
        <div class="artmet-modal" id="MetricsModal">
            <div class="artmet-modal-contents">
                <a class="artmet-close-modal">&#215;</a>
            </div>
        </div>

        
        
    


            <div class="widget-SigninModals widget-instance-AMA_SigninModals">
        <div class="js-modal-no-access-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Access your subscriptions</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195120">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

            <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_NoAccess_AdvancedSeamlessAccessButton">
        <div class="seamless-access-button--wrap">
    <button class="d-flex sa-button align-items-center" role="button" type="button">
        <div class="sa-button-logo-wrap">
            <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" />
        </div>
        <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate">
            <div class="sa-button-text-primary text-truncate">Access through your institution</div>
        </div>
    </button>
    <div class="sa-access-text text-truncate hide">
        <div class="sa-cta-access"><span>Add or change institution</span></div>
    </div>
</div>
 
    </div>

    <div class="widget-SelfServeContent widget-instance-AMA_NoAccess_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_NoAccess_SigninModal_PurchaseOptions_NoAccessAndPaidPDF">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_NoAccessAndPaidPDF" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Purchase access</div>
<hr>
<button class="modal--btn js-btn-subscribe-journal" type="button" role="button">
<div class="text-truncate">Subscribe to journal</div>
</button>
<div class="modal--btn-desc">Get full journal access for 1 year</div>
<button class="modal--btn js-btn-purchase-article" type="button" role="button">
<div class="text-truncate">Buy article</div>
</button>
<div class="modal--btn-desc">Get unlimited access and a printable PDF ($40.00)<br>
<em>Sign in or create a free account</em></div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_NoAccessAndPaidPDF</div>-->


</div>

 
    </div>

            <div class="widget-DeepDyve widget-instance-AMA_NoAccess_DeepDyve">
                <button type="button" role="button" class="modal--btn js-deepdyve-link hiddenRentalLink" data-deepdyveurl="https://www.deepdyve.com/doc-view?docId=10.1001/jama.288.3.321&amp;fieldName=journal_doi&amp;affiliateId=JAMA" data-doi="10.1001/jama.288.3.321" data-fieldname="journal_doi" 
                data-issneissn="0098-7484" data-affiliate="JAMA">Rent article</button>
        <div class="modal--btn-desc js-deepdyve-desc hiddenRentalLink">Rent this article from DeepDyve</div>
 
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-paid-pdf-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Access your subscriptions</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195120">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

            <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_PaidPdf_AdvancedSeamlessAccessButton">
        <div class="seamless-access-button--wrap">
    <button class="d-flex sa-button align-items-center" role="button" type="button">
        <div class="sa-button-logo-wrap">
            <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" />
        </div>
        <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate">
            <div class="sa-button-text-primary text-truncate">Access through your institution</div>
        </div>
    </button>
    <div class="sa-access-text text-truncate hide">
        <div class="sa-cta-access"><span>Add or change institution</span></div>
    </div>
</div>
 
    </div>

    <div class="widget-SelfServeContent widget-instance-AMA_PaidPdf_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_PaidPdf_SigninModal_PurchaseOptions_NoAccessAndPaidPDF">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_NoAccessAndPaidPDF" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Purchase access</div>
<hr>
<button class="modal--btn js-btn-subscribe-journal" type="button" role="button">
<div class="text-truncate">Subscribe to journal</div>
</button>
<div class="modal--btn-desc">Get full journal access for 1 year</div>
<button class="modal--btn js-btn-purchase-article" type="button" role="button">
<div class="text-truncate">Buy article</div>
</button>
<div class="modal--btn-desc">Get unlimited access and a printable PDF ($40.00)<br>
<em>Sign in or create a free account</em></div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_NoAccessAndPaidPDF</div>-->


</div>

 
    </div>

            <div class="widget-DeepDyve widget-instance-AMA_PaidPDF_DeepDyve">
                <button type="button" role="button" class="modal--btn js-deepdyve-link hiddenRentalLink" data-deepdyveurl="https://www.deepdyve.com/doc-view?docId=10.1001/jama.288.3.321&amp;fieldName=journal_doi&amp;affiliateId=JAMA" data-doi="10.1001/jama.288.3.321" data-fieldname="journal_doi" 
                data-issneissn="0098-7484" data-affiliate="JAMA">Rent article</button>
        <div class="modal--btn-desc js-deepdyve-desc hiddenRentalLink">Rent this article from DeepDyve</div>
 
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-free-pdf-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Sign in to access free PDF</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195120">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

            <div class="widget-AmaAdvancedSeamlessAccess widget-instance-AMA_FreePdf_AdvancedSeamlessAccessButton">
        <div class="seamless-access-button--wrap">
    <button class="d-flex sa-button align-items-center" role="button" type="button">
        <div class="sa-button-logo-wrap">
            <img src="//cdn.jamanetwork.com/UI/app/svg/seamless-access.svg" class="sa-button-logo" alt="Seamless Access Logo" />
        </div>
        <div class="d-flex justify-content-center align-items-center sa-button-text text-truncate">
            <div class="sa-button-text-primary text-truncate">Access through your institution</div>
        </div>
    </button>
    <div class="sa-access-text text-truncate hide">
        <div class="sa-cta-access"><span>Add or change institution</span></div>
    </div>
</div>
 
    </div>

    <div class="widget-SelfServeContent widget-instance-AMA_FreePdf_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-save-search-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Save your search</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195120">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

    <div class="widget-SelfServeContent widget-instance-AMA_SaveSearch_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_SaveSearch">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_SaveSearch" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Purchase access</div>
		<hr />
		<button class="modal--btn js-btn-subscribe-now">Subscribe now</button>
		<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_SaveSearch</div>-->


</div>

 
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-follow-collection-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Customize your interests</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195120">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

    <div class="widget-SelfServeContent widget-instance-AMA_FollowCollection_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_FollowCollection">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_FollowCollection" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--sub-title">Create a personal account or sign in to:</div>
		<ul>
			<li>Register for email alerts with links to free full-text articles</li>
			<li>Access PDFs of free articles</li>
			<li>Manage your interests</li>
			<li>Save searches and receive search alerts</li>
		<ul>
		<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_FollowCollection</div>-->


</div>

 
    </div>

            <div class="modal--link-wrap">
        <a class="modal--link" href="/pages/privacy-policy" rel="nofollow">Privacy Policy</a>
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="js-modal-user-comment-reveal no-access reveal-modal modal tiny" data-reveal>
    <div class="modal--box">
        <div class="modal--title">Make a comment</div>
        <hr />
                <button type="button" role="button" class="modal--btn js-btn-signin-personal" data-oauth-signin-url="https://jamanetwork.com/oauthsignin?return_url=https%3a%2f%2fjamanetwork.com%2fjournals%2fjama%2ffullarticle%2f195120">
            Sign in<span class="fw-normal"> | personal account</span>
        </button>

    <div class="widget-SelfServeContent widget-instance-AMA_UserComment_SigninModal_CreateAccount">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_CreateAccount" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--title">Free access to newly published articles</div>
<hr>
<button class="modal--btn js-btn-create-personal-account" type="button" role="button">
<div class="text-truncate">Create a free personal account</div>
</button>
<div class="modal--btn-desc">To register for email alerts, access free PDF, and more</div>
<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_CreateAccount</div>-->


</div>

 
    </div>
            <div class="widget-SelfServeContent widget-instance-AMA_SigninModal_PurchaseOptions_UserComment">
        


<div class="self-serve">
    <input type="hidden" class="SelfServeContentId" value="SigninModal_PurchaseOptions_UserComment" />
    <input type="hidden" class="SelfServeVersionId" value="0" />

<div class="modal--sub-title">Create a personal account or sign in to:</div>
		<ul>
			<li>Register for email alerts with links to free full-text articles</li>
			<li>Access PDFs of free articles</li>
			<li>Manage your interests</li>
			<li>Save searches and receive search alerts</li>
		<ul>
		<!--<div class="jn-selfServe-modal-label">JAMA|SigninModal_PurchaseOptions_UserComment</div>-->


</div>

 
    </div>

            <div class="modal--link-wrap">
        <a class="modal--link" href="/pages/privacy-policy" rel="nofollow">Privacy Policy</a>
    </div>

    </div>
        <a class="close-reveal-modal icon-close"></a>

</div>

<div class="hidden-true js-modal-page-data"
     data-store-url="https://store.jamanetwork.com"
     data-store-purchase-url="https://jamanetwork.com/oauthsignin?return_url=https://store.jamanetwork.com"
     data-store-subscribe-url="https://store.jamanetwork.com/index.aspx?productcode=64">
</div>






 
    </div>

        

        
        <script src="//cdn.jamanetwork.com/UI/app/vendor/jquery-2.2.4.min.js?v=638473295270790799"></script>
        <script>window.jQuery || document.write('<script src="/UI/app/vendor/jquery-2.2.4.min.js">\x3C/script>')</script>

        <script src="//cdn.jamanetwork.com/UI/app/dist/app.min.js?v=638488852374030681"></script>
        
    
    
    <script src="//cdn.jsdelivr.net/chartist.js/latest/chartist.min.js" type="text/javascript"></script>

    
    
        <script src="//d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script>
    
    <script defer src='//js.trendmd.com/trendmd.min.js' data-trendmdconfig='{"element":"#trendmd-suggestions"}'></script>
        <script type='text/javascript' src='https://platform-api.sharethis.com/js/sharethis.js#property=643701de45aa460012e1032e&amp;product=sop' async='async'></script>


    <script>
        var App = App || {};
        App.showCmePromo = false;
    </script>


    </form>
    

    
    
    <link rel="stylesheet" href="//cdn.jamanetwork.com/UI/app/scss/modules/_trendMD.css">
</body>
</html>

 contentType 9 text/html url 60 https://jamanetwork.com:443/journals/jama/fullarticle/195120 responseCode 3 200 